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ABSTRACT: 
 
Mycobacteriuam tuberculosis, the bacillus that causes tuberculosis (TB), utilizes 
mycothiol (MSH), a low molecular weight thiol, as its main antioxidant and a 
protectant against toxins. MSH maintains the bacterial intracellular redox homeostasis 
and is essential for the growth of M. tuberculosis. MSH reacts with toxins to form 
MSH S-conjugates which are cleaved by MSH S-conjugate amidase (mca), in the 
detoxification pathway which excretes drugs such as rifamycin and cerulenin from the 
cell as mercapturic acids. The biosynthesis of MSH proceeds in four steps catalyzed 
by enzymes denoted mshA, mshB, mshC and mshD. MSH-deficient mutants are 
hypersensitive to alkylating agents, free radicals and antibiotics like streptomycin, and 
the protective roles facilitated by MSH are critical to the survival of M. tuberculosis 
in the hostile environments of activated alveolar macrophages. Thus the inhibition of 
MSH biosynthesis and of the MSH-dependent detoxification pathway is an attractive 
avenue for the development of new drugs against TB and drug-resistant TB. The work 
in this thesis was carried out with the aim evaluating the inhibition of both mca and 
mshB by a range of analogs of the pseudodisaccharide substructure of MSH. 
MSH was purified from M. smegmatis and used to synthesize MSmB and Acetyl-
GlcN-Ins, the natural substrates for mca and mshB, respectively. Mca was partially 
purified from M. smegmatis, while the recombinant mshB from M. tuberculosis was 
expressed in E. coli and purified to homogeneity. 8 structural analogs of Acetyl-GlcN-
Ins which contain either a cyclohexane or a thiophenyl in place of inositol were 
evaluated as substrates of mshB. 21 novel compounds, including thioglycosides, O-
glycosides and naphthoquinones, were evaluated as inhibitors against both enzymes. 
The heterodisulfide, MSSNaph, was found to be a substrate for mca with a Km value 
of 328 μM. Amongst the Acetyl-GlcN-Ins structural analogs evaluated as substrates 
for mshB, MCL2 was the best giving Vmax value twice lower than that of the natural 
substrate and the Km 5-fold higher. The naphthoquinones were the best inhibitors 
against both enzymes, giving the inhibition of up to 44% and 95% for mca and mshB, 
respectively. A pattern was observed where naphthoquinones with longer carbon 
chains were better inhibitors of mca and mshB. The Ki values of the 
naphthoquinones, Vu2, Vu4 and Vu5, against mshB were 162.7, 93.9 and 16.8 μM, 
respectively. From the docking experiments, Vu2 and Vu5 occupied the active site of 
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mshB providing a hypothetical model for the binding mode of the naphthoquinones 
and the MSH biosynthetic enzyme. Vu5 was the best mshB inhibitor because its 
longer carbon chain extends the molecule such as to allow interaction of the 
naphthoquinone group with the hydrophobic dipeptide of Val 184 and Leu 185. For 
future research on identifying potential drug targets, an evaluation of compounds 
bearing apolar groups, attached through spacers of variable length to the glucosamine 
moiety, as potential inhibitors of both mca and mshB will be especially fruitful.  
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Acetyl-GlcN-Ins/GlcNAc- 
Ins 
acetylcysteine S-conjugates 
1-O-(2-acetamido-2-deoxy-α-D-glucopyranosyl)-D-
myo-inositol 
AIDS acquired immune difficiency syndrome 
AMP adenosine monophosphate 
APS ammonium per sulphate 
ATP adenosine triphosphate 
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Bp base pairs 
CDNB 1-chloro-2,4-dinitrobenzene 
CoA 
CPM 
 
coenzyme A 
7-diethylamino-3-(4’-maleimidylphenyl)-4-
methylcoumarin 
Cys-GlcN-Ins                     1-O-[2-[[(2R)-2-amino-3-mercapto-1-oxopropyl]amino]- 
2-deoxy-α-D-glucopyranosyl]-D-myo-inositol 
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Dabsyl chloride 4-dimethylaminoazobenzene-4'-sulfonyl chloride 
DCM dichloromethane 
DEAE diethylaminoethyl 
DMSO dimethyl sulphoxide 
DNA 
DnsCl 
deoxyribonucleic acid 
5-dimethylamino-1-naphthalenesulfonyl chloride 
DOTS directly observed treatment, short-course 
dTdP dithiodipyridyl 
DTNP 
DTT 
5,5’-dithiobis(2-nitrobenzoic acid) 
dithiothreitol 
IL-2                                      interleukin 2 
IL-12                                    interleukin 12 
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IMAC Immobilized Metal Ion Affinity Chromatography 
INF-γ                                    gamma interferon 
INO1 inositol 1-phosphate synthase 
Ins-2-P                                 myo-inositol 2 phosphate 
IPTG isopropyl-beta-D-thiogalactopyranoside 
kcat turnover number 
kcat/Km                                specificity constant 
Km   catalytic constant 
Ki inhibition constant                                    
Da dalton 
LDH lactate dehydrogenase                             
Lpd lipoamide dehydrogenase 
Mca                                 mycothiol S-conjugate amidase 
MDMPI                           mycothiol-dependent maleylpyruvate dehydrogenase 
MDR-TB                         multidrug resistant tuberculosis 
Min minute 
ml/hour                                    millilitre per hour 
ml/min                             millilitre per minute 
mM              millimolar 
MscR S-nitrosothiol reductase 
MSH mycothiol 
MshA2                                Acetyl-GlcN-Ins-P phosphatase 
MshA UDP-N-acetylglucosamine: 1L-myo-inositol-1- 
phosphate  
1-α-D-N-acetylglucosaminyltransferase 
MshB                        1-O-(2-acetamido- 2-deoxy-α-D-glucopyranosyl)-D-
myo-inositol deacetylase 
MshC ATP-dependent L-cysteine: 1-O-(2-amino-2-deoxy- 
α-D-glucopyranosyl)-D-myo-inositol ligase 
MshD                                     mycothiol synthase 
MSmB monobromobimane derivative of mycothiol 
MSNO                                 S-nitrosomycothiol 
MSSM mycothiol disulfide 
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MSSNaph                           2’-s-(mycothiolyl)-6-hydroxynaphthyldisulfide 
M-1.cm-1 Per molar per centimetre 
NAD nicotinamide adenine dinucleotide  
NADH reduced nicotinamide adenine dinucleotide 
NADPH reduced nicotinamide adenine dinucleotide phosphate 
N-AcCys-Naph 
N-AcCys-Mb                           
acetylcysteine naphthyldisulfide 
N-Acetylcysteine-bimane 
n nano 
NO nitric oxide 
OD optical density 
ORF open reading frame 
PAS p-aminosalicylic acid 
PCR polymerase chain reaction 
PI3P phosphotidylinositol 3-phosphate 
PMSF phenylmethylsulphonyl fluoride 
PPD purified protein derivative 
Redox reduction-oxidation reactions 
RNA ribonucleic acid 
RNI reactive nitrogen intermediate 
ROI reactive oxygen intermediate 
RPM        revolutions per minute 
SDS-PAGE  sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
[S] substrate concentration 
TB tuberculosis 
TEA triethylamine 
TEMED N N N `N`-tetramethyl-1,2-diaminoethane 
TFA trifluoroacetic acid 
TLC thin later chromatography 
TLCK N-p-tosyl-L-lysine chloromethyl ketone 
TPCK N-p-tosyl-L-phenylalanine chloromethyl ketone 
tRNA transfer ribonucleic acid 
TSH2 trypanothione 
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UDP-GlcNAc  uridine diphosphate acetylglucosamine 
UV                                           ultraviolet 
v initial velocity 
Vmax maximum rate of reaction 
W/V weight/volume 
WHO world health organizaton 
XDR-TB extensively drug resistant tuberculosis  
Zn2+  Divalent zinc cation 
μ micro 
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CHAPTER 1:  
GENERAL INTRODUCTION 
 
1.1 TUBERCULOSIS 
 
1.1.1 Tuberculosis Infection 
 
Amongst all human diseases resulting from bacterial infection, tuberculosis (TB) 
remains the deadliest. TB is a contagious disease which is caused by Mycobacterium 
tuberculosis, a bacillus that is transmitted in air droplets when an infectious person 
coughs or sneezes. Because the immune system is capable of fighting the progression 
into active TB, not all people who are infected with the bacillus develop the disease. 
The bacillus can remain dormant inside the lungs for years without causing the 
disease but is activated when the immune system is weakened (WHO, 2008).  
 
Symptoms of TB include chest pain, difficulty in breathing, loss of appetite, excessive 
sweating, fever and coughing with blood in mucus that lasts for over two weeks. The 
advanced pathology may also cause blood vessel disruption resulting in haemoptysis1 
(Bloom and Murray, 1992). Multiple symptoms of TB may lead to gradual 
debilitation and physical exhaustion; hence the disease is often referred to as 
consumption (Ducati, 2006). 
 
1.1.2 History of Tuberculosis 
 
The great white plague of man, Captain of death, King’s Evil, Phthisis, consumption 
and lupus vulgaris are some of the names that have been used to describe TB in the 
past centuries. Archeological works from a number of neolithic sites from ancient 
Egypt to the Roman and Greek empires indicate evidence of a disease consistent with 
modern TB. TB was described by Hippocrates’ work dated back in 400 BC and was 
clearly documented by Claudius Galen during the Roman Empire (Mathema et al., 
2006).  
                                                 
1 Haemoptysis is the coughing up of blood from the respiratory tract. 
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The presence of spinal tuberculosis was demonstrated on the fossil bones dated 8000 
BC (Ayvazian, 1993) and there is evidence that bone and tissue cell samples from 
Egyptian mummies of people that lived around 2400 BC contained Mycobacterium 
tuberculosis (Zink et al., 2003). 
  
The study was done in which samples from the Egyptian mummies were analyzed for 
the presence of the ancient mycobacterial complex DNA and further characterized 
using spoligotyping. When the spoligotyping signatures were compared to those in the 
database they all showed either a M. tuberculosis or a M. africanum pattern, and none 
of the samples analyzed were indicative of M. bovis, the causative agent of bovine 
tuberculosis (Zink et al., 2003). These findings contradicted the theory that M. 
tuberculosis evolved from M. bovis and were further comfirmed by Brosch et al. 
(2002) who showed that a progenitor of M. tuberculosis was a human pathogen 
(Brosch et al., 2002) 
  
A major breakthrough was made in 1882 when Robert Koch discovered M. 
tuberculosis from crushed tubercles2. He identified M. tuberculosis as a causative 
organism of tuberculosis and in 1890 developed the tuberculin test3 for diagnosis of 
the disease. Following this, Koch discovered the staining methods for the 
identification of the bacillus. His work allowed more researchers to focus on the 
development of TB therapy and his staining technique was subsequently improved by 
Paul Ehrlich, whose method provided the basis for the popular Ziehl Nielsen staining 
technique (Ducati, 2006).  
 
1.1.3 Tuberculosis Infection and Epidemiology  
 
1.1.3.1 Global TB incidence 
 
According to the WHO global TB control report released in March 2008 (table 1.1), 
the largest number of new TB cases reported in 2005 occurred in the South-East Asia 
region and accounted for 34% of incident cases globally. 1.58 million people died of 
                                                 
2Tubercles, also known as granuloma, are formed at the site of infection which has been remodelled 
into a cellular mass by host reponse to TB infection (Russell, 2007).  
3 The tuberculin test is explained in section 1.4. 
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TB in 2005. Of these mortalities, 544 000 deaths occurred in the Africa region 
followed by the South-East Asia region where 512 000 people died of the disease. In 
the 1990s, the TB epidemic increased rapidly in Africa, but current reports indicate 
that the incident rate has begun to stabilize (WHO, 2008). 
 
In all six WHO regions, the estimated per capita incident rate was stable in 2005. 
However, the slow decrease in the   incident rate was offset by the rapid population 
growth. As a result, the number of new cases arising each year is still increasing 
globally (WHO, 2008). Thus TB is still a global problem that needs urgent attention 
and advanced treatment strategies.  
 
Table 1.1: Estimated TB Incidence, Prevalence and Mortality, 2005 (WHO, 2008) 
  Incidence4 Prevalence5 TB Mortality 
  All forms Smear-positive6         
number 
(thousands) 
WHO region (% of 
global 
total) 
per 
100 000 
pop 
number 
(thousands)
per 
100 000 
pop 
number 
(thousands)
per 
100 000 
pop 
number 
(thousands)
per 
100 000 
pop 
Africa 2 529 (29) 343 1 088 147 3 773 511 544 74 
The Americas 352 (4) 39 157 18 448 50 49 5.5 
Eastern 
Mediterranean 565 (6) 104 253 47 881 163 112 21 
Europe 445 (5) 50 199 23 525 60 66 7.4 
South-East 
Asia 2 993 (34) 181 1 339 81 4 809 290 512 31 
Western 
Pacific 1 927 (22) 110 866 49 3 616 206 295 17 
Global 8 811 (100) 136 3 902 60 14 052 217 1 577 24 
Pop denotes population. 
 
 
                                                 
4 Incidence - new cases arising in a given period. 
 
5 Prevalence - the number of cases which exist in the population at a given point in time. 
 
6 Smear-positive cases are those confirmed by smear microscopy, and are the most infectious cases. 
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1.1.3.2 TB Incidence in South Africa 
 
South Africa has one of the worst TB epidemics in the world, ranking fifth amongst 
the world’s high-burden TB countries. According to the WHO global TB report 2006, 
South Africa had about 339 000 new cases in 2004 (table 1.2), with an incidence rate 
of 718 cases per 100 000 people. The incidence rate more than doubled in 6 years and  
in 1998  was estimated at 338 per hundred thousand (WHO, 2006). 
 
In 1996, South Africa adopted the directly observed treatment, short-course (DOTS) 
approach as a strategy to minimize TB cases. The success rate of DOTS was 
estimated to be 67%, significantly lower than the WHO standard rate of 85% (Gandhi 
et al., 2006). The substantial increase in number of tuberculosis cases in this area is 
compounded with the high levels of HIV and the emergence of drug resistant strains, 
indicating an urgent need for chemotherapeutic intervention. 
 
Table 1.2: TB statistics in South Africa, all data was taken in 2004. (WHO, 2006) 
Country population 47 207 653 
Estimated number of new TB cases 339 078 
Estimated TB Incidence (all cases per 
100 000 population) 
718 
DOTS population coverage (%) 93% 
DOTS treatment success rate in 2003 (%) 67 
Estimated adult TB cases HIV+ (%) 60 
Multi-drug resistant TB cases (%) 1.8 
 
 
1.1.3.3 Tuberculosis and AIDS 
 
TB is the leading cause of death amongst people who are HIV-positive or have 
progressed into full-blown AIDS (hivforum.org, 2007). Globally, about 42 million 
people are infected with HIV and almost one-third of these are also infected with TB. 
The HIV/TB co-infection is more persistent in Africa, where in most countries more 
than 50 percent of patients with TB are also HIV positive. The HIV/TB co-infection is 
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also a growing concern in Asia where TB accounts for 40% of AIDS deaths. The 
former Soviet Union and Eastern Europe have the fastest growing HIV epidemic in 
the world, and this could exacerbate MDR-TB in the region (usaid, 2008; WHO, 
2008).   
 
The relationship between the HIV and TB epidemics is a complex one as each 
contributes to the prevalence and mortality of the other (Sharma et al., 2005). In later 
stages of HIV infection the immune system in the lung becomes compromised and is 
characterized by the recruitment of fewer lymphocytes to the site of infection and the 
less efficient activation of macrophages (Collins et al., 2002).  
 Thus, people infected with both HIV and TB are 30-times more likely to develop the 
active TB disease. Conversely, TB infection enhances HIV replication and accelerates 
the HIV progression to AIDS (usaid, 2008).  
 
1.1.4 Mycobacterium tuberculosis  
 
M. tuberculosis is the main etiological agent of TB in humans and was first 
discovered in 1882 by Robert Koch. M. tuberculosis is a weakly gram positive rod-
shaped bacterium that has a width varying from 0.3 to 0.6 μm and a height of 1 to 4 
μm. Unlike other bacteria, for example E. coli, which have division times measured in 
minutes, the generation time of M. tuberculosis ranges from 15 to 24 hours in both 
synthetic media and infected animals (Cole et al., 1998).  
 
The cell wall structure of the mycobacterium is arranged in such a way that the 
peptidoglycan contains N-glycolylmuramic acid instead of the N-acetylmuramic acid 
common in other bacteria. About 60% of the cell wall is made up of mycolic acids, 
lipids which consist of fatty acids with 60 to 90 carbons (Brennan and Nikaido, 1995). 
The mycobacterial cell wall is believed to be important in the pathology of TB, but 
due to its complex characteristics it is difficult to identify critical genes which would 
lead to attenuation if inactivated (Cole et al., 1998). 
There are about 60 known species in the genus mycobacterium, of which three 
species, M. tuberculosis, M. bovis and M. africunum are causative agents of TB while 
one species, M. leprae causes leprosy in humans. The M. tuberculosis complex 
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consists of M. bovis, M. bovis BCG, M. africanum, M. microti, M. canetti and M. 
tuberculosis (Pérez-Martinez et al., 2008). Of all these mycobacterial species, the 
mostly studied strain in the biomedical research is M. tuberculosis H37Rv (Mtb 
H37Rv) due to its virulence and resistance against drugs (Cole et al., 1998) 
 
The complete sequence of the M. tuberculosis H37Rv genome was reported in 1998 
by Cole and co-workers (Cole et al., 1998).  
               
 
Figure 1.1: Circular map of the chromosome of H37Rv. The outer circle shows the 
scale in Mb, with 0 representing the origin of replication. The first ring from the 
exterior denotes the positions of stable RNA genes (tRNAs are blue, others are pink) 
and the direct repeat region (pink cube); the second ring inwards shows the coding 
sequence by strand (clockwise, dark green; anticlockwise, light green); the third ring 
depicts repetitive DNA. The histogram (centre) represents G + C content, with <65% 
G + C in yellow, and >65% G + C in red. (Cole et al., 1998) 
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Mtb H37Rv has a circular chromosome comprising 4 411 529 base pairs (figure 1.1). 
The genome contains about 4000 genes and 65.6% G+C content. Although Mtb 
H37Rv genome is smaller than E.coli, it codes for typical bacterial catabolic and 
anabolic pathways as well as for protein synthesis and degradation (Cole et al., 1998). 
About 16% of proteins in Mtb H37Rv have no similarity to any known protein, 
probably being involved in mycobacterial unique pathways.  Another unique feature 
of Mtb H37Rv is that a very large portion of its coding capacity is devoted to the 
production of lipogenesis and lipolysis enzymes as well as to two families of glycine-
rich proteins with a repetitive structure that may represent a source of antigenic 
variation (Cole et al., 1998; Camus et al., 2002).  
 
Mtb H37Rv also contains enzymes required for processes such as glycolysis, the 
pentose phosphate pathway and glyoxylate and tricarboxylic acid cycles, thereby 
indicating that the pathogen has a dynamic metabolism (Ducati et al., 2006; Cole et 
al., 1998). All genes involved in the metabolism of mycothiol, the main antioxidant 
unique to actinomycetes, are present in the Mtb H37Rv genome (Steenkamp and 
Spies, 1994).  
The completion of the genome sequence of M. tuberculosis has definitely opened 
gates for further research into the bacillus pathogenicity and its response against 
chemotherapy. 
 
1.1.5 Clinical identification and Diagnosis of Tuberculosis 
 
TB diagnosis involves detection of acid-fast bacilli in the sputum using Ziehl-Neelsen 
staining. The sputum sample is treated with NaOH to eliminate contaminating 
microoganisms, while mycobacteria survive these conditions as they are resistant to 
alkaline compounds due to their lipid layer. M. tuberculosis cultured from the sputum 
takes 4-6 weeks to form visible colonies. Another TB detection method is the Bactec 
system, which utilizes a medium containing radio-labelled palmitate as the sole 
carbon source. As M. tuberculosis multiplies, it breaks down palmitate to release 
radioactive C02. With the Bactec method, M. tuberculosis can be detected in 9-16 
days (Todar textbook online, 2008).  
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The tuberculin skin test is the epidemiological surveillance method that can be used to 
detect infection through delayed hypersensitivity against mycobacterial antigens 
(Glickman and Jacobs, 2001). Purified protein derivative (PPD), which is employed 
as the test antigen in the tuberculin test, is generated by boiling a culture of M. 
tuberculosis. The PPD is intracutaneously injected in the forearm and the test results 
can be observed within 48 to 72 hours. The test is considered positive if the lesion, 
which is characterized by redness and swelling, is at least 10 mm in diameter (Todar, 
2008). However this method is not reliable in patients vaccinated with BCG, since 
this vaccination also produces activity to PPD (Bloom and Murray, 1992).  
 
More TB detection methods with sensitivity and specificity over 90% have been 
developed based on molecular techniques. These methods usually initiate with 
genomic sequence amplification, through PCR, which uses specific repetitive copy 
sequences, and can give sensitive results in few hours (Bloom and Murray, 1992; 
Ducati et al., 2006). Most of these methods are available commercially but are very 
expensive for some parts of the developing world to afford.   
 
1.1.6 Protective immunity during tuberculosis infection 
 
M. tuberculosis primarily infects alveolar macrophages7, which represent the first line 
of defence against inhaled bacteria (Lohmann-matthes et al., 1994). Upon infection, 
the bacilli are ingested by phagocytic alveolar macrophages where they can be 
immediately eliminated or grow inside the intracellular environments in the localized 
lesions called tubercles. Two to six weeks after infection, cellular immunity is 
established in which lymphocytes and activated macrophages are infiltrated to the 
lesions where they eliminate bacilli and end the primary infection even before 
presentation of disease symptoms (Ducati et al., 2006). Phagocytosed bacilli are 
transported via the phagosomal and endocytic pathways to the lysosomes where they 
undergo degradation.  
 
M. tuberculosis can parasitize macrophages by arresting the default process of 
phagosomal maturation into the phagolysosome (Vergne et al., 2003). 
                                                 
7 Alveolar macrophages are located in the interphase between air and lung tissues. They are very 
actively involved in phagocytic and equipped to kill microorganisms.  
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Phosphatidylinositol 3-phosphate (PI3P) is a membrane trafficking regulatory lipid 
and is essential for phagosomal acquisition of lysosomal characteristics. PI3P was 
reported to be involved in the pathway that involves the maturation of phagosomes to 
become phagolysosomes (Chua and Deretic, 2004).  
 
The immune system defence against infection includes activities of Th1 or Th2 cells 
which act in concert with CD8+ and other numerous cell types including 
macrophages, B cells and stromal cells. Collectively, these interactions give rise to 
two patterns of cytokine release, type 1 and type 2 (Roitt et al., 2001). Strong 
evidence exists that in mice the immunity correlates with type 1 response8, a pattern 
of cytokine release dominated by gamma-interferon (INF-γ), interleukin-2 (IL-2) and 
interleukin-12 (IL-12) (Clerici et al., 1994, Salgame et al., 1991). Interferons and 
interleukins are group of molecules involved in signalling between cells of the 
immune system, the former are also involved in protection against viral infections 
(From immunology textbook by Roitt et al., 2001). 
  
About two weeks after initial M. tuberculosis infection, growth of the bacteria is 
reduced due to the activation and differentiation of lymphocytes which supply INF-γ 
required to initiate the innate response. This leads to activation of macrophages which 
induce the production of nitric oxide (NO), one of the main mediators with 
antimycobacterial properties in mice (Ehlers, 1999). The NO production results in 
limitation of O2 thereby inhibiting aerobic respiration. This impairs growth of M. 
tuberculosis, an obligate aerobe, and induces its dormancy program (Voskuil et al., 
2006). The importance of INF-γ in the immunity of mice was also established in some 
studies where its gene knockout resulted in an increased susceptibility to M. 
tuberculosis and death within 3 weeks (Dalton et al., 1993).   
 
 Although most of the bacilli are destroyed by the immune system, some will survive 
and establish primary infection in macrophages, residing in the phagosome (Glickman 
and Jacobs, 2001). The phagosome containing the living pathogen is able to resist the 
delivery to the degradation site in the lysosomes. The pathogen can therefore remain 
dormant in the alveolar macrophages embodied in the calcified structures of tubercles. 
                                                 
8  Type 1 response refers to overall pattern of cytokine release by all cell types in the infected sites. 
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1.1.7 TB Vaccination 
 
Bacillus Calmette Guérin (BCG) was first developed in 1924 by Albert Calmette and 
Camille Guérin and is currently the most widely used vaccine against TB. BCG 
vaccine, which is administered intradermally, is prepared from a strain of attenuated 
live M. bovis that has lost its virulence in humans. Since BCG vaccination produces 
PPD, the tuberculin skin test, which also relies on detection of PPD, gives false 
positive results in vaccinated patients (Bloom and Murray, 2002). This has led to 
some countries with low TB cases forbidding the BCG vaccination in favour of the 
more accurate disease detection test. 
 
Studies by Weir and coworkers indicated that the BCG vaccination in infancy and 
adolescence induces an immunological memory to mycobacterial antigens that 
remains at measurable levels for at least 14 years (Weir et al., 2008). At best, BCG 
vaccine is 80% effective in preventing TB for about 15 years, although its protective 
effects seem to be variable according to geography (Colditz et al., 1994). Because of 
this variable efficacy as well as the loss of protective effects of BCG after a specific 
time there is a need for a search of more vaccines using recombinant modification and 
other attenuated live mycobacterial strains (Ducati et al., 2006).  
 
1.1.8 TB Treatment 
 
1.1.8.1 Directly Observed Treatment, Short-course  
 
Directly Observed Treatment, Short-course (DOTS) is the treatment strategy that was 
launched by WHO in 1994 to tackle the global problem of inadequate TB control. 
This strategy is widely used globally, has an average success rate of 80% in curing TB 
(USAID, 2008) and remains at the heart of WHO TB treatment strategies. DOTS uses 
a 6 month course of drugs, including first line anti-tubercular drugs, isoniazid and 
rifampicin, and its implementation is dependent on 5 elements, namely, political 
commitment with sustained financing, case detection through quality-assured 
bacteriology, standardized treatment with supervision and patient support, effective 
drug supply and management system, and lastly, a system of monitoring and 
evaluation, and impact measurement (WHO, 2008). Although DOTS has been the 
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most effective strategy to combat TB, it may seem paternalistic to some patients as it 
involves direct observation by a health worker (Volmink and Garner, 2003). Fresh 
research is needed to shorten observed treatment duration, a measure that should 
make DOTS even more effective in controlling TB (Jawahar, 2004). 
 
1.1.8.2 Anti-tubercular Drugs 
 
In 1943 Selman Abraham Waksman, a microbiologist from Rutgers university who 
later won the Nobel prize, purified streptomycin from the soil bacterium Streptomyces 
griceus. The purified compound could kill a wide spectrum of bacteria, including M. 
tuberculosis, both in cultures and in animals (Shatz et al., 1944a; Shatz et al., 1944b). 
Streptomycin was quickly approved as an anti-tubercular drug by United States food 
and drugs administration and within 2 years about 25 000 kg per day of the drug was 
produced industrially. Although Waksman’s discovery of streptomycin marked the 
beginning of the TB treatment era, single drug therapy using streptomycin, or other 
anti-tubercular drugs since then discovered, became ineffective due to the 
development of drug resistant strains of M. tuberculosis (Reviewed in Fox et al., 
1999). 
The development of streptomycin was followed by the discovery of another TB drug, 
para-aminosalicylic acid (PAS) (Reviewed by Sacchettini et al., 2008), by Jorgen 
Lehmen in 1948, followed by the introduction of Isoniazid and other antibiotics in the 
1950s.  
 
Today TB is curable with first line drugs, namely, isoniazid, rifampicin, ethambutol, 
pyrazinamide and streptomycin (figure 1.2). Isoniazid requires katG for activation and 
its mechanism of action includes inhibition of mycobacterial mycolic acids while 
rifampicin, ethambutol, and streptomycin inhibit transcription, arabinogalactan 
synthesis and protein synthesis, respectively. The mechanism of action of 
pyrazinamide is unknown but it is believed to inhibit membrane energetics and it 
requires pncA for activation (Sacchettini et al., 2008).  
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Figure 1.2: The commonly used first line anti-tubercular drugs  
 
1.1.8.3 Multi Drug Resistant Tuberculosis 
 
TB drug resistance is a global public health problem that hampers the progress of 
treatment strategies such as DOTS. Multi-drug resistant tuberculosis (MDR-TB) 
develops when M. tuberculosis becomes resistant to the first-line drugs, isoniazid and 
rifampicin. Resistance to any other combination of first line anti-tubercular drugs 
except these two is not classified as MDR-TB (WHO, 2008). In the Western Cape 
region of South Africa, DRF155, the M. tuberculosis strain that is resistant to 
rifampicin, isoniazid and streptomycin was identified. Factors leading to the 
development and spread of this resistant strain include inappropriate chemotherapy 
and poor adherence to treatment (Victor et al., 2007).  
Resistance against anti-tubercular drugs is thought to be conferred by spontaneous 
chromosomal mutations which occur at a predictable rate in M. tuberculosis. Because 
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these mutations are unlinked, resistance against a particular drug is usually not 
associated to resistance against an unrelated drug. Thus, the fact that the primary 
mechanism of TB drug resistance is due to perturbations in the specific target genes, 
forms the basis for resistant TB chemotherapy (Ramaswamy and Musser, 1998; 
Sharma and Mohan, 2004). The molecular mechanisms for drug resistance are 
summarized in table 1.3 (Sharma and Mohan, 2004). 
 
Table 1.3: Anti-tubercular drugs and the genes involved in their resistance 
    Drug Genes involved in drug resistance 
    
    Isoniazid 
 
 
 
 
 
 
Enoyl acp reductase (inhA) 
Catalase-peroxidase (katG) 
 
Alkyl hydroperoxide reductase (ahpC) 
 
 
 
  Ethambutol 
 
Arabinosyl transferase (emb A, B and C) 
 
 
  Pyrazinamide 
 
 
Pyrazinamidase (pncA) 
 
 
  Rifampicin 
 
 
RNA polymerase subunit B (rpoB) 
   
Streptomycin 
 
 
 
 
 
 
 
 
    
 
Ribosomal protein subunit 12 (rpsL) 
 
16s ribosomal RNA (rrs) 
 
Aminoglycoside phosphotransferase gene   
(strA)                      
 
 
 
 
 
 
Unlike with non-resistant strains which can be eliminated within 6 months using first-
line drugs, MDR-TB requires prolonged and expensive treatment with second-line 
drugs (Sacchettini et al., 2008). The commonly used second-line anti-tubercular drugs 
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are shown in figure 1.3. More drugs and new treatment strategies are therefore needed 
to aid the control of MDR-TB. 
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Figure 1.3: Second-line anti-tubercular drugs. 
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1.1.8.4 Extensively Drug Resistant Tuberculosis  
 
Extensively drug resistant tuberculosis (XDR-TB) develops when M. tuberculosis 
MDR strains develop additional resistance to a fluoroquinolone and to at least one of 
the following second line drugs; kanamycin, capreomycin and amikacin (WHO, 
2006). Because XDR-TB strains are resistant to most of the first and second line 
drugs, it remains extremely difficult to treat. It is understood that the high incidence of 
MDR-TB has arisen from factors such as poor patient compliance as well as the HIV 
co-infection. To prevent XDR-TB, it is crucial that the second line drugs are 
administered under controlled conditions so that they retain their potency (MRC-SA, 
2006; WHO, 2006). 
 
In the first detailed global XDR-TB survey, 18 000 individual isolates were tested. 
About 20% of the cases were MDR-TB, and 7% of these resistant strains were XDR-
TB. Of MDR-TB isolated in South Korea and East Europe/West Asian, 15% were 
XDR strains while only one XDR-TB case was found amongst 156 MDR isolates 
from Africa/middle east (Centers for Disease Control and Prevention, 2006). 
Currently, the geographical spread of XDR-TB is still uneven. Although Sub-Saharan 
Africa has one of the highest TB incidences, XDR prevalence among the MDR 
isolates in this region is relatively low (Jones et al., 2008).  
  
The first XDR-TB cases in South Africa were reported in 2006 (Gandhi et al., 2006) 
in the study carried out in Kwazulu Natal province. Of 1539 patients tested, 221 were 
diagnosed of MDR-TB, of which the 53 had XDR-TB. 52 patients with XDR-TB died 
within the median survival of 16 days after the disease was diagnosed (Gandhi et al., 
2006). 44 of the 53 were tested for HIV and found to be HIV-positive (MRC, 2006). 
These observations indicate that XDR-TB is associated with high mortality and 
threatens the success of treatment programmes against TB and HIV (Gandhi et al., 
2006). An urgent intervention in the form of controlled treatment programmes and the 
discovery of new drugs is needed.   
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1.1.9 New strategies for Drug Development 
 
During infections like TB, a molecular understanding of host-pathogen interactions 
requires clear characterization of the mycobacterial defence against oxidative and 
nitrosative stress (Nathan and Shiloh, 2000). A large fraction of genes required for 
mycobacterial growth is specific to M. tuberculsosis and its closely-related species 
indicating that the bacillus uses survival strategies which are fundamentally different 
from other pathogens (Sassetti and Rubin, 2003). Understanding how M. tuberculosis 
evades harmful attacks in the hostile environments of the activated macrophages and 
how it detoxifies drugs could be essential in tackling the emergence of MDR- and 
XDR-TB.   
   
Infected and lysed alveolar macrophages release reactive oxygen intermediates 
(ROI)9, reactive nitrogen intermediates (RNI)10 and other toxins which help to inhibit 
the replication of M. tuberculosis (Nathan and Shiloh, 2000; Clark-Curtiss and 
Haydel, 2003). In response M. tuberculosis employs various defence mechanisms to 
detoxify the stress caused by these harmful compounds.  
 
AhpC is a mycobacterial protective gene that encodes alkyl hydroperoxide reductase 
(ahpC), a member of the peroxyredoxin family. An adaptor protein, ahpD, links ahpC 
to dihydrolipoamide dehydrogenase (lpd) and dihydrolipoamide succinyltransferase 
(SucB) which support mycobacterial antioxidant defence hydrogen and alkyl 
peroxides (Bryk et al., 2002).  AhpC, ahpD, lpd and SucB together constitute an 
NADH-dependent peroxidase and peroxinitrite reductase. Because of its antioxidation 
role ahpC could be a drug target (Bryk et al., 2002).  
 
Another important gene in the virulence of M. tuberculosis is katG which catabolizes 
the superoxides generated by phagocyte NADPH oxidase. However in the absence of 
the phagocyte oxidative burst, the role of katG is dispensable for the M. tuberculosis 
                                                 
9 Reactive oxygen intermediates (ROI) are intermediate reduction products of O2, namely, superoxide, 
hydrogen peroxide and hydroxyl radical (Nathan and Shiloh, 2000). 
 
10 Reactive nitrogen intermediates (RNI) refer to adducts of the nitrogenous products of nitric oxide 
synthases. These intermediates include nitric oxide (-NO), N2O3, N2O4, s-nitrosothiols, peroxynitrites 
and dinitrosyl-ino complexes (Nathan and Shiloh, 2000).  
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virulence. Also inactivating mutations in KatG confers resistance to isoniazid, 
because this enzyme has been implicated in activation of the drug. Similarly MSH-
deficient M. smegmatis is less sensitive to Inh and is somehow also involved in its 
activation (Ng et al., 2004).  
 
1.1.10 Low molecular weight thiols: an avenue for chemotherapeutic 
intervention 
 
While defence mechanisms like those by katG and ahpC serve as an effective 
response to specific dangers in the host cells, there is also a need for an effective, 
immediate, and universal response to the wide spectrum of threats a bacillus may 
encounter during its life cycle (Ung and Av-Gay, 2006). Low molecular weight thiols 
may serve such a role, since they are involved in cellular redox potentials and protein-
disulfide ratios, as well as for the protection of cells against reactive oxygen species 
(Hand and Honek, 2005). Therefore, the inhibition of key enzymes in the metabolism 
of low molecular weight thiols represents a new area for drug development 
 
Mycobacteria contain two major low molecular weight thiols, namely, ergothioneine 
(ESH) and Mycothiol (MSH). Most important, MSH was shown to be essential in 
M.tb grown in culture, but no enzyme involved in ESH biosynthesis has ever been 
isolated and so its role is unknown (Williams M.J, 2007). 
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1.2. MYCOTHIOL 
 
1.2.1 Mycothiol is the major low molecular weight thiol in Mycobacteria 
 
 
Figure 1.4: Overview of mycothiol metabolism. Green: biosynthesis of mycothiol 
catalyzed by mshA, mshB, mshC and mshD. Blue: degradation reactions to scavenge 
mycothiol for cysteine in times of nutrient starvation. Yellow, protective reactions 
catalyzed by: mycothiol amidase (mca) and nitrosothiol reductase (mscR) and thiol 
peroxidases or peroxiredoxins involved in oxidative and nitrosative stress protection 
and mycothiol reductase (mtr), which maintains mycothiol in a reduced form within 
the mycobacterial cell. Red, metabolic reactions catalyzed by enzymes such as 
maleylpyruvate isomerase requiring mycothiol as a cofactor for growth on diverse 
carbon sources. Permission to reproduce this figure was granted by the corresponding 
author of the published article (Rawat and Av-Gay, 2007). 
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1-D-myo-inosityl-2-(N-acetyl-L-cysteinyl)amino-2-deoxy-α-D-glycopyranoside was 
identified in its disulfide form in Streptomyces sp AJ 9463 by Zhou and co-workers 
(Sakuda et al., 1994), and in an independent study at about the same time, Spies and 
Steenkamp  discovered it as a free thiol in Mycobacterium bovis and assigned it the 
name mycothiol (Spies and Steenkamp, 1994). From the structure analysis of this 
thiol, it came out that MSH was the compound which was identified as U17 by 
Newton et al. (Newton et al., 1993; 1995). MSH is a major low molecular weight 
thiol produced in virtually all actinomycetales, a group which includes streptomyces 
and mycobacterium (Newton et al., 1996). Since actinomycetales do not produce 
glutathione (GSH) and trypanothione (TSH2), it seems that MSH is responsible for the 
protective roles performed by these thiols in their respective organisms. 
 
Pathogens which produce MSH seem to use this thiol as a protectant against 
electrophilic attack and alkylating agents as well as for the detoxification against ROI 
and RNI (Hand and Honek, 2005). M. tuberculosis utilizes MSH to detoxify toxins in 
a manner similar to mercapturic acid derivatives formation in the GSH detoxification 
pathway (Newton et al., 2000b). MSH in conjunction with mycothiol disulfide 
reductase controls cellular homeostasis by maintaining the reducing intracellular 
environments in M. tuberculosis (Patel and Blanchard, 1999). 
 
1.2.2 Structure of MSH 
 
O
OH
HO
HO
HN
O
NH
O
OH
OH
OHOH
HO
O
HS
Figure 1.5: Structure of MSH 
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MSH is a glycothiol made up of myo-inositol, D-glucosamine and N-acetyl-cysteine. 
The most reactive group with which MSH forms S-conjugates is the sulfhydryl of the 
cysteine moiety.  
 
1.2.3 Overview of MSH Biosynthesis 
 
Acetyl-GlcN-Ins is the ultimate product of a sequence of reactions involved in the 
first step of the MSH biosynthetic pathway catalyzed by mshA and mshA2 (Newton 
et al., 2006), its deacetylation to form GlcN-Ins is catalyzed by Acetyl-GlcN-Ins 
deacetylase (mshB) (Maynes et. al., 2003), which was identified in M. tuberculosis as 
a homolog of MSH S-conjugate amidase (mca) (Newton et. al., 2000a,b). The ligation 
of cysteine to the amino group of GlcN-Ins is catalyzed by GlcN-Ins:Cys ligase 
(mshC) in an ATP-dependent reaction that produces AMP, pyrophosphate and Cys-
GlcN-Ins (Sareen et al., 2002). The final step in the MSH biosynthesis involves the 
acetylation of Cys-GlcN-Ins by acetyl-CoA and is catalyzed by MSH synthase 
(mshD) (Koledin et. al., 2002).  
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Figure 1.6: MSH biosynthetic pathway 
 
  
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 22
1.2.3.1 MshA 
 
1.2.3.1.1 MshA catalyzes the initial steps in mycothiol biosynthesis 
                                                                     
         
                                                                     Exogenous Inositol 
 
                                                                                                  
Glucose-6-Phosphate   inositol-1-phosphate synthase       1L-Ins-1-P + UDPGlcNAc   
                                                     
                                                                                     mshA 
                          
                              
Acetyl-GlcN-Ins            mshA2                      Acetyl-GlcN-Ins-P 
 
Figure 1.7: The initial steps of MSH biosynthesis 
 
Based on amino acid sequence similarities, mshA, a gene encoding UDP-N-
acetylglucosamine:1L-myo-inositol-1- phosphate 1-α-D-N-acetylglucosaminyl-
transferase (mshA), was identified as a member of the glycosytransferases family 4 
which includes enzymes such as sucrose synthase, sucrose phosphate synthase, 
mannosyl transferase and GlcNAc transferase. These enzymes catalyze the transfer of 
a sugar moiety from an activated donor to a specific acceptor, resulting in the 
formation of a glycosidic bond (Campbell et al., 1997).  
 
The mshA-catalysed step was characterized in a work that completed a full 
elucidation of the MSH biosynthetic pathway. This step proceeds through two 
reactions leading to the formation of a pseudodisaccharide Acetyl-GlcN-Ins, an 
intermediate precursor of mycothiol (Newton et al., 2000a). In the first part of the 
reaction, UDP-GlcNAc donates a sugar moiety to 1L-Ins-1-P resulting in the 
formation of Acetyl-GlcN-Ins-P. 1L-Ins-1-P serves as the best optimal acceptor in this 
reaction compared to other inositol-containing compounds such as 1D-Ins-1-P and 
Ins-2-P which were inefficient substrates when used as acceptors. In the second part 
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of the reaction, Acetyl-GlcN-Ins is produced by dephosphorylation of Acetyl-GlcN-
Ins-P by a phosphatase called MshA2 (Newton et al., 2006). 
 
Bacchawat and Mande reported that L-myo-inositol-1-phosphate is produced from 
glucose-6-phosphate in a reaction catalyzed by inositol-1-phosphate synthase, 
encoded by INO1. This is also the case in other organisms. Inositol-1-phosphate is 
then dephosphorylated by inositol-1-phosphatase and the resultant free inositol is 
subsequently used by the host to produce inositol-derived metabolites (Bacchawat and 
Mande, 1999). Thus 1L-Ins-1-P is an acceptor in mshA catalyzed reaction and also a 
precursor in the biosynthesis of inositol. Alternatively, 1L-Ins-1-P can be derived 
from exogenous inositol (Reviewed in Newton et al., 2006). 
 
1.2.3.1.2 MshA as a drug target 
 
Both streptomycetes and mycobacteria belong to Actinomycetes, a group which 
produces mycothiol as a low molecular weight thiol (Spies and Steenkamp, 1994; 
Sakuda et al., 1994). Park et al. (2006) identified the homologues of mshA, B, C and 
D in the genome of Streptomyces coelicolor which were found to serve the same role 
as their counterparts in Mycobacteria. The disruption of mshA by PCR gene targeting 
mutagenesis resulted in no production of MSH. In addition, when the mutant was 
complemented with the mshA gene, MSH synthesis was fully restored to the same 
levels as in the parent strain indicating that MSH production was indeed shut down by 
gene disruption of mshA. This indicates that mshA is essential for MSH biosynthesis 
in S.coelicolor (Park et al., 2006). Newton et al showed that mshA is also essential for 
production of mycothiol in Mycobacterium smegmatis, but not for growth of the 
organism (Newton et al., 2003). Recently, disruption of mshA in Mycobacterium 
tuberculosis Erdman showed that this gene is also essential for the growth of this 
pathogen (Buchmeier and Fahey, 2006), a similar effect as in the targeted mutagenesis 
of mshC in the same strain (Sareen et al., 2003). MshA is therefore a target for 
development of compounds that could block MSH biosynthesis. 
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1.2.3.2 Acetyl-GlcN-Ins Deacetylase 
 
The formation of GlcN-Ins from the deacetylation of Acetyl-GlcN-Ins is catalyzed by 
mshB. Although mshB is not essential for the growth of mycobacterium, it is the key 
enzyme in the biosynthesis. The mshB- mutants of Mtb produces about 15% of 
wildtype MSH suggesting that the loss of deacetylase activity might be compensated 
for by another gene, most probably mca due to its homology with mshB (Newton et 
al., 2000a; Maynes, 2003). Because this study is aimed at inhibiting both mshB and 
mca, they will both be discussed in details at the end of this chapter. 
 
1.2.3.3 GlcN-Ins:Cysteine ligase  
 
The activity of GlcN-Ins:Cysteine ligase from mycobacterial crude extracts was first 
identified by Bornemann and coworkers in the work that elucidated the final steps of 
MSH biosynthesis. They reported the synthesis of GlcN-Ins and showed that it is 
enzymatically linked to L-cysteine in ATP- dependent ligation to form Cys-GlcN-Ins. 
The acetylation of Cys-GlcN-Ins with acetyl-CoA produces MSH (Bornemann et al., 
1997). GlcN-Ins:Cysteine ligase has been purified to homogeneity from 
Mycobacterium smegmatis from which apparent Km values for Cys and GlcN-Ins 
were determined to be 40±3 and 72±9 μM, respectively. The gene, mshC, was also 
identified from the N-terminal sequence in Mycobacterium tuberculosis (Sareen et al., 
2002). MshC is related to cysteinyl-tRNA synthetases due to its mode of activating 
cysteine through the formation of a cysteine-AMP derivative which subsequently 
undergoes an attack by the amino group of GlcN-Ins (Meinnel et al., 1995).   
 
The absence of MSH and its metabolic enzymes in eukaryotes suggests that their 
inhibition is a possible avenue for drug development. The evidence of MSH 
involvement in the protection of mycobacteria was demonstrated in MSH-dependent 
detoxification mechanism facilitated by MSH S-conjugate amidase in which the toxin 
moiety is eventually excreted out of the cell as a mercapturic acid (Newton et al., 
2000b).  
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Rawat et al. (2002) found that the depletion of MSH in M. smegmatis increases its 
susceptibility to toxins and antibiotics. MSH-deficient mutants of Mycobacterium 
smegmatis created by both chemical and transposon mutagenesis are sensitive to 
alkylating agents such as Diamide, iodoacetamide and mBBr. They are also sensitive 
to oxidative stress and a range of antibiotics indicating that MSH is important in 
protection of the M. smegmatis against stress caused by those compounds. A chemical 
mutant I64 and two transposon mutants, Tn1 and Tn2 were shown to be 3 to 16-fold 
more sensitive to penicillin G, erythromycin, vancomycin, and azithromycin than the 
wild-type strain. Both transposon mutants, Tn1 and Tn2 were reported to be more 
susceptible than chemical mutant I64 to anti-tubercular drugs, rifamycin and rifampin. 
However I64 and both transposon mutants are respectively 16-fold and 125-fold more 
resistant to isoniazid than the wild type strain. These mutants also lack cys:GlcN-Ins 
ligase activity. The absence of ligase activity in the chemical mutant is due to the 
point mutation in mshC. The complementation of this mutant with mshC restored the 
MSH production in the mutant and revert its antibiotic susceptibility (Rawat et al., 
2002). This indicates that lack of MSH production was due to the mutated mshC gene.  
 
In the other work which confirmed the importance of mshC in the growth of 
mycobacteria, Sareen et al found that no viable clones possessing MSH were 
produced after the targeted disruption of a native mshC in M. tuberculosis Erdman. 
However, when mshC gene was incorporated into the chromosome, the clones 
produced normal levels of MSH demonstrating that mshC gene and the production of 
MSH are essential for the growth of this strain (Sareen et al., 2003). 
 
1.2.3.4 Acetyltransferase (mshD) catalyzes the reaction that produces MSH   
 
Mycothiol synthase (mshD) belongs to the N-acetyltransferase superfamily, a group 
of enzymes which use acyl-CoA to acylate their substrates (Vetting et al., 2005). The 
presence of mycothiol synthase activity was first demonstrated in M. smegmatis 
(Bornemann et al., 1997), later identified in as ORF Rv0819 and cloned in E. coli 
(Koledin et al., 2002). Rv0819 has orthologs in the genomes of other actinomycetes, a 
group to which MSH production is confined (Newton et al., 1996). Orthologs with 
sequence identities of 62%, 75%, 46% and 34% to the M.tuberculosis enzyme are 
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present in M. smegmatis, M. leprae, Streptomyces coelicor A 3(2) and 
Corinebacterium diphtheriae respectively.  
 
MshD catalyzes the final step in the production of MSH, where Cys-GlcN-Ins is 
acetylated with acetyl-CoA. The MshD::Tn5 mutant of M. smegmatis, accumulates 
high levels of Cys-GlcN-Ins and accumulates all of the intermediates in the 
biosynthetic route to MSH but produces only ~1% MSH indicating that mshD is 
important in the biosynthesis of MSH (Koledin et al., 2002). Cys-GlcN-Ins exists as a 
disulfide form at different growth stages of MshD::Tn5 suggesting that the cells are 
susceptible to autooxidation due to the extremely low levels of MSH. The MshD::Tn5 
mutant produces two novel thiols related to MSH, namely, N-Succinyl-Cys-GlcN-Ins 
and N-formyl-Cys-GlcN-Ins. The latter substitutes MSH in helping mutant cells to 
resist the peroxides stress (Newton et al., 2005). Although N-formyl-Cys-GlcN-Ins 
serves as a weak surrogate of MSH, in mshD-deficient mutant of M. tuberculosis, it is 
not sufficient to support the normal growth of the cells under stress conditions similar 
to those in macrophages (Buchmeier et al., 2006).   
 
1.2.4 Mycothiol-Dependent Enzymes 
 
1.2.4.1 Redox status of MSH 
 
Oxidation is harmful to vital cellular components such as the nucleic acids, lipids and 
proteins (Chae et al, 1994). Thiols tend to be oxidized to disulfides when exposed to 
extracellular environments. MSH also undergoes oxidation to form mycothiol 
disulfide (MSSM). NADPH dependent mycothioldisulfide reductase (mtr) maintains 
MSH in a reduced state and thus contributes to the intracellular redox homeostasis of 
the mycobacterial cell. Mtr from M. tuberculosis was cloned and expressed in M. 
smegmatis using a shuttle vector with hsp60 promoter. This 50 kDa subunit enzyme is 
NADPH-dependent and it utilizes MSSM as a substrate. The Km values of MSSM 
and NADPH were reported to be 73 and 8 μM respectively. Mtr requires FAD as a 
cofactor (Patel and Blanchard, 1999).  
 
AcCys-GlcN is also a substrate for mtr, although with a five-fold larger Km value 
than MSSM (Patel and Blanchard, 1998). This indicates that although mtr is selective 
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for MSSM, the removal of the inositol residue from MSH does not eliminate the 
reductase activity. Alpha-configured methyl- and benzyl-glycosides have also been 
described as alternate substrates of mtr (Stewart et al., 2008).  M.tuberculosis mtr is a 
flavoenzyme and is a member of pyridine nucleotide-disulfide reductase superfamily, 
which contains proteins such as glutathione reductase, thioredoxin reductase and 
trypanothione reductase (Patel and Blanchard, 2001). Inspite of its broad similarity to 
GSH and TSH2 reductases, mtr does not display activity against disulfides of GSH 
and TSH2 indicating its specific importance to the stability of MSH in mycobacteria 
(Patel and Blanchard, 1999).  
 
Because of its protective role against oxidation in mycobacteria, mtr is an attractive 
drugable target. The properties of 7-methyljuglone derivatives as potential subversive 
substrates have been reported (Mahapatra et al., 2007), providing the basis that more 
specific naphthoquinones could serve as good subversive substrates for mtr. 
 
1.2.4.2 Maleylpyruvate isomerase 
 
Gentisate (2,5-dihydroxybenzoate) and  substituted gentisates serve as key 
intermediates in the aerobic pathways for the metabolism of compounds such as 
salicylate (Ohmoto et al., 1991), dichloromethoxybenzoate ( Werwath et al., 1998), 
and naphthalene (Grund et al., 1992). In Gentisate pathway p-dihydroxylated 
aromatic ring is cleaved by gentisate 1,2-dioxygenase to form maleylpyruvate. 
Maleylpyruvate isomerase catalyzes the conversion of maleylpyruvate to 
fumarylpyruvate. This enzyme requires GSH as a cofactor in GSH-containing 
organisms such as Klebsiella pneumoniae and Ralstonia strains (Zhou et al., 2001). 
 However, the identification of a gene (ncgl2918) with maleylpyruvate isomerase 
activity in C. glutamicum indicated that a different cofactor is employed since GSH is 
absent in this bacterium (Shen et al., 2005).  
 
In subsequent studies, Feng et al established a link between MSH biosynthesis and 
GSH-independent gentisate pathway in C. glutamicum.  It was reported that MSH is a 
cofactor of maleylpyruvate isomerase and also essential for growth of C. glutamicum 
when gentisate is used as a carbon source (Feng et al., 2006). Ncgl2918 was cloned, 
expressed and purified in E.coli, and it is a monomer of 34 kDa with Km(app) of 148 
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μM when maleylpyruvate is used as a substrate and MSH as a cofactor (Feng et al., 
2006). MSH-dependent maleylpyruvate isomerase (MDMPI) is a metalloprotease 
with a divalent metal-binding domain and its C-terminal domain possesses a folding 
pattern, αβαββα (Wang et al., 2007).  
 
1.2.4.3 NAD/MSH-dependent Formaldehyde dehydrogenase 
 
Detoxification of formaldehyde in various organisms is catalyzed by reductases 
differing in coenzyme/cofactor used.  In larger eukaryotes and gram-negative bacteria, 
toxic formaldehyde is detoxified by NAD/GSH-dependent formaldehyde 
dehydrogenase. NAD/MSH-dependent formaldehyde dehydrogenase, the first enzyme 
of MSH metabolism to be identified, serves the same detoxification role in 
actinomycetes (Misset-Smits et al., 1997). MSH-dependent detoxification of reactive 
nitrogen species such as nitric oxide radical leads to intermediate formation of 
nitrosomycothiol (Vogt et al., 2003). NAD/MSH-dependent formaldehyde 
dehydrogenase catalyzes the oxidation of the thiohemiacetal group of MSH with 
formaldehyde which is present in aqueous solutions as a H20 adduct (Norin et al, 
1997; Misset-Smits et al., 1997).  
 
A class III alcohol dehydrogenase gene of Mtb, Rv2259, was cloned and expressed in 
M. smegmatis as the C-terminally His-tagged product (Vogt et al., 2003). This 
enzyme catalyzed two activities, the NAD-dependent conversion of S-
hydroxymethylmycothiol into formic acid and MSH, as well as the NADH-dependent 
decomposition of S-nitrosomycothiol (MSNO). Hence, the enzyme is also denoted S-
nitrosomycothiol reductase. The protective role of MscR in macrophages has not been 
fully established yet. 
 
 
1.2.4.4 Mycothiol S-Conjugate Amidase 
 
1.2.4.4.1 MSH-dependent detoxification pathway 
 
In mammals the complete detoxification pathway is more complicated since more 
than one enzyme is involved. The conversion of alkylating agents to glutathione S-
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conjugates is catalyzed by glutathione S-transferases and it occurs in various tissues 
(Ketterer et. al., 1988, Mannervik et al., 1988). Glutathione S-conjugates are exported 
to the plasma and transported into the liver and kidney where they are degraded by γ-
glutamyltranspepetidase to form CySR-Gly which is cleaved by dipeptidase to 
produce CysR (Stevens and Jones, 1989). CysR is a Cysteine S-conjugate which is 
imported and acetylated by Acetyl CoA to produce AcCysSR, a mercapturic acid 
which is excreted in urine and bile.  
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Figure 1.8: The detoxification pathway in Mycobacteria  
(Modified from Newton et al., 2000b) 
 
In mycobacteria, a single enzymatic activity is responsible for a detoxification 
pathway that leads to the excretion of AcCysSR. MSH reacts with a toxin to form a 
mycothiol S-conjugate which is cleaved by mycothiol S-conjugate amidase (mca) to 
form GlcN-Ins and a mercapturic acid. The latter is excreted from the cell while 
GlcN-Ins is used to resynthesize MSH (Newton et al., 2000b). Mca was first isolated 
from M. smegmatis and its N-terminal sequence analysis revealed an orthologous 
gene in M. tuberculosis annotated as Rv1082. The M. smegmatis enzyme had a Km 
value of 95 μM and kcat of 8 s-1 when the S-conjugate of a fluorescent alkylating agent, 
monobromobimane (MSmB), was used as a substrate (Newton et al., 2000b).   
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Mca recognizes specifically the MSH moiety of conjugates and can accommodate 
different groups attached to the sulphur moiety in the MSH-toxin conjugate. 
However, mca does not have a significant activity with conjugates that lack the acetyl 
moiety present in mycothiol S-conjugates. MSH itself is a poor substrate of mca 
(Newton et al., 2006). Thus the thiol serves as a more autooxidation resistant reservoir 
of cysteine.  The M. tuberculosis amidase, which was cloned and expressed in E. coli 
has a similar substrate specificity to the M. smegmatis amidase. It also utilizes MSmB 
as a substrate, albeit with a Km value of 160 μM and kcat of 14 s-1. Other substrates of 
mca include S-conjugates of iodoacetamide, N-ethylmalemide, and 7-diethylamino-3-
(4’-maleimidylphenyl)-4-methylcoumarin (CPM) (Steffek et al., 2003).  
 
1.2.4.4.2 Bioinformatic analysis of mca 
 
Mycobacterium tuberculosis mca is an 864-bp gene that codes for a metalloenzyme of 
288 amino acids. Its product has a molecular mass of 32.7 kDa and an isoelectric 
point of 5.1. Mycobacterium smegmatis mca also codes for an 864-bp protein that 
contains 288 amino acids. The amino acid sequence of M. tuberculosis mca is 72% 
identical to that of the M. smegmatis enzyme (Newton et al., 2000b; Steffek et al, 
2003). This gene is present in all mycobacterial species sequenced so far. Comparable 
identity was also found in the orthologues of mca in M. bovis and M. leprae. In other 
actinomycetes, the amino acids identities between mca orthologues range from 51% 
for S. avermitilis to 72% for N. farcinica. There are at least four major domains that 
are highly conserved throughout the amidase family and histidine residues are 
conserved in three of these domains (Rawat and Av-Gay, 2007).  
 
The M. tuberculosis genome contains two paralogues, Rv0323c and mshB. Rv0323c 
codes for a 24.2 kDa protein which is non-essential and is only present in pathogenic 
M. tuberculosis and not in M. smegmatis (Sassetti et al., 2003). The second paralogue, 
mshB, codes for a deacetylase which catalyzes the second step in the biosynthesis of 
MSH (Newton et al., 2000a). The amino acid sequences of MshB and mca have a 
36% identity in 299 amino acids and both enzymes are Zn-dependent 
metalloproteases. MshB possesses a weak amidase activity in vitro and, conversely, 
mca also displays the deacetylase activity when Acetyl-GlcN-Ins is used as a substrate 
(Newton et al., 2000a; Newton et al., 2006). 
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1.2.4.4.3 Mca is involved in the detoxification of antibiotics     
 
The presence of mca homologs within the antibiotic biosynthetic operons for 
streptomycin, rifamycin and erythromycin indicates that the expression of these mca 
genes occurs at the same time as the antibiotic production. In order to understand 
whether mca plays a role in the detoxification of antibiotics, the presence of 
mercapturic acid derivatives of antibiotics in the fermentation broth of such 
mycobacteria should be investigated. Reports exist in which experiments were 
performed and numerous mercapturic acids of drugs were found in the broth 
(Supplementary material that came with a review by Newton and Fahey, 2002). These 
mercapturic acids are weaker in activity than the parent antibiotic. These findings 
gave a further evidence of mca involvement in the protection of the bacterial cell 
against its own antibiotics or those produced by its competitor. It was also reported 
that the S-conjugate of cerulenin, an antibiotic from actinomycete Cephalosporin 
cerulens which inhibits fatty acid synthetase, was a good substrate of mca (Newton 
and Fahey, 2002). 
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Figure 1.9: The formation of MS-conjugate of Rifamycin-S and its cleavage with 
Mca to release AcCys-Rifamycin-S and GlcN-Ins. 
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MSH-deficient mutants are more sensitive to alkylating agents and antibiotics like 
erythromycin, vancomycin, penicillin G, azithromycin and rifamycin (Rawat et al., 
2002). Rifamycin-S, a precursor of antituberculous rifampicin, also reacts with MSH 
to form an S-conjugate, which together with its oxidized form are substrates of mca. 
The Km values of mca when MS-Rifamycin-S reduced and oxidized forms are used 
as substrates are 190 μM and 450 μM respectively (Steffek et al., 2003). 
 
1.2.4.4.4 Mutant of a gene encoding mca 
 
A targeted mutant of mca from M. smegmatis was generated and characterized (Rawat 
et al., 2004).  Unlike in the wild type strain where mercapturic acid is released after 
the cleavage of S-conjugates, the mca mutant does not possess an amidase activity. 
The mca mutant accumulates the S-conjugates of monobromobimane and rifamycin-S 
and also becomes more susceptible to electrophilic toxins such as N-ethylamalemide, 
iodoacetamide and chlorodinitrobenzene.  
However the introduction of M. tuberculosis mca epichromosomally or M. smegmatis 
mca integratively into the mutant resulted in the complementation of the amidase 
activity and decreased levels of S-conjugates (Rawat et al., 2004). The mca mutant 
also displayed similar phenotypic characteristics to the mshC-deficient mutant in that 
it was sensitive to drugs like streptomycin (Rawat et al., 2002). However, it has not 
been established whether MSH can form S-conjugates with streptomycin, which could 
eventually be released as mercapturic acids. 
 
1.2.4.4.5 Inhibitors of mca as potential drug targets 
 
The involvement of mca in the mycobacterial detoxification of antibiotics makes it a 
promising target for drug development and indeed some efforts have been directed 
towards the synthesis of mca inhibitors. Bewley and coworkers screened 1500 natural 
products extracts and identified several inhibitors as lead candidates. Two 
bromotyrosine-derived alkaloids isolated from Oceania sp. were found to be 
competitive inhibitors of mca from M. tuberculosis (Nicholas et al., 2001; Nicholas et 
al., 2002). This was followed by the concise total synthesis of a bromotyrosine oxime 
which competitively inhibited mca with an IC50 value of 30 μM (Fetterolf and 
Bewley, 2004). 
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Based on the known structure of a naturally occurring alkaloid, a series of compounds 
were synthesized and tested as anti-infective agents against mycobacteria and other 
gram positive bacteria (Pick et al., 2006). EXEG1706 was identified as a lead 
compound that exhibited low minimum inhibition constants ranging from 2.5 to 25 
μg.ml-1 for methicillin-sensitive and methicillin–resistant Staphylococcus aureus, M. 
smegmatis and M. bovis whilst displaying minimum toxicity against mammalian 
macrophages and monocytes. EXEG1706 was also active against M. smegmatis 
mutant in which mca is deleted indicating that in addition to mca this compound 
possibly inhibits other target proteins in mycobacteria (Pick et al., 2006). 
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Figure 1.10: Thioglycosidic analog of MSH 
 
The thioglycosidic analog of MSH has been synthesized and S-alkylated with 
monobromobimane (Knapp et al., 2002). The evaluation of this analog as a substrate 
for mca revealed the specific activity of 7500 nmol.min-1.mg-1 versus 14200 
nmol.min-1.mg-1 for MSmB (Knapp et al., 2002). Although its specific activity was 
almost half that of the natural substrate, the thioglycoside can be used as an 
alternative substrate and its structure can serve as a starting material for anti-
tubercular drug design. 
 
 The substitution of inositol with cyclohexane and replacement of O with S as a 
bridging atom seems to be an ideal approach for inhibitor designing. It combines 
several possible advantages because R-GlcNAc thioconjugates can be prepared 
stereoselectively and in good yield by S-derivatization (Knapp and Myers, 2002). 
Thioglycosides are more resistant to degradation by glycosidases than O-glycosides 
(Knapp et al., 1996; Bousquet et al., 2000; Cohen and Halcomb, 2000). 
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Since inhibition of the MSH-dependent detoxification pathway could leave M. 
tuberculosis vulnerable to drugs, efforts are needed to generate more mca inhibitors. 
To this end, naturally occurring extracts have shown great promise as potential 
inhibitors of mca (Fetterolf and Bewley, 2004; Nicholas et al., 2001; Nicholas et al., 
2002), however, there is still a need for the synthesis and testing of structure-based 
inhibitors against mca. Part of the current study is to evaluate several novel 
compounds as mca inhibitors. In an attempt to identify a single compound which can 
inhibit both the MSH biosynthetic and detoxification pathways, compounds which 
exhibit good inhibition against mca will also be evaluated as mshB inhibitors.     
 
1.2.5 MSH B 
 
1.2.5.1 1-D-myo-nosityl-2-acetamido-2-deoxy-α-D-glucopyranoside Deacetylase is 
the key enzyme in the biosynthesis of MSH 
 
Rv1170, a gene which encodes mshB in M. tuberculosis, was first identified as a 
homolog of Rv1082, a gene encoding an MSH S-conjugate amidase (mca) (Newton et 
al., 2000b). Since mshB cleaves an amide bond similar to that hydrolyzed by mca, it 
was thought that mshB would be a broad spectrum enzyme involved both in MSH 
biosynthesis and in the detoxification pathway. However the comparison of mshB 
activities with MSmB and Acetyl-GlcN-Ins as substrates revealed that the deacetylase 
activity with Acetyl-GlcN-Ins as substrate was 23-fold higher than the amidase 
activity on MSmB. No deacetylation was detected with MSH and MSmB as substrate. 
This indicates that mshB does not possess significant activity for the degradation of 
MSH and it is not a broad spectrum deacetylase but is specific to Acetyl-GlcN-Ins 
(Newton et al., 2000a).   
 
 MshB catalyzes the deacetylation of Acetyl-GlcN-Ins to form GlcN-Ins in the second 
step of MSH biosynthesis. The level of Acetyl-GlcN-Ins in M. smegmatis at stationary 
and log phases is twice that of MSH and about 100-fold higher than that of other 
MSH precursors, GlcN-Ins and Cys-GlcN-Ins. This indicates that substantial amount 
of MSH can be produced upon demand from an endogeneous pool of Acetyl-GlcN-
Ins under the control of mshB. It was shown that Acetyl-GlcN-Ins is absent in a 
MSH-deficient mutant strain 49 from M. smegmatis, and that this mutant strain can 
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assimilate Acetyl-GlcN-Ins from the medium and convert it to MSH (Newton et al., 
2000a). This indicates that Acetyl-GlcN-Ins is a key intermediate leading to the 
biosynthesis of MSH.  
 
The purification of recombinant mshB from M. tuberculosis was reported by Newton 
et al (Newton et al., 2006). The pure mshB had Km value of 340 +/- 80 μM and kcat of 
0.49 s-1for its natural substrate, Acetyl-GlcN-Ins. As judged by activities at 0.1 mM 
substrate concentration, Acetyl-GlcN-Ins was 87-fold more reactive than GlcNAc on 
mshB indicating that inositol is important for binding (Newton et al., 2006). Other 
compounds which have been evaluated as mshB substrates were formyl-CySmB-
GlcN-Ins and MS-acetophenone. Relative to Acetyl-GlcN-Ins, the activities of 
formyl-CySmB-GlcN-Ins and MS-acetophenone were 42 and 66%, respectively. MS-
acetophenone was also cleaved by mca, indicating that a single inhibitor may inhibit 
both mshB and mca. The surprising finding by Newton and co-workers was that 
CySmB-GlcN-Ins proved to be a better substrate for mshB than its natural substrate 
with three times lower Km value (Newton et al., 2006). However, since the 
concentration of Cys-GlcN-Ins is almost undetectable inside the cells (Newton et al., 
2000a), it seems highly unlikely that it could compete with MSH to form S-
conjugates. Thus, the finding that mshB utilized CySmB-GlcN-Ins as a substrate 
better than Acetyl-GlcN-Ins is unlikely to have a physiological significance (Newton 
et al., 2006). 
 
1.2.5.2 Crystal structure and Bioinformatics of mshB 
 
Rv1170 (mshB) encodes a metalloenzyme consisting of 304 amino acid residues with 
a molecular mass of 33 000 kDa. The deacetylase activity of mshB is dependent on 
the divalent zinc ion (Newton et al., 2000a; Newton et al., 2006). The sequence 
V10HAHPDDES is a conserved region in mshB orthologs of other actinomycetes 
including SCO5126, a gene encoding the MSH biosynthetic enzyme in Streptomyces 
coelicolor A(3)2  (Park et al., 2006) and TT1542 from Thermus thermophillus (Handa 
et al., 2003). mshB is a paralog of M. tuberculosis Rv1082 encoding the amidase, 
mca, which is also dependent on a divalent metal cation for activity (Newton et al., 
2000a,b). MshB also possesses an amidase activity, albeit not as substantial as its 
deacetylase. 
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The crystal structure of mshB has been reported independently by Maynes et al. and 
McCarthy et al. (Maynes et al., 2003; McCarthy et al., 2004). The x-ray 
crystallographic structure of mshB reveals a folding pattern similar to lactate 
dehydrogenase (LDH) in the N-terminal domain. The zinc binding site in the N-
terminal domain occupies a position equivalent to that of the NAD-cofactor in LDH 
and there are two water molecules which coordinate to the Zn2+ ion (Maynes et al., 
2003).  
 
MshB consists of a large nine-stranded mixed β-sheet and one small three stranded 
antiparallel β-sheet. The first five strands of the large β-sheet with the associated α-
helices adopt a pattern that resembles Rossmann fold of LDH (White et al., 1976).  
McCarthy et al. also resolved a 3-D structure of mshB in which helices are packed 
against parallel β-sheets. Large loops emanating from the C-terminus of the β-strands 
form a cavity in which the active site is located (McCarthy et al., 2004).  
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Figure 1.11: Overall structure of MshB.  
A. One of the four MshB molecules present in the crystallographic asymmetric unit. 
The colouring is blue at the N terminus and red at the C terminus. The catalytic zinc is 
shown as a magenta sphere. B. Secondary structure present in the structure of MshB, 
showing the large central mixed β-sheet and lactate dehydrogenase (Rossmann) fold. 
The green sphere denotes the location of two of the zinc binding ligands (His-13 and 
Asp-16) and of the general base for the proposed catalytic mechanism (Asp-15). The 
yellow sphere represents the location of the third zinc binding ligand (His-147) and 
the electrophile for the catalytic mechanism (His-144). C. Electrostatic surface of 
mshB with positive electronegativity in blue and negative electronegativity in red 
(taken from Maynes et al., 2003). The permission to reproduce the figure was granted 
by the corresponding author of the paper, Prof M. James). 
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1.2.5.3 The mshB substrate binding pocket 
 
Many molecules which bind carbohydrates contain hydrophilic residues which form 
hydrogen bonding with the sugar hydroxyl groups (Quiocho, 1993). Because Acetyl-
GlcN-Ins is a very hydrophilic molecule, its binding pocket in mshB is expected to be 
hydrophilic. It was indeed reported that the active site and substrate binding pocket of 
mshB is hydrophilic and electronegative. The binding pocket contains carboxylate 
groups (Asp-15, -95 and -146), three hydroxyl groups (Ser-20,-260 and Tyr-142), four 
main chain carbonyls (Gly-140, Tyr-142, Glu-213 and Ile-214), one amide from the 
side chain of Gln-247 and two positively charged amino acids (Arg-68 and His-144) 
(Figure 1.12). The zinc ion is attached to three ligands, His-13,-147 and Asp-16 and is 
in proximity with two water molecules. One of these molecules is near the general 
base Asp-15 and is a nucleophilic water molecule (McCarthy et al., 2004 and Maynes 
et al., 2003).  
 
 
Figure 1.12: The active site of MshB. a, active site representation of one of the 
MshB molecules in the asymmetric unit. The catalytic zinc is shown as a cyan sphere, 
and two zinc-bound water molecules are shown as red spheres. The leftmost water 
molecule is within 2.83 Å of the catalytic Asp-15, and both water molecules are 
within 3 Å of the metal ion. The other metal ligands are 2.10 (His-13), 2.07 (Asp-16), 
and 2.13 Å (His-147) from the metal. b, Representative electron density from the 
active site region of MshB (Maynes et al., 2003). (The permission to reproduce the 
figure was granted by the corresponding author of the paper, Prof M. James). 
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The 300-fold decrease in the mshB catalytic activity after the removal of the inositol 
moiety from Acetyl-GlcN-Ins indicates that inositol may also be interacting with 
mshB (Newton et al., 2000a). Although inositol does not participate in the 
deacetylation mechanism it is possible that its hydroxyl groups could interact via 
hydrogen bonding with the hydrophilic groups of mshB. To establish this, more 
compounds in which inositol is substituted with a spacefilling cyclohexane or phenyl 
group could be evaluated as mshB substrates. 
 
1.2.5.4 Catalytic mechanism of mshB 
 
The mechanism of Acetyl-GlcN-Ins deacetylation by mshB is very similar to that of a 
protease hydrolysing a peptide bond. The catalytic hydrolysis of Acetyl-GlcN-Ins 
involves displacement of the second water molecule on Zn2+ by the carbonyl oxygen 
of the acetyl group (Figure 1.13). This leaves the second water molecule activated for 
the nucleophillic attack of the carbonyl carbon of the acetyl group. The water-
facilitated nucleophilic attack is assisted by a general base, the carboxylate of Asp-15, 
and the resultant tetrahedral transition state possesses a negatively charged oxygen 
which is stabilized by the positively charged Zn ion and the imidazolium chain of 
His144. Proton transfer to the nitrogen of the deacetylation product, GlcN-Ins, is 
through the general acid function of the carboxyl group of Asp-15 (Maynes et al., 
2003). This mechanism is similar to that of typical zinc metalloproteinases such as 
carboxypeptidase (Christianson and Lipscomb, 1989). However in most zinc 
proteinases the role of a general base and general acid is accomplished by glutamate 
rather than Asp-15. 
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Figure 1.13: Catalytic mechanism of mshB (modified from Maynes et al., 2003). 
 
1.2.5.5 Disruption of mshB results in decreased production of MSH 
 
A mshB- mutant strain of M. smegmatis, Myco504, was constructed and analyzed for 
MSH content. The disruption of the mshB gene resulted in a substantial decrease of 
MSH production, yielding only 5-10% of the level produced by M. smegmatis wild-
type mc2155 (Rawat et al., 2003). Complementation of Myco504 with the mshB gene 
resulted in increased MSH production to the parental level confirming that the 
decrease of MSH production was indeed due to the disruption of mshB (Rawat et al., 
2003).  
 
The same scenario was observed with a mutant strain created by knocking out the 
mshB homolog in Streptomyces coelicolor A(3)2, annotated as SCO5126. The 
SCO5126 deficient mutant produced only 10% MSH but when it was complemented 
with the SCO5126 gene, the MSH production was restored to the levels similar to that 
of the wild type (Park et al., 2006).   
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Myco504 does not exhibit significant sensitivity to iodoacetamide, DTNP, cumene 
hydroperoxide and to antibiotics like vancomycin, cerulenin, rifampicin and 
erythromycin (Rawat et al., 2003). This was in contrast to the mshC- mutant which 
was reported to be sensitive to these antibiotics (Rawat et al., 2002). Furthermore, 
unlike with other MSH mutants, Myco504 displayed the same resistance to isoniazid 
as the wild type strain. Myco504 was sensitive to ethionamide, mBBr and the 
glutathione S-transferase substrate, CDNB (Rawat et al., 2003).  
 
The presence of 5-10% MSH, as compared to the wildtype, produced in Myco504 
indicates that another gene compensates for the loss of deacetylase activity in the 
mshB- mutant. Since mshB and mca in M. tuberculosis share 36% identity, it is likely 
that mca is the enzyme responsible for the deacetylase activity in the mutant (Rawat et 
al., 2003). The inhibition of both mca and mshB could therefore result in the complete 
stoppage of MSH production.  
 
AIMS AND OBJECTIVES 
 
The aim of this study was to identify and evaluate structure-based compounds which 
can inhibit mshB, a key enzyme in the biosynthesis of MSH, and mca, an enzyme that 
catalyzes MSH-dependent detoxification pathway in M. tuberculosis. Due to the 
overlapping deacetylase activities of mca and mshB a complete disruption of MSH 
production at the deacetylase step can only be achieved by simultaneous inhibition of 
both these enzymes (Newton et al., 2006). Since MSH and its precursors are not 
commercially available, the synthesis of the natural substrates and the identification of 
alternate substrates for both mca and mshB was also the objective of the project.  
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CHAPTER 2:  
MATERIALS AND METHODS 
 
2.1. MATERIALS 
 
Chemical/Reagent:                                            Supplier: (company details in Appendix B) 
 
2,2-dithiodipyridyl                                                  Aldrich 
4,4’-dithiodypyridyl                                                Aldrich 
2-mercaptoethanol                                                   Merck 
2-monobromobimane                                              Fluka                                                                              
AccQ-Fluor                                                             Waters 
Acetic acid                                                              Merck 
Acetic anhydride                                                     Aldrich 
Acrylamide                                                              Sigma 
Ammonium persulfate                                             Merck 
Ammonium sulphate                                               Riedel-de Haën 
Ampicillin                                                               Sigma 
Bacto Middlebrook 7H9                                         Difco  
Bis-acrylamide                                                        Fluka 
Chloramphenicol                                                    Boehringer Mannheim                                              
Coomasie Brilliant Blue R250                               Merck 
Dithiothreitol                                                          Roche 
DnsCl                                                                      Sigma 
EDTA                                                                     Sigma-Aldrich 
Glycerol                                                                  Sigma 
Glycine                                                                   Merck 
HCl                                                                         BDH 
HEPES                                                                    Fluka 
Imidazole                                                                Fluka 
IPTG                                                                       Fermentas 
K2HPO4                                                                                                   Fluka 
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KH2PO4                                                                                                 Merck 
Li2CO3                                                                                                   Sigma 
LiOH.H2O                                                            Aldrich 
Methylene Blue                                                    Sigma 
N-Acetyl-L-cysteine                                             Fluka 
NaCl                                                                      Fluka 
NaHCO3                                                                                               BDH 
NaOH                                                                    Fluka 
N N N `N`-tetramethyl-1,2-diaminoethane          BDH 
Perchloric acid                                                      BDH 
PMSF                                                                    Boeringer Ingelheim 
Ready Flow III Scintillation fluid                         Beckman Coulter 
SDS                                                                       BDH 
Sodium borohydride                                             Aldrich 
TLCK                                                                    Sigma 
TPCK                                                                    Sigma 
Tris                                                                        Merck 
Tween 80                                                               Sigma 
ZnSO4                                                                                                     BDH             
 
Solvents: 
Acetonitrile (HPLC grade)                                   Sigma 
Butanol                                                                 Merck                                             
Ethanol                                                                  Sigma 
Methanol                                                               Fluka 
TEA                                                                      Sigma 
TFA (HPLC grade)                                               Sigma 
 
Chromatography Resins: 
 
Iminodiacetic acid agarose                                   Sigma 
Deae Sepharose                                                    Sigma-Aldrich 
Sephacryl S300                                                     Pharmacia 
Hydroxyapatite                                                     Bio-Rad                                                 
DEAE Cellulose                                                   Pierce 
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Vydac C-18 resin                                                 Vydac 
C-18 SepPack Cartridges                                     Waters 
Normal phase TLC Silica G60                             Macherey-Nagel 
G-60 Desalting columns                                       Pierce 
 
Dialysis: 
 
Dialysis tubing                                                      Sigma                                     
 
Radio-chemicals: 
 
3H-Myo-inositol                                                   Perkin Elmer                                                                   
 
HPLC columns: 
 
 
Biosep SEC-S2000 column (250 x 4.6 mm)           Phenomenex  
Phenyl-hexyl HPLC column (250 x 4.6 mm)         Phenomenex 
Phenyl-hexyl HPLC column (250 × 22 mm)          Phenomenex 
Luna 5μ C-18 HPLC column (250 x 4.6 mm)        Phenomenex 
Vydac TP1022 HPLC column (250 × 22 mm)       Vydac 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. GENERAL METHODS 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 46
 
2.2.1 Preparation of Middlebrook media  
 
4.7 g Bacto Middlebrook 7H9 broth (Difco) was dissolved in 800 ml H2011, 50 ml 
glycerol and 0.5 g Tween 80 (Sigma) were added to the medium and more water 
added to make up 1000 ml. The medium was autoclaved at 1210C, 15 psi for 20 
minutes.  
 
2.2.2 Maintenance of M. smegmatis in Middlebrook media 
 
Mycobacterium smegmatis cells were maintained on Löwenstein–Jensen slants and 
stored at -40C.  Liquid cultures were grown on Middlebrook medium which was 
shaken in Erlenmeyer flasks at 200 rpm at 37 °C. For primary cultures, a lump of 
bacteria was transferred from stock culture to 50 ml of liquid medium and grown for 
up to 3-5 days. For secondary cultures, 5 ml of densely grown primary culture was 
inoculated into 250 ml of medium and incubated overnight. The purity of the cultures 
was checked routinely with the Ziehl–Neelsen staining method. The cells were 
harvested by centrifugation at 7 000 g. The supernatant was discarded and the pellet 
frozen at -80 °C. 
 
2.2.3 Ziehl-Neelsen staining 
 
Mycobacterium smegmatis smear was dried on a slide for 3-5 min and then stained 
with Ziehl carbol fuchsin while applying enough heat for gentle steaming. The slide 
was washed with distilled water and decolorized in 95 % acid alcohol until only a 
suggestion of pink color remained. It was washed with tap water and counter-stained 
with Methylene Blue. The slide was then washed with tap H20, dried and examined 
microscopically under 1000X magnification microscopy. 
 
2.2.4 Radiolabelling of M. smegmatis 
 
                                                 
11 Water used in this project was deionized. At some point, the water was sparged with argon but it did 
not make a difference.  
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M. smegmatis cells were inoculated in Middlebrook medium. 25 ml of cells was 
diluted to 100 ml, and 20 μl 3H-myo-inositol was added. Incubation was continued for 
another 3 hours. The cells were harvested and stored at -80 °C. 
 
2.2.5 Absorbance Spectrophotometry 
 
Spectrophotometric analysis of thiols and their derivatives was performed using an 
Ocean Optics USB2000 spectrometer. For quantitation of 2-S-(2-thiopyridyl)-6-
hydroxynaphthyldisulfide, 20 μL of the sample was added to 980 μl of 25 mM 
K2HPO4 buffer, pH 8,0 and the absorbance measured at 298 nm while reducing with 
dithiothreitol (Δε =18500M-1.cm-1). 
 
For the estimation of thiol content 20 μl of a sample was added to 970 μl of 25mM 
K2HPO4 buffer, pH 8.0, followed by the addition of 10 μl of 20 mM 4,4-
dithiodipyridyl (dTdP). The thiol concentration was estimated from the resultant 
change in absorbance at 325 nm, due to the formation of pyridine-4-thione (Δε325 
=19800M-1cm-1), using an Ocean Optics Mini-diode array spectrometer. MSmB was 
also quantified spectrophotometrically by measuring absorbance at 396nm (Δε =5300 
M-1.cm-1). Eluates from chromatographic steps used in the purification of enzymes 
were monitored by measuring absorbance at 280nm. 
 
2.2.6 HPLC methods 
 
Table 2.1: Method 1: 
 
Time 0 minute 5 min 35 min 40 min 45 min 
Buffer A% 
 
95% 95% 10%  10%  95% 
Buffer B% 
 
5% 5% 90% 90% 5% 
 
The column was eluted by running this gradient at a rate of 0.8 ml/min in which 
buffer A was 0.1% TFA in water and buffer B 100% acetonitrile. This method was 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 48
also used for analysis of the dansylation reaction with TEA:Acetic acid 
(0.088%:0.57%) as buffer A in place of 0.1% TFA.   
 
Table 2.2: Method 2 (modified from Anderberg et. al, 1998): 
 
 
Time 0 minute 10 min 50 min 53 min 57 min 60 min 
Buffer A% 
 
100% 100% 40% 0% 0% 100% 
Buffer B% 
 
0% 0% 60% 100% 100% 0% 
 
Samples were injected into the Phenomenex phenyl hexyl C-18 HPLC column (250 x 
4.6mm). The column was eluted by running the gradient at a rate of 0.8 ml/min in 
which buffer A was 0.1% TFA in water and buffer B 0.1% in methanol. UV detector 
was set at 250 nm and emission at 395 nm wavelength. 
 
Table 2.3: Method 3: 
 
Time 0 minute 5 min 35 min 40 min 45 min 
Buffer A% 
 
95% 95% 55%  10%  95% 
Buffer B% 
 
5% 5% 45% 90% 5% 
 
The column was eluted for 5 mins with 5% B, for 30mins with a linear gradient to 
45%B, for 5mins to 90%B, followed by a return to initial conditions (Solvent A: 
0.1%TFA and Solvent B: acetonitrile). The flowrate was 0.8ml/min. 
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2.2.7 Preparation of Standard curves 
 
2.2.7.1 Preparation of N-Acetyl-L-Cysteine-mB Standard curve 
 
10 mM N-Acetyl-L-cysteine was prepared in 1 ml distilled water and derivatized with 
two-fold mBBr. The samples were injected into the Phenomenex phenyl hexyl C-18 
HPLC column (250 x 4.6mm). The column was eluted by running method 1 at a rate 
of 0.8 ml/min in which buffer A was 0.1% TFA and buffer B was 100% acetonitrile. 
UV wavelength detector was set at 396 nm and emission at 482 nm wavelength. The 
amounts injected were plotted against the fluorescence area of the N-Acetyl-L-
Cysteine. 
 
2.2.7.2 Standard Curve of GlcN-Ins derivatized with AccQ-Fluor 
 
 
GlcN-Ins was dissolved in water to make up 3.65 mM stock solution. Different 
concentrations ranging from 250 μM to 2000 μM were prepared in eppendorf tubes to 
the final volume of 30 μL with 200 mM Hepes buffer pH 8.0. 15 μL acetonitrile and 
15 μL of 10 mM AccQ-Fluor were added to each eppendorf tube and the reactions 
were vortexed and left standing at room temperature for 1 minute. To complete the 
derivatization the reaction mixtures were heated for 10 minutes at 60 0C. They were 
then diluted 4-fold with water and stored at -80 0C. The samples were thawed and 
injected into the C-18 HPLC column (250 x 4.6mm). The column was eluted by 
running method 2 at a rate of 0.8 ml/min in which buffer A was 0.1% TFA in water 
and buffer B 0.1% in methanol. UV detector was set at 250 nm while the fluorescent 
detector was set at 250 nm for excitation and 395 nm for emission. The amounts 
injected were plotted against the area of the peaks of AccQ-Fluor derivatized GlcN-
Ins. 
 
2.2.8 Methods for Derivatization of Amines 
 
The AccQ-Fluor method is more rapid and sensitive than the other amine 
derivatization methods, including dansylation and dabsylation of amines, used in this 
study. Thus, AccQ-Fluor was utilized throughout the kinetic analysis of inhibitors in 
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presence of Acetyl-GlcN-Ins. Dansylation was only used for the evaluation of Acetyl-
GlcN-Ins structural analogs as alternate substrates of MshB. 
  
2.2.8.1 AccQ-Fluor 
 
6-aminoquinolyl-N-hydroxysuccinamidyl carbamate (AccQ-Fluor) is a derivatizing 
agent used to perform AccQ-Tag amino acid analysis (Cohen and Michaud, 1993).   
10 mM AccQ-Fluor was purchased from Waters and reconstituted as instructed by the 
manufacturer. 50 μl of 200 mM Hepes buffer, pH 8 was added to the enzymatic 
reaction mixture and vortexed. The Hepes was found to be working better than borate 
buffer that came with the kit. 30 μl of 10 mM reconstituted AccQ-Fluor reagent was 
added and the fractions were vortexed for about 5 seconds. Fractions were incubated 
for 1 minute at room temperature followed by 10 minutes at 550C. The samples were 
analyzed by TLC or HPLC with the UV detector set at 250 nm and the fluorescent 
detector at 250 nm for excitation and 395 nm for emission. 
 
2.2.8.2 Dansylation 
 
Dansylation is one of the widely used methods for derivatization of amino acids (Gros 
and Labouesse et al, 1981). This method was used because AccQ-fluor is suitable for 
the analysis of polar amines. With apolar amines the derivatized amine co-elutes with 
a lot of interfering compounds, possibly reagent derived degradation products, and so 
the method fails. Therefore the derivatization with dansyl chloride was used as an 
alternate method for the analysis of the amide cleavage of alternate substrates of 
mshB, especially where the aglycon had no absorbance such as in the case of 
cyclohexane. 70 µL of mshB-treated Acetyl-GlcN-Ins samples were mixed with 80 
µL of 40 mM Li2CO3 pH 9.0 and 200 µL of 40 mM DnsCl. The dansylation reaction 
was kept in the dark for 1 hour and 25 µL was diluted 5-fold with 50 μL TEA:acetic 
acid (starting buffer) and 50 μL and was injected in to a Luna 5μ c-18 HPLC column 
(250 x 4.6mm). The column was eluted by running method 1. On the fluorescent 
detector emmision was set at 578 nm and excitation at 254 nm while the UV detector 
was set at 254 nm. 
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2.2.8.3 Dabsylation  
 
Derivatization of amino acids with 4-dimethylaminoazobenzene-4'-sulfonyl chloride 
(dabsyl chloride) was introduced by Lin and Chang, 1975. Dabsylation requires no 
fluorescent detector but only a UV detector set at 436 nm (Lin and Chang, 1975). An 
attempt was made to utilize this method for the evaluation of alternate substrates of 
mshB. However it was dropped since the product peaks were too small at lower 
substrate concentrations. 
 
 
2.2.9 SDS-Polyacrylamide Gel Electrophoresis of Proteins 
 
2.2.9.1 Preparation of materials 
Resolving gel buffer  
36.35g Trizma base (1.5 M) and 0.8g SDS (0.4%) were dissolved in 200ml distilled 
water. The pH was adjusted to 8.8 with concentrated HCl. 
Stacking gel buffer 
12.1g Trizma base (0.5 M) and 0.8g SDS (0.4%) were dissolved in 200ml distilled 
water. The pH was adjusted to 6.8 with concentrated HCl. 
Acrylamide-bis-acrylamide stock solution 
29.2g acrylamide and 0.8g bis-acrylamide were dissolved to 100ml distilled water. 
The solution was filtered through Whatman No 1 paper and stored in a bottle covered 
with foil at 40C.  
Ammonium persulfate solution (APS) 
10% APS was prepared by dissolving 0.05g in 500µl water. 
N N N `N`-tetramethyl-1,2-diaminoethane(TEMED) Catalyst 
TEMED Catalyst was used as a stock solution from BDH Chemicals Ltd. 
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Sample treatment buffer 
2.5 ml stacking gel buffer, 4 ml of 10% (w/v) SDS, 2 ml glycerol, 1 ml 2-
mercaptoethanol and 0.5 ml distilled water were mixed together in a bottle and stored 
at -200C. 
Coomasie blue staining solution  
1.25 g Coomasie Brilliant Blue –R250 (Merck) was dissolved in 227 ml methanol, 
227 ml water was added and the contents were mixed.  46 ml glacial acetic acid was 
added and the mixture was left standing overnight and filtered. 
Destaining solution 
The destaining solution had the composition ethanol:acetic acid: water:: 2:1:7. 
2.2.9.2 Loading the gel 
 
SDS-polyacrylamide gel electrophoresis was performed on vertical slab gels 
(Laemmli, 1970). Resolving buffer was prepared according to the table and poured in 
to the plates. It was left for 1 hour to polymerize and overlaid by a stacking buffer 
(composition in the table). 
Table 2.4: SDS Poly-acrylamide gel electrophoresis composition   
Solutions Resolving gel Stacking gel 
 12.5 % electrophoresis gel  
Resolving buffer 6.25 ml - 
Stacking buffer - 3.75 ml 
Distilled Water 8.25 ml 9.0 ml 
Acrylamide solution 10.25 ml 2.25 ml 
APS 75 µl 45 µl 
TEMED 50 µl 30 µl 
 
Protein samples were mixed with 1/10th the volume of Sample Treatment 
Buffer and heated at 80oC for 5min before loading. A tank buffer consisting 
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of 25mM Tris-Cl, 0.1% SDS, 0.19M glycine was used and gels were electrophoresed 
at 30mA. The electrophoresis Calibration Kit from Pharmacia and the Fermentas 
protein Molecular Weight Marker were used to estimate protein size. 
 
 
2.2.9.3 Visualisation of Proteins Separated on SDS PAGE 
 
Gels were stained overnight in the solution of 0.45% methanol and 0.18% glacial 
acetic acid, containing 0.25% Coomasie Brilliant Blue R250. Destaining was 
performed in the solution containing 20% ethanol and 10% acetic acid. 
 
2.2.10 Detection of Bimane-derivatives 
 
Samples derivatized with mBBr were injected onto a Phenomenex Phenyl-hexyl 
HPLC column (250 x 4.6mm). The column was eluted using Method 1 with the 
emission set at 482 and excition at 396 nm. 
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CHAPTER 3:  
SYNTHESIS OF SUBSTRATES 
 
3.1. INTRODUCTION 
 
The fact that MSH or any of its immediate precursors are not commercially available 
is a serious impediment in studies of the metabolism of this thiol. 
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2-S-(2'-pyridyl)-6-hydroxynaphthyldisulfide
 
Figure 3.1: The reaction of 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide and 
MSH.  
 
In previous studies, the chemical synthesis of MSH was reported (Jardine et. al., 
2002). However, this approach yielded only relatively small quantities of MSH. 
Steenkamp and Vogt (2004) devised a methodology used for the isolation of MSH 
from M. smegmatis at milligram levels. The method has proved useful in producing 
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reasonable amounts of MSH for further biochemical studies. The protocol is based on 
the formation of an apolar heterodisulfide, 2’-s-(mycothiolyl)-6-
hydroxynaphthyldisulfide, which is retained on C-18 reverse phase columns. After 
reduction the hydrophilic MSH is no longer adsorbed onto C-18 reversed phase resins 
while the apolar thionaphthol is retained (Steenkamp and Vogt, 2004). Because a 
quick and efficient method was required to generate substrates for the current study, 
the above procedure was used as a starting point for the purification of MSH  
 
3.2. METHODS 
       
3.2.1 Synthesis of 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide 
 
The synthesis of 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide was performed with 
modifications of the previously described method by Steenkamp and Vogt, 2004. 6-
Hydroxy-2-naphthyldisulfide (300 mg) was dissolved in 150 ml of a 1:1 (v/v) mixture 
of acetonitrile:water. The mixture was reduced by the addition of 900 mg sodium 
borohydride at room temperature, a yellow colour was observed due to the formation 
of the 2-thio-6-hydroxynaphthalene anion. The borohydride ions were destroyed by 
the addition of 3 ml glacial acetic acid and the pH of the resulting solution adjusted to 
4.6 by the addition of dipotassium phosphate. The pH of 4.6 was chosen to be 
significantly below the pKa of 2-thio-6-hydroxynaphthalene, which was estimated to 
be approximately 6.4 by spectrophotometric titration (Steenkamp and Vogt, 2004). 
 
 The 2-thio-6-hydroxynaphthalene solution was added dropwise and with stirring over 
a period of 20 min to 75 ml of a solution containing 711 mg 2,2-dithiodipyridyl in a 
1:1 mixture of acetonitrile and water. The mixture was left for 60 min and was then 
diluted with three parts of water to a final acetonitrile concentration of ~ 12.5% and 
left overnight at 40C. It was then cooled overnight at 40C. The resultant precipitate 
was collected by centrifugation and dissolved in a 60% (v/v) acetonitrile/water 
mixture. The precipitate consisted principally of 6-hydroxy-2-naphthalenedisulfide 
and 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide. These components were 
separated isocratically on a preparative Vydac TP1022 reversed-phase HPLC column 
(250 × 22 mm) with 65% acetonitrile and 35% of 0.1% Trifluoroacetic acid. The 
quantity of 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide was determined 
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spectrophotometrically as described in general methods using a molar extinction 
coefficient of 11184 M-1.cm-1 at 343 nm wavelength. The yield was 463 μmols in 470 
ml. 
 
3.2.2 Extraction of thiols from mycobacterial extract 
 
Mycobacterium smegmatis mc2 cells were purchased from the Center for Biocatalysis 
and Bioprocessing, University of Iowa, where it was grown in a 100 litre fermentor 
using the medium described by Isabelle et al. (2002). The cells (2.65kg) were 
harvested in the early stationary phase of growth and stored at -800C.  
 
M. smegmatis mc2 (138.7 g) was mixed with 1.0 g of 3H-myo-inositol radiolabeled M. 
smegmatis and suspended in 300 ml of a solution containing 0.25 M perchloric acid, 2 
mM EDTA, and 40% (v/v) acetonitrile/water. The cells were disrupted by sonication 
at an output control of 8 and duty cycle of 30 for 10 minutes. The mixture was 
clarified by centrifugation at 6 000 g for 15 minutes at Tmax of 4oC using Beckman 
Rotor JA-3050. The pellets were discarded and the pH of the clear 335 ml supernatant 
was adjusted to 4.6 by the addition TEA. To get rid of hydrogen sulphide from the 
extract, the mixture was sparged for two hours with argon. The dithiodipyridyl-
reactive thiols in the mycobacterial extract were estimated to be 462 μmols in a 
volume of 305 ml.  
 
3.2.3 Synthesis of S-2-(Mycothiolyl)-6-hydroxynaphthyldisulfide 
 
Because MSH tends to undergo oxidation reactions during storage and manipulations, 
it is usually difficult to maintain it in its reduced form. The best possible way to 
preserve this thiol at a stable form is to form the heterodisulfide, 2’-s-(mycothiolyl)-6-
hydroxynaphthyldisulfide (MSSNaph) (Steenkamp and Vogt, 2004). 
The solution that contained 462 μmols in a volume of 305 ml was added dropwise 
with stirring to 470 ml of 65% (v/v) acetonitrile/water solution containing 463 μmols 
2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide. The formation of S-2-(Mycothiolyl)-
6-hydroxynaphthyldisulfide was monitored by injecting 25 μl aliquots of the reaction 
mixture onto a Luna 5μ C-18 analytical HPLC column (250 x 4.6mm) at different 
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times of incubation. The column was eluted using method 1 (Section 2.2.6). After 25 
hours of the reaction, the mixture was diluted five-fold with water, filtered and then 
passed through SepPak C-18 cartridges. The cartridges were washed with water. 
MSSNaph was retained on the cartridge solid stationary phase and then eluted using a 
minimal quantity of 50% (v/v) acetonitrile/water. The S-2-(Mycothiolyl)-6-
hydroxynaphthyldisulfide eluted from the cartridge was bubbled with air to reduce the 
excess acetonitrile concentration in the mixture to less than 10%. 10 μl was injected 
onto a Luna 5μ C-18 analytical HPLC column (250 x 4.6mm) and eluted with method 
1. The peaks were collected and S-2-(Mycothiolyl)-6-hydroxynaphthyl disulfide 
(MSSNaph) identified by determining the radioactivity by scintillation counting. The 
concentration of MSSNaph was estimated spectrophotometrically and by recording 
the absorbance spectrum of an aliquot in 25mM K2HPO4 after reduction with 1mM 
dithiothreitol using molar extinction coefficient of 18500 mM-1 cm-1 at 298 nm. 
 
3.2.4 Synthesis of MSH 
 
The MSSNaph mixture was reduced with 25 mg sodium borohydride for one hour and 
1 ml glacial acetic acid was used to get rid of borohydride. The reduced mixture was 
run through the C-18 SepPak cartridge which had been wet with 100% acetonitrile 
and then washed with water before use. Hydrophilic MSH ran through the C-18 
SepPak cartridge while apolar thionaphthol was retained. Reduced MSH was then 
freeze-dried overnight and stored in glass vessels at 40 C. Since the addition of acetic 
acid in the sample of MSSNaph resulted in the formation of some ions such as sodium 
acetate, MSH which was now in powder form was redissolved in 5 ml water and 
injected on Vydac 218TP1022 HPLC reversed phase preparative column at 230 nm. 
The separation was achieved using the method which starts with 100% (0.1% TFA) 
until 10 minutes, followed by the gradient from 0% to 50% B (100% (CH3CN) until 
55 min and then back to 100% A at 60 minutes of the run.   
 
The reduced MSH from HPLC was quantified as in section 2.2.5. Pure MSH was then 
freeze-dried overnight and stored at 4 0C.  
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3.2.5 Synthesis of Mycothiol-Bimane 
 
MSH was redissolved in 4 ml distilled water and its pH converted to 8.0 with 
triethylamine. Monobromobimane (40 μmols) in 2 ml acetonitrile was mixed with 4 
ml of 20 μmols MSH and the mixture was left in the dark until the derivatization was 
complete. The mixture was run on reverse-phase Vydac preparative column. Pure 
MSmB eluted was collected and freeze dried overnight. MSmB was redissolved in 2 
ml distilled water and quantified spectrophotometrically using a molar extinction 
coefficient of 5300 M-1.cm-1 at 396 nm. The final MSmB concentration was 10.83 
mM in 1.8 ml. 
 
3.2.6a. Synthesis of GlcN-Ins 
 
MSmB, 10.83 mM in 1.5 ml, was incubated with 1 ml of 25 mM Hepes buffer 
containing 1 mM Zn2+, pH 7.5, at 37 C with 1 ml of partially purified amidase. The 
reaction was monitored for the formation of N-AcCys-mB using TLC. Additional 
aliquots (0.6 ml) of enzyme were added as necessary to achieve complete hydrolysis 
of the MSmB over a maximum interval of 8 hours, after which the reaction mixture 
was acidified to a pH less than 3 with perchloric acid. A 1 ml SepPak, C-18 cartridge 
(Waters) was prepared by sequentially washing with 5 ml of methanol, 5 ml of 50% 
methanol, 5 ml methanol in 0.1% trifluoroacetic acid, and 20 ml 0.1% trifluoroacetic 
acid in water. The acidified reaction mixture was applied to the SepPak C18 cartridge, 
and material not retained was freeze-dried, and resuspended in 1 ml of water.  
 
3.2.6b. Synthesis of GlcN-Ins from the thialysine derivative of MSH 
 
MSH is more reactive at slightly alkaline pH. It can undergo derivatization and 
oxidation reaction at this pH, for instance, during oxidation with diamide and 
derivatization with monobromobimane. Bromoethylamine also reacts with MSH at 
the sulfhydryl group to give a product which has an analog of lysine in its structure, 
thialysine. Since trypsin cleaves next to arginine and lysine, its enzymatic action can 
be exploited for the synthesis of GlcN-Ins by cleaving at the thialysine residue.  
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The pH of MSH was adjusted to 8.0 with triethylamine. Ten-fold excess 
bromoethylamine was added into MSH under the steam of argon to avoid oxidation. 
The reaction was left standing at room temperature to ensure all MSH has reacted 
with excess bromoethylamine to form a thialysine residue. The resultant derivative of 
MSH was then cleaved at the thialysine moiety with trypsin to give GlcN-Ins.  
 
3.2.7 Synthesis of Acetyl-GcN-Ins 
 
Acetylation of GlcN-Ins was carried out using the modification of Newton et al, 2000. 
A solution containing 5.0 μmols of GlcN-Ins was prepared by dissolving 1.7 mg 
GlcN-Ins in 1 ml of 20 mM NaHCO3 pH 8.7. A two-fold excess of acetic anhydride 
was added to the 5.0 μmols GlcN-Ins over a period of 20 minutes while stirring. The 
disappearance of amino group of GlcN-Ins was monitored by HPLC and TLC after 
derivatizing with AccQ-Flour. 
 
3.2.8 Attempted Synthesis of Sulfonamides 
 
In addition to the enzymatically synthesized GlcN-Ins, chemically synthesized GlcN-
Ins was also donated as a generous gift by Prof Stefan Oscarson of University College 
Dublin. 5 μmols GlcN-Ins was prepared by dissolving 1.7 mg in 1.0 ml of 20 mM 
NaHCO3 pH 8.7. Four-fold methanesulfonyl chloride was added over the period of 5 
minutes while stirring. The disappearance of amino group of GlcN-Ins was monitored 
by HPLC and TLC. To optimize reaction conditions, the amounts of methanesulfonyl 
chloride were varied from 1 to 10-fold relative to the GlcN-Ins and the reactions 
incubated up to 10 hours. 
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3.3 RESULTS AND DISCUSSION 
 
3.3.1 Isolation of MSSNaph and MSH using 2-S-(2-thiopyridyl)-6-
hydroxynaphthyldisulfide  
 
The methodology of isolating MSH at milligram levels involves the conversion of 
thiols in to a heterodisulfide in which a thiol partner is 2-S-(2-thiopyridyl)-6-
hydroxynaphthyldisulfide, an apolar compound with strong affinity to hydrophobic 
stationary phase. 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide was synthesized by 
reacting 6-hydroxy-2-naphthyldisulfide and 2,2-dithiodipyridyl as previously 
described (Steenkamp and Vogt, 2004).  
The mixture was loaded on a C-18 HPLC analytical column which was then eluted 
using method 1. 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide eluted at 31 minutes 
while the unreacted 6-hydroxy-2-naphthyldisulfide eluted later at the 34th minute as 
shown on the figure 3.2. The excess 6-hydroxy-2-naphthyldisulfide can be collected 
and recycled by freeze-drying.    
Tim e (m in)
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Figure 3.2: Analytical HPLC elution profile showing the reagent,  
2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide that is formed from the reaction of 
2,2-dithiodipyridyl  and 6-hydroxy-2-naphthyldisulfide (naphthyldiS). The reagent 
eluted at 31 minutes while the unreacted naphthyldiS eluted at 34 minutes.  
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2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide clearly reacts specifically with MSH 
as it is evidenced by the formation of a prominent peak of MSSNaph eluting at 19 
minutes in figure 3.3. At the end of the reaction of the M. smegmatis extract with 2-S-
(2-thiopyridyl)-6-hydroxynaphthyldisulfide, several compounds were present in the 
mixture. Pyridine-2-thione eluted within 5 minutes at 5% acetonitrile followed by an 
uncharacterized peak at about 15th minute. This peak could possibly be attributed to 
the formation of either CoASSNaph or CysSSNaph.  2-thiopyridyldisulfide eluted at 
27 minutes while excess 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide and 6-
hydroxy-2-naphthyldisulfide eluted at 31 and 34 minutes respectively.  
 
Based on the fact that the estimated amounts of the thiols in the mycobacterial extract 
were almost in equal proportion to the reagent in the reaction mixture, it was expected 
that the reagent would be consumed in the reaction. However, the size of the 
MSSNaph peak that eluted at 19 minutes did not increase any further when the 
reaction was left to continue beyond 21 hours while the reagent was still present. This 
suggests that 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide reacts specifically with 
MSH and that the equilibrium had been reached. Other possibilities may be that some 
of the MSH may have oxidised to MSSM and hence could no longer be trapped as a 
mixed disulfide.  
 
The formation of heterodisulfides containing the 2-thio-6-hydroxynaphthalene 
chromophore can be monitored either by TLC or injecting aliquots on HPLC, in each 
case without any need for derivatization. Because the heterodisulfides exhibit 
excellent chromatographic properties, the quantitation of MSSNaph can be followed 
by measuring the area of the peaks in the HPLC profiles. The method of isolating 
thiols by derivatizing mycobacterial perchlorate extracts with 2-S-(2-thiopyridyl)-6-
hydroxynaphthyldisulfide was described by Steenkamp and Vogt, 2004, in which 11.5 
μmoles was recovered as MSSNaph while 10.7 μmoles was recovered as pure MSH 
from 4.0 mg of M. smegmatis cells. This proved to be a reasonable yield compared to 
chemical methods which are costly and can take long to prepare while yielding only 
small amounts of MSH (Jardine et al., 2002). 
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Figure 3.3: Analytical HPLC elution profile of a mixture containing perchlorate 
extract of M. smegmatis and 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide (the 
reagent). The reaction progress was monitored after 30 minutes, A; 2 hours, B 
and 21 hours, C. Method 1 was used for this analysis and MSSNaph eluted after 
19 minutes. 
 
na
ph
th
yl
di
S 
re
ag
en
t 
M
SS
N
ap
h 
   
   
 
A: 30 m inutes
A 2
80
 
2-
th
io
py
rid
yl
di
su
lfi
de
 
Py
rid
in
e-
2-
th
io
ne
 
A 2
80
A : 30  m inu tes
A 2
80
re
ag
en
t 
re
ag
en
t 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 63
The perchlorate extract of M. smegmatis grown to stationary phase in the medium 
described by Isabelle et al., 2002, contained 462 μmols of 4,4-thiopyridyl reactive 
thiols from 138.7 g of cells. This was about twice the amount of thiols produced by 
the M. smegmatis cells utilized in the report by Steenkamp and Vogt, 2004, where 8.0 
μmoles was obtained from 4.0 grams. The excellent amount of thiols in this work can 
be attributed to differences between the medium and conditions used during the 
fermentor growth as opposed to growth in shake culture. 
 
The reaction of the perchlorate extract of M. smegmatis and 2-S-(2-thiopyridyl)-6-
hydroxynaphthyldisulfide gave 137.5 μmoles of MSSNaph in 208 ml, about 30% 
recovery of the thiols initially present in the extract. Although, in addition to MSH, M. 
smegmatis contains other thiols such as free hydrogen sulphide, ergotheineine and 
coenzyme A12, it is unlikely that these thiols could account for the 70% of thiols lost, 
as they are available in lower levels in the cells (Newton et al., 2006, Williams M.J, 
PhD Thesis, 2007).  
 
Most of the product loss occurred during purification which involves several 
injections on HPLC preparative column where MSSNaph peak is separated from 
other eluates such as pyridine-2-thione, 2-thiopyridyldisulfide, 6-
hydroxynaphthyldisulfide and the excess reagent as shown in figure 3.2.  
Separation on an immobilized column packed with C-18 resin could overcome 
problems associated with poor yield of thiols. This method saves time and could allow 
the running of high volume of the mixture through the resin where the impurities can 
be separated from the desired compound by eluting with corresponding percentage of 
the solvent.  
 
                                                 
12 MSH is over 10-fold more abundant than ergotheineine and hydrogen sulphide and about 6-fold 
more  than coenzyme A (Newton et al,1996, Williams M.J, PhD Thesis, 2007). 
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HPLC analytical profile of M SS-Naph
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Figure 3.4: HPLC elution pattern showing MSSNaph at 19th minute. 
 
MSH was obtained by reducing purified MSSNaph, shown in figure 3.3, with sodium 
borohydrate followed by acidifying the mixture with acetic acid. The mixture was 
separated on C-18 cartridges where hydrophilic MSH passes through while the apolar 
thionaphthol is retained. To get rid of ions such as sodium acetate, which formed 
when borohydride was destroyed with the acid, MSH that passed through the C-18 
cartridge was run on a C-18 preparative column.  
 
At the end, 120 μmols (58 milligrams)13 of pure MSH was obtained from 138 grams 
of M. smegmatis. The yield is slightly higher than the estimation by Steenkamp and 
Vogt that it would require 250 g M. smegmatis to obtain 100 mg MSH (Steenkamp 
and Vogt, 2004).   
 
Direct isolation and purification of thiols from natural sources is usually associated 
with problems such as oxidation, reversible oxidation to sulfinic acids as well as low 
concentrations of thiol species from cell-free extracts. The isolation of thiols is also 
complicated by their reactivity which result in undesirable addition reactions to 
aldehydes and activated double bonds.  
 
To circumvent these problems thiols could be converted to less labile disulfide forms 
which can be concentrated selectively. Thus MSSNaph affords a form of MSH that is 
                                                 
13 The molecular mass of MSH is 485 g/mol 
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stable to oxidation and the addition of alkylating agents. It is also considerably less 
hygroscopic than MSH and its disulfide form, MSSM. 
 
3.3.2 Synthesis of Mycothiol-Bimane 
 
mBBr is a highly efficient derivatizing agent with a broad application in biological 
procedures such as labelling of proteins, cells and thiols like GSH to form fluorescent 
derivatives (Kosower et al., 1979). The separation method of mBBr-thiols derivatives 
with HPLC was reported by Newton et al in 1981 and is still used today (Newton et 
al., 1981). Mycothiol itself was also discovered as mBBr derivative by Spies and 
Steenkamp (Spies and Steenkamp, 1994).    
 
 
Monobromobimane-derivatized MSH 
0 10 20 30 40 50
Elution Time (Minutes)
 
Figure 3.5: mBBr-derivatized MSH purified using Phenyl-Hexyl column on 
HPLC. Clear MSmB peak eluted at 17th minute. 
 
MSmB (19.5 μmols) was synthesized by derivatizing 20 μmols MSH with 2-fold 
monobromobimane (mBBr) at pH 8.0. The complete derivatization was achieved 
within 30 minutes in the dark at room temperature, and the resultant MSmB eluted as 
a sharp peak at 17 minutes on the phenyl-hexyl analytical column eluted with method 
1, figure 3.4. To get rid of excess mBBr which was still present in the mixture, the 
sample was run on a Vydac preparative column where the fluorescent peak was 
collected as pure MSmB.  
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MSmB is the best and most widely used substrate of mca not only because of its 
obvious benefit of low Km value, but because of its great separative characteristics on 
HPLC and fluorescence which makes it easily visible on the TLC under the UV light. 
The labelling procedures of thiols with mBBr are simple and can be carried out 
rapidly under physiological conditions (Kosower et al., 1979). 
 
3.3.3 Investigation of different methods for GlcN-Ins synthesis 
 
1-D-myo-inosityl-2-amino-2-deoxy-α-D-glucopyranoside (GlcN-Ins), a precursor in 
the biosynthetic pathway of MSH, was first synthesized chemically by Bornemann et 
al. In the same study it was reported that a cell-free extract of M. smegmatis catalyzes 
the ligation of cysteine, acetate and GlcN-Ins to produce MSH. In the absence of 
acetate, desacetylmycothiol, the precursor in the last step of MSH biosynthesis, 
accumulated in the reaction mixture indicating that MSH synthesis proceeds by 
sequential addition of cysteine and acetate to GlcN-Ins (Bornemann et al., 1997).  
GlcN-Ins can therefore serve as a starting point for the synthesis of several substrates 
needed to characterize MSH enzymes. Since the current study was also aimed at 
producing substrates for MSH enzymes, several methods to produce GlcN-Ins were 
investigated.  
 
3.3.3.1 Trypsin-mediated Synthesis of GlcN-Ins from MS-thialysine 
 
Trypsin is highly applied in enzymatic degradation of proteins into smaller peptides. 
This protease has high specificity, exclusively cleaving the C-terminal of arginine or 
lysine (Olsen et al., 2004).    
 
Based on the proteolytic characteristics of trypsin, a method to synthesize GlcN-Ins 
was devised in which MSH was reacted with 10-fold bromoethylamine to form 
mycothiol-thialysine (MS-thialysine) conjugate, figure 3.6. Thialysine contains a 
functional group that mimics the structure of lysine, and could be cleavable by 
trypsin.  
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Figure 3.6: The reaction of bromoethylamine and MSH to form MS-thialysine. 
MS-thialysine has the functional group that mimics lysine and could therefore be 
cleaved by trypsin. HBr is released during the formation of MS-thialysine. 
 
The HPLC elution profile of the bromoethylamine-MSH reaction is shown in figure 
3.7, where MS-thialysine peak eluted after 21 minutes as judged by radioactive 
counting. The excess free reagent eluted as an off scale peak at 5 minutes. When 
trypsin was incubated with the mixture that contained thialysine, no GlcN-Ins 
formation was evident suggesting that the lysine moiety on the substrate was not a site 
of proteolysis for trypsin. 
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Figure 3.7: Formation of MS-thialysine from the reaction of MSH and excess 
bromoethylamine. MS-thialysine eluted at 21st minute. The cleavage of MS-
thialysine was inhibited by abundant free bromoethylamine which eluted at 5 minutes. 
 
It is well established that trypsin cannot cleave the C-terminal of a lysine or arginine 
that is followed by a proline (Keil, 1992). This indicates that trypsin cleavage can be 
affected by the nature of groups neighbouring the lysine, as it is also believed that the 
trypsin activity is suppressed by the presence of acidic residues on either side of the 
cleavage site (Rodrigues et al., 2008).  
Accordingly, the disaccharide moiety of thialysine might have inhibited the 
proteolysis at the lysine cleavage site. On the other hand, it is possible that the 
presence of excessive free bromoethylamine in the mixture effected cleavage failure. 
To solve this problem, MS-thialysine should be purified first by HPLC. Thus, seeing 
that the production of GlcN-Ins by trypsin was not as quick and effective as expected, 
a different method was considered.  
 
3.3.3.2 Hydrolysis of MSmB with M. smegmatis crude extracts  
 
M. smegmatis cells which were radiolabelled with 3[H]-myo-inositol during growth as 
described in general methods were lysed as described in section 4.2.1. After 50% 
overnight ammonium sulphate saturation, the crude extracts were run through G-60 
desalting columns. The protein that eluted from these columns was used to hydrolyze 
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MSmB to GlcN-Ins and N-AcCys-mB as judged by the normal phase TLC analysis 
shown in figure 3.8.  
  
 
Figure 3.8: Normal phase TLC showing the hydrolysis of MSmB to form GlcN-
Ins and N-AcCys-mB. The separation was carried out in a solvent system containing 
2:1:1 of butanol:acetic acid:H2O. In lane 1 is the MSmB before hydrolysis; lane 2 
shows mixture of MSmB and M. smegmatis crude extract at time 0. All other lanes 
i.e, 3,4, and 5 show the product of the reaction after 17 hours of hydrolysis. GlcN-Ins, 
the other product of hydrolysis, is not visible in the TLC plate because it is not 
fluorescent. 
 
From TLC results there was a complete conversion of the amidase substrate, MSmB, 
to the mercapturic acid, N-AcCys-mB. The spots of MSmB and N-AcCys-mB gave 
the Rf values of 0.42 and 0.67 respectively.  Given that only samples attached to the 
fluorescent monobromobimane can be visualized on the TLC plate under the uv light, 
another method was needed to confirm the formation of non-fluorescent GlcN-Ins. 
Thus, the same enzymatic reaction mixture was injected on C-18 analytical HPLC 
column run at the rate of 0.8 ml/min and 0.8 ml aliquots were collected. The 3H-
radioactivity was determined on Beckman scintillation counter and the cpm (count per 
minute) units were exported and plotted on Microsoft-Exel.  
 
Because the entire substrate was consumed in the reaction mixture as shown on TLC 
above, only GlcN-Ins was expected to have radioactivity. Indeed, the results in figure 
N-AcCys-mB  
Rf = 0.67 
MSmB 
Rf = 0.42 
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3.9 confirm the presence of GlcN-Ins in fraction 17. Surprisingly, there was an extra 
peak which eluted in the 5th minute indicating that another radioactive compound was 
formed during the enzymatic reaction. Because polar compounds elute early on the 
reverse-phase resin, it was expected that the compound that eluted at 5 minutes should 
be highly polar and most likely inositol. 
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Figure 3.9: Radioactivity in the 17th fraction confirming the presence of GlcN-Ins 
after the hydrolysis of MSmB.  The radioactive peak at 5th minute is free inositol 
which resulted from the glycosidase cleavage. 
 
These results suggest that the release of free inositol during the hydrolysis of MSmB 
might have been due to glycosidase14 activity present in the M. smegmatis crude 
extracts.  
 
Although GlcN-Ins was produced using these crude extracts, substantial amount of 
yield was lost due to the release of inositol from both GlcN-Ins and MSmB. Thus, an 
extensive purification of mca was required to get rid of undesired proteins like the 
glycosidases. 
 
 
 
 
 
                                                 
14 Glycosidases are enzymes which hydrolyze the glycosidic bond between two sugars. 
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3.3.3.3 Hydrolysis of MSmB with Amidase 
 
The MSH S-conjugate amidase was purified with three different steps of 
chromatography, i.e, ion exchange, hydroxyapatite and size exclusion as described in 
chapter 4. 16.2 μmols of MSmB, 5.0 μmols Hepes buffer containing 1 μmol of Zn2+, 
pH 7.5, and 1.54 mg of amidase in a final volume of 3.5 ml were incubated at 37 C. 
At end of the reaction, as monitored by the TLC, the enzyme was deactivated by 
perchloric acid and discarded after centrifugation. The reaction mixture was applied to 
the SepPak C-18 cartridge. GlcN-Ins eluted with just water while the mercapturic acid 
was retained on the hydrophobic packing of C-18 cartridge. This method, which 
utilized purer enzyme, gave 15 μmols of pure GlcN-Ins (93% yield). A good yield of 
GlcN-Ins and the absence of free inositol at the end of enzymatic reaction indicate 
that the three-step purification of mca had been sufficient to separate mca from other 
proteins with a potential of yielding undesired results.  
The successful synthesis of GlcN-Ins was a significant boost towards characterizing 
and inhibiting MSH enzymes, particularly mshB and mca which are the main focus of 
this project. GlcN-Ins is the product of both mshB and mca and can therefore be used 
as a standard for the assays of these enzymes; on the other hand, its acetylation 
produces the substrate of mshB. 
 
GlcN-Ins can be reacted with sulfonyl chloride to form a sulfonamide which could be 
tested as mshB and mca inhibitor. Metaferia et al synthesized sulfonamides by 
attaching sulfonylchloride to the glycodic analog of MSH which contains cyclohexane 
instead of inositol and an S link in place of an O between two rings. Two of their 
compounds, 21 and 23, gave IC50 values of 90 and 120 μM against mca and 105 and 
101 μM for mshB, respectively (Metaferia et al., 2007).  
 
The sulfonamides synthesized from GlcN-Ins could provide a clue about the 
significance of inositol in inhibitors. There is a precedence of inhibitors containing 
inositol, as it was found that the 2-deoxy-2-C-alkylglucosides of myo-inositol, inhibit 
the incorporation of 3[H]-inositol by the whole cells of M. smegmatis into inositol-
containing metabolites (Gammon et al., 2003). 
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3.3.4 Acetylation of GlcN-Ins to produce the substrate of mshB 
 
Acetylation is the introduction of an acetyl functional group in to an organic 
compound, mostly, the substitution of an acetyl group for an active hydrogen atom. 
Acetic anhydride is the commonly used acetylating agent reacting with amines and 
free hydroxyls (Das et al., 2007).  
 
The acetylation of 5.0 μmols GlcN-Ins with two-fold acetic anhydride resulted in the 
formation of the Acetyl-GlcN-Ins, as confirmed by the disappearance of the amino 
group of GlcN-Ins. The HPLC results in  figure 3.10 A,  show the derivatized amino 
group of GlcN-Ins eluting at 24 minutes, while in B, the peak disappeared due to the 
complete acetylation  of the amino group. The reagent, AccQ-Fluor, elutes as multiple 
peaks at 32 and 42 minutes, while the fluorescent by-product, 6-aminoquinoline 
(AMQ), eluted at 30 minutes.  
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 Figure 3.10: A. The HPLC elution profile showing the amino group of GlcN-Ins 
derivatized with AccQ-Fluor; the peak eluted at 24 minutes. B. After acetylation, 
the peak disappeared indicating that all the GlcN-Ins was converted to Acetyl-GlcN-
Ins. The Samples were separated on the C-18 analytical column with method 2. 
 
 
A previous synthesis of Acetyl-GlcN-Ins was reported whereby 10-fold acetic 
anhydride was used to acetylate GlcN-Ins (Anderberg et al., 1998). The disadvantage 
of substantial amount of acetic anhydride in a mixture is that when the amino group 
acetylation is complete, the excess acetylating agent can acetylate the hydroxyl groups 
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on the inositol and glucosamine rings. Thus, in order to avoid such effect, in the 
current study only two-fold acetic anhydride was used to acetylate GlcN-Ins. The 
successful acetylation of GlcN-Ins was important as the product of this step was 
required in reasonable yield to be able to evaluate a library of potential inhibitors 
against mshB.      
 
3.3.5 Synthesis of sulfonamides as potential inhibitors 
 
A successful synthesis of sulfonamides is indicated by the disappearance of the amino 
group of GlcN-Ins which is reacted with a sulfonyl chloride. GlcN-Ins was dissolved 
in sodium carbonate buffer and reacted with methanesulfonyl chloride. Aliquots were 
taken from the reaction mixture at 5 minutes intervals and derivatized with AccQ-
Fluor. TLC and HPLC analysis of samples left to react up to 10 hours indicated that 
the reaction was unsuccessful. As part of optimizing reaction conditions, the amounts 
of the methanesulfonyl chloride were varied ranging from one to ten-fold relative to 
GlcN-Ins and yet no sulfonamide was formed.  
 
Sulfonyl chloride derivatives are generally prone to hydrolysis in conjugation 
reactions, and methanesulfonyl chlorides, in particular, react with water and rapidly 
become unstable when exposed to aqueous environments (Lefevre et al., 1996). 
The failure of the reaction could therefore be explained by the possibility that the 
methanesulfonyl chloride readily reacted with water in the sodium carbonate buffer 
faster than with the amino group of GlcN-Ins. As a result, several non-aqueous 
solvents such as DMSO, DCM and pyridine were tried in an attempt to dissolve 
GlcN-Ins but with no success.  
 
It would be of great interest to evaluate GlcN-Ins-derived sulfonamides as inhibitors 
against mca and mshB, however this should start with identification of a relevant 
solvent in which to dissolve GlcN-Ins. 
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CHAPTER 4:  
EXTRACTION, PURIFICATION AND INHIBITION OF 
MYCOTHIOL-S-CONJUGATE AMIDASE 
 
4.1. INTRODUCTION  
 
MSH forms S-conjugates cleavable by mca in the mycobacterial detoxification 
pathway which excretes drugs such as rifamycin and cerulenin from the cell as 
mercapturic acids (Newton et al., 2000b, Steffek et al., 2003). The mutant of M. 
smegmatis created by knocking out mca gene was more susceptible to electrophilic 
toxins such as N-ethylamalemide, iodoacetamide and chlorodinitrobenzene. The 
mutant was also found to be susceptible to oxidants such as menadione and 
plumbagin as well as to streptomycin (Rawat et al., 2006), indicating the protective 
role which mca serves in conjunction with MSH in the mycobacterial cells.  Because 
of this role, mca inhibition has received significant attention from researchers in an 
attempt to discover new drugs for TB. Some naturally occurring extracts and 
substrate-mimic compounds have shown great promise as potential inhibitors of mca 
(Nicholas et al., 2002; Nicholas et al., 2003; Fetterolf and Bewley, 2004; Metaferia et 
al., 2006; Pick et al., 2006). 
 
As part of ongoing efforts to identify more effective anti-tubercular drugs, one of the 
objectives in the current study was to evaluate novel structure-based chemically 
synthesized compounds as inhibitors of mca. This chapter, thus, focuses on the 
extraction, characterization with alternative substrate, MSSNaph, and inhibition of 
mca with the novel compounds.   
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4.2. METHODS 
 
4.2.1. Cell lysis 
 
50 grams Mycobacterium smegmatis was suspended in 160 ml of 50 mM Hepes 
buffer, pH 7.5, which contained 3 mM 2-mercaptoethanol and 0.1 Mm each of the 
protease inhibitors, TPCK, TLCK and PMSF. The cells were disrupted by sonication 
for 10 minutes with cooling on ice in 1 minute intervals and the mixture was clarified 
by centrifugation at the speed of 100 000g for 45 minutes at 40C. The pellet was 
discarded. 
 
4.2.2. Ammonium Sulfate Saturation 
 
The supernatant was brought to 15% saturation with ammonium sulphate by addition 
of the solid and incubated on ice for 1 hour. The mixture was centrifuged at 15 000g 
for 30 minutes at 40C. The pellet was discarded and the supernatant adjusted to 50% 
ammonium sulfate saturation and incubated overnight on ice. The mixture was 
centrifuged at 15 000g for 45 minutes at 40C, the supernatant was discarded and the 
pellet resolubilized in 120 ml of cold 50 mM Hepes, pH 7.5. A 1 ml stored with 20% 
glycerol at -800C for future assays. 
 
4.2.3. Ion Exchange Chromatography 
 
4.2.3.1. DEAE Cellulose column 
 
DEAE resin was suspended in 0.5 M HCl and filtered on a Buchler funnel. The resin 
was washed with deionized water until the pH of the effluent was 7.0 and then with 
100 mM and later 25 mM Tris-Cl, pH 8.0. The column was packed and equilibrated 
by elution with 5 volumes of 25 mM Tris-Cl, pH 8.0. 120 ml enzyme sample which 
had been dialyzed overnight against 25 mM Tris-Cl, pH 8.0 was loaded onto the 
column. The DEAE column (45 x 4.5 cm) was then eluted with a gradient from 25 
mM NaCl in 25 mM Tris-Cl, pH 8.0 to 600 mM NaCl in 25 mM Tris-Cl, pH 8.0 at 48 
ml/hour. 10 ml aliquots were collected and absorbance measured at 280 nm using an 
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Ocean Optics spectrophotometer. The elution profile was plotted from absorbance 
values against volume of eluent. 
 
4.2.3.2. TLC and HPLC Assay of mca  
 
Mca was assayed by following the appearance of the amino group of Gln-Ins, the 
product of amidase cleavage. Assay mixtures contained 54nmoles of MSmB, 
0.25μmoles of Na-Hepes pH 7.5, 5nmoles of ZnSO4 and the enzyme in a final volume 
of 20μl.   The reactions were incubated for 1 hour at 370C. The reactions were 
terminated by the addition of 20µl of 5%TFA and 20µl of 100% acetonitrile. 2ul from 
each reaction mixture was spotted on Silica G-60 TLC plates and dried with a hair 
drier. The TLC plate was developed using butanol:acetic acid:water :: 4:2:2. MSmB 
and N-acetylcysteinylbimane migrated with Rf values of 0.42 and 0.67 respectively 
and were visualized with a UV lamp. Fractions which indicated the amidase activity 
were further analyzed by HPLC on a C-18 Reversed phase column using method 1 
(See Chapter 2, p54). The activities for individual fractions were calculated and 
plotted to obtain a DEAE elution profile.  
 
4.2.4. Hydroxyapatite 
 
Active fractions from DEAE-Cellulose chromatography were pooled and 
concentrated by ultrafiltration using a membrane with 30 kDa exclusion limit. The 
concentrated enzyme preparation was dialyzed overnight against 10 mM potassium 
phosphate (KPi), pH 7.2 and was then loaded onto a hydroxyapatite column (2.2 x 30 
cm) that had been equilibrated with 6 volumes of the starting buffer. The column was 
eluted with a 1000 ml gradient from 10 mM to 400 mM KPi, pH 7.2 at 48 ml/hour. 
10 ml fractions were collected from the column and absorbance was measured at 280 
nm wavelength. The elution profile was plotted from absorbance measurements 
versus volume of eluent. The active fractions were pooled together, concentrated by 
ultrafiltration and stored with 20% glycerol at -200C.  
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4.2.5. HPLC Biosep SEC-S2000 
 
Active fractions were again concentrated by ultrafiltration and 100 μl mca was loaded 
onto a Biosep SEC-S2000 HPLC Column. The HPLC column was eluted with 100 
mM KPi, pH 7.2 at 1 ml/min and all tubes assayed for activity.  
 
4.2.6. Characterization of Mca  
 
4.2.6.1. Activity of Mca with MSmB  
   
Assay mixtures contained 5.65nmoles of MSmB, 0.1µmoles of Na-Hepes, pH 8.0, 
and the enzyme in a total volume of 80µl. The assay conditions were modified from 
those used for the TLC assays in section 4.2.3.2. ZnSO4 was not added because the 
earlier experiments showed no change in the amount of mca activity with or without 
Zn2+. Reaction mixtures were incubated at 37ºC for various lengths of time and the 
reactions stopped by the addition of 20µl of 0.5% trifluoroacetic acid and 20µl of 
100% acetonitrile. A 2µl aliquot was spotted onto a Silica Gel G thin-layer plate 
which was then developed using n-butanol:acetic acid: water :: 4:2:2.  
 
In the kinetic studies, the formation of N-AcCys-Bimane was quantified by HPLC. 
Reaction mixtures contained variable amounts of MSmB, 1.0 µmoles of Na-Hepes 
buffer, pH 8.0, and 7.7μg enzyme in 40 µl. Reactions were started by addition of the 
enzyme and were terminated after 10 mins by addition of 20µl of 5%TFA and 20µl of 
100% acetonitrile. The mixtures were clarified by centrifugation and the supernatant 
were injected onto the HPLC column where method 1 was run. 
 
4.2.6.2. Assessment of MSSNaph as a substrate of Mca  
 
The formation of N-AcCys-Naph was quantified by HPLC. Reaction mixtures 
contained variable amounts of MSSNaph, 1.0 µmoles of Na-Hepes buffer, pH 8.0, 
7.7μg of the enzyme in 80µl. Reactions were started by addition of the enzyme and 
were terminated after 10 mins by addition of 20µl of 5%TFA and 20µl of 100% 
acetonitrile. The mixtures were clarified by centrifugation and an aliquot was diluted 
5-fold with 0.1%TFA before injection onto a Phenomenex phenyl-hexyl HPLC 
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column (250 x 4.6mm). Method 3 was run with the absorbance detector set at 280 nm. 
The amount of product formed was determined by measuring the difference the 
MSSNaph peak areas before and after the cleavage. 
 
4.2.7. Mca inhibition reactions 
 
MSmB which had been freeze-dried was dissolved in water to make 0.4 mM.  21 
compounds, J1, J2, JDF1, JDF2, SP2, SP3, SP4, SP5, SP6, SP7, Th1, Th2, Th3, Th4, 
Th5, Th6, Th7, Vu1, Vu2, Vu3 and Vu4 were tested as inhibitors of mca. Each 
compound was tested in the presence of substrate and enzyme in a buffer. Assay 
mixtures contained 8.0 nmoles MSmB, 8.0 nmoles of an inhibitor and 1.0 µmoles of 
Na-Hepes buffer, pH 7.5, and 7.7μg mca in a final volume of 40 μl. The reaction 
mixtures were incubated for 10 minutes at 37 0C. 1.0 µmol NaCl was added to the 
assay reactions because the activities of mca with MSmB as a substrate were reported 
to be optimized at this level of ionic strength (Steffek et al., 2003). 
 
The reaction was stopped by adding 20 μ1 acetonitrile and 20 μl 5.0% TFA. The 
mixtures were centrifuged for 3 minutes at 13 000 rpm and 75 μ1 of the supernatant 
was diluted four times with 0.1 % TFA and stored at -800C. 25 μl of the sample was 
injected into the Phenomenex phenyl hexyl C-18 HPLC column (250 x 4.6mm) which 
was eluted with method 1. The HPLC conditions were as described in general 
methods section. The inhibition percentage for each inhibitor was determined by 
calculating the amount N-AcCys-mB formed relative to the control reaction. For 
control reactions everything was added except the inhibitors. 
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4.3 RESULTS AND DICUSSION 
 
4.3.1. Purification of Mycothiol S-conjugate Amidase 
 
Mca from wild type M. smegmatis was partially purified 68-fold using a three-step 
procedure and the results are summarized in table 4.1. Dialysed ammonium sulfate 
fraction was loaded on DEAE cellulose column and eluted with 25-600 mM NaCl 
gradient.  
 
 
Figure 4.1: Elution pattern of mca eluted with 25-600 mM NaCl gradient on 
DEAE cellulose column. 
 
 
The protein content from 10 ml gradient fractions is shown in figure 4.1 which also 
shows a band of activity spread between tubes 45 and 58. 59 mg of the protein with 
specific activity of 205.7 nmol/min/mg was generated in 138 ml from this purification 
step (table 4.1).  
 
 In view of the fact that the amidase activity eluted with the largest peak between 
tubes 30 and 60 where most of the bacterial protein content also eluted, more steps 
were required to further purify mca from other proteins present in the mixture (lane 3, 
figure 4.4). The active fractions were pooled, concentrated by ultrafiltration on an 
Amicon membrane with a 30kDa molecular size cut-off and dialyzed overnight 
against 10 mM Potassium phosphate (KPi), pH 7.2.  
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The enzyme preparation was then loaded onto a hydroxapatite column which had 
been equilibrated with the same buffer. 
 
 
 
Figure 4.2: Amidase purification on Hydroxyapatite.  
 
In the first isolation of mca from M. smegmatis by Newton and coworkers, DEAE 
650C, phenyl sepharose and sephadex G-100 were used to purify the enzyme 
(Newton et al., 2000b). In the current work, hydroxyapatite was preferred in favour of 
phenyl sepharose because of a dramatic drop of activity encountered during the first 
purification attempt using the latter method. It was not surprising to lose activity 
during chromatography on phenyl sepharose, since partial denaturation of proteins 
during hydrophobic interaction chromatography is known to occur (Jungbauer et al., 
2005).  
 
Chromatography on hydroxyapatite was found to be useful in separating proteins 
which eluted in the first 10 fractions and between fractions 20 and 50 (figure 4.2).  
The amidase activity eluted in fractions 11 to 18 from which 27 mg of protein with a 
specific activity of 433 nmol/min/mg was recovered in 80 ml (table 4.1). Some 
activation of the enzyme occurred during purification as shown by increase of the 
total activity in the DEAE and hydroxyapatite step. In their work on mca from M. 
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smegmatis, Newton et al in 2000 also observed some activation, going through their 
DEAE and Phenylsepharose steps (Newton et al., 2000b).  
Judged from the HPLC elution profile (figure 4.5), it seemed at this stage of 
purification that a glycosidase responsible for inositol cleavage, as dicussed in section 
3.3.3.2, had been separated. Since the release of free inositol from MSmB was the 
main impediment, it appeared that the mca obtained from hydroxyapatite was 
sufficiently pure to be used for the synthesis of GlcN-Ins.     
 
Table 4.1: Purification of Mycothiol S-conjugate Amidase (mca) from 
Mycobacterium smegmatis 
 
 
100 μl mca from hydroxyapatite was loaded onto a Biosep SEC-S2000 HPLC 
Column which was eluted at 1 ml/min with 100 mM KPi, pH 7.2. 1.0 ml aliquots 
were collected until 25 minutes and assayed for amidase activity, which eluted at the 
8th minute (figure 4.3).  
 
Purification Step Protein 
Concentrati
on 
   
(mg/ml) 
 
Volume 
of 
enzyme 
 
(ml) 
Total 
Protein  
 
 
(mg) 
Activity 
3ul 
enzyme  
Assay  
(nmols/
min)  
 
Total 
Activity 
 
 
(nmols/
min) 
Specific 
Activity 
 
 
(nmol/mg/
min) 
Purification 
Factor 
 
 
SA/SA 1 
Extract 5,00 195 ml 975  0.0948 6162 6.32 1 
50%AmSO4 21.8 20 ml 438 0.236 1576 3.59 0.57 
Dialysis 15.6 19 ml 295.4 0.262 1662 5.63 0.89 
DEAE 0.43 138 ml 59.1 0.264 12159 205.7 32 
Hydroxyapatite 0.338 80 ml 27.07 0.45 12000 433 68 
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Elution pattern of mca on Biosep sec-2000 HPLC 
column
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Figure 4.3: Elution pattern of 100 μl mca loaded on Biosep SEC-S2000 HPLC 
Column. The HPLC was run at 1 ml/min and all fractions assayed for activity. The 
activity was found in fraction 8 as indicated with a red dot in the chromatogram.  
 
When analyzed by SDS-PAGE (which was performed as described in section 2.2.9 in 
the general methods), a significant separation was achieved on HPLC Biosep SEC-
S2000 in which a dominant band was viewed at 36 kDa (lane 1, figure 4.4), 
corresponding to the molecular mass of mca (Newton et al., 2000b).  
 
                                            
 
Figure 4.4: SDS-PAGE showing purification of mca from M. smegmatis. 
The purification of mca is shown in lanes 1,2 and 3 corresponding to HPLC Biosep 
SEC-S2000, hydroxyapatite and DEAE cellulose, respectively. In lane 4 is the protein 
marker. 
 
Judged by the HPLC analysis, the pure protein that eluted from Biosep SEC-S2000 
gave significantly low levels of amidase activity, even after it was concentrated by 
ultrafiltration. Possible justification for the loss of activity may be that the HPLC and 
66 kDa 
45 kDa 
35 kDa 
25 kDa 
18 kDa 
mca 
1   2    3          4         
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the elution buffer, both at room temperature, were not set at optimal conditions for the 
enzyme activity. In some instances, during the assays of the activity, it was 
established in this study that extensive dilution of enzymes with water results in 
reduced activity. However, this effect was not expected with mca from Biosep SEC-
S2000 since the dilution was done in the relevant buffer. Therefore, seeing that a lot 
of activity was lost in this step, the characterization of the enzyme was perfomed with 
the partially purified mca from the hydroxyapatite column. 
 
4.3.2. Amidase activity assays  
 
During isolation of the enzyme its presence in column effluents was ascertained by 
detection of the bimane derivative of N-acetylcysteine, as a product of the amidase 
cleavage of MSmB, by thin layer chromatography. MSmB and N-AcCys-mB 
migrated with Rf values of 0.42 and 0.67, respectively.  For kinetic quantification, 
HPLC peak areas were used to determine the amount of product formed with 
reference to the standard curve constructed using N-AcCys-mB. 
 
HPLC assay of hydrolysis of MSmB with mca
0 5 10 15 20 25 30 35 40
Elution Time (Minutes)
 
Figure 4.5: HPLC elution profile of MSmB after hydrolysis with mca. 
On the reverse-phase column with method 1, MSmB and N-AcCys-mB eluted at 17 
and 19 mins respectively. 
 
Method 1 was run on a C-18 phenyl-hexyl analytical column at 0.8 ml/min with 0.1% 
TFA and 100% acetonitrile. Under these conditions MSmB eluted at 17 mins and the 
product, N-AcCys-mB at 19 mins. 
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4.3.3. Enzyme kinetics and substrate specificity 
 
S
S
OH
M
MSSNaph
N
N
O
O
S M
MSmB
 
Figure 4.6: Structures of bimane derivative of MSH, MSmB, and the 
heterodisulfide, MSSNaph. 
 
4.3.3.1. Activity of mca with MSmB 
 
Different values for the kinetic parameters of mca have been reported in the literature. 
The Km of mca from M. tuberculosis was almost two-fold higher than that reported 
for the same enzyme from M. smegmatis (Newton et al., 2000b; Steffek et al., 2003). 
In addition, the double reciprocal plots for the competitive inhibition of mca by 
bromotyrosine-containing natural products, compound 5 and psammaplysin A, in the 
presence of MSmB, intersected at the origin (Nicholas et al., 2002). This indicated 
that the Km value in their study would be different from the other two obtained in the 
studies by Newton et al. (2000) and Steffek et al. (2003). Kinectic parameters of 
MSmB cleavage with mca were reported to be sensitive to assay conditions, including 
temperature and the ionic strength (Steffek et al., 2003). The discrepancies may 
therefore exist due to different conditions used in different laboratories.      
  
In the present study, the enzymatic assays were carried out at 370C in the presence of 
50 mM Hepes and 50 mM NaCl, and the following kinetic values were obtained: Km 
= 187.6 ± 19.3 μM, Vmax = 64.2 ± 5.5 nmols/min/mg. The Km value is comparable to 
the 160 ± 40 μM previously obtained with the same conditions (Steffek et al., 2003).  
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Figure 4.7: Lineweaver-Burk plot of mca with MSmB as a substrate.  
 
4.3.3.2. Activity of mca with 2-S-mycothiolyl-6-hydroxynaphthyldisulfide  
 
The evaluation of the heterodisulfide, 2-S-mycothiolyl-6-hydroxynaphthyldisulfide 
(MSSNaph) (figure 4.6) as a substrate of mca was carried out as described in the 
methods. The hydrolysis gave the two products, GlcN-Ins and N-AcCys-Naph, which 
are easily separated by means of SepPak cartridge. When analyzed by HPLC using 
Phenomenex phenyl-hexyl column and Method 3, MSSNaph eluted at 29 mins and 
the product, N-AcCys-Naph at 37 mins. The kinetic constants were determined from 5 
substrate concentrations ranging from 88 to 350 μM using Lineweaver-Burk plot. The 
Km value was found to be 328 ± 22 μM, and the Vmax of 189.6 ± 33 nmols/min/mg. 
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Figure 4.8: Lineweaver-Burk plot of mca with MSSNaph as a substrate. 
 
MSSNaph is produced as a product of the thiol-disulfide exchange reaction in the first 
step of the preparation of mycothiol from natural sources (Steenkamp and Vogt, 
2004). The synthesis of MSSNaph, as discussed in section 3.3.1, is simply achieved 
by reacting 2-S-(2-thiopyridyl)-6-hydroxynaphthyldisulfide with the perchlorate 
extract of Mycobacterium smegmatis followed by the purification on a reversed phase 
resin. It is, therefore evident that MSSNaph affords not only a convenient route to 
MSH by reduction, but also a convenient route to Gln-Ins by amidase cleavage using 
mca. 
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4.3.4. Inhibition of Mycothiol S-Conjugate Amidase 
 
 Table 4.2: Inhibition of Mca by Thioglycosides 
O
OH
HO
HO
R1R2
NO2
O2N
S
O
O
H3C
HO
S
S
S
S
NH
O
NH
O
NH
O
NH
O
NH
O
Cl
R1 R2
S NH
S NH
S S
CH3
OO
NH
S N
HH2CN
NH
NH
OS
J1
A1120
JDF1
JDF2
SP2
SP3
SP4
SP5
SP6
SP7
0%
27%
0%
0%
17%
0%
0%
0%
7%
15%
Mca Inhibtion
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 Table 4.3: Inhibition of Mca by Naphthoquinones 
 
O
OH
HO
HO
NH
R
O S
O
O
OH
O
O OH
O
O
OH
O
O OH
Mca Inhibition
29%
38%
23%
44%
R
Vu2
Vu3
Vu4
Vu5
 
 
 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
 90
Table 4.4: Inhibition of Mca by O-glycosides 
 
O
OH
HO
HO
OR
OH
O
O
O
Th1 (β-linkage)
Th2
Th3
Th4
Th6
Th5
Th7
R Mca Inhibition
9%
74%
22%
20%
17%
19%
35%  
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Figure 4.9: The inhibition of mca with MSH structural analogs.  
Twenty one compounds were tested at 200 μM for inhibition of mca using HPLC 
assays. The experiments were performed in the presence of 200 μM MSmB. The bars 
represent the average of duplicate assays and the errors were within 10% of the 
indicated values.   
 
A total of 21 chemically synthesized MSH analogs, grouped as thioglycosides, 
naphthoquinones and O-glycosides, were tested as inhibitors of mca at 200 μM using 
HPLC assays in presence of 200 μM MSmB as a substrate. Th2 exhibited the highest 
activity against mca giving 74% inhibition indicating that the substitution at position 3 
of the glucose by an allyl group to form compounds like Th2 favours the binding of 
the scaffold to the mca active site. Nevertheless, Th1, which is similar to Th2 except 
that the cyclohexane is β-linked to the glucose moiety, exhibited poor inhibition of 
less than 10% against mca indicating that the α-linkage is preferable for the binding in 
the active site. The high inhibition exhibited by Th2 against mca clearly suggests an 
interaction with specific amino acids in the active site. Due to limited amount of the 
compound, further kinetic studies could not be carried out for Th2. Thus for future 
work, Ki determination and docking of Th2 in the active site of mca could establish 
its nature of inhibition.  
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The naphthoquinones, Vu5 and Vu3 which inhibited mca by 44% and 38% 
respectively, gave the second highest inhibition of mca after Th2, indicating that the 
quinone groups may be interacting with specific amino acids in the active site of mca. 
Also mca generally recognizes MSH conjugated to hydrophobic S-conjugates. So it is 
likely that the naphthoquinone motif, due to its hydrophobic characteristics, occupies 
the binding site where the S-conjugate of the natural substrate normally bind.   
 
Because of the high homology and similarities in substrate preference between mca 
and mshB, the compounds tested as mca inhibitors were also evaluated against the 
activity of the deacetylase. The next chapter is therefore dedicated to the 
characterization and inhibition of mshB with chemically synthesized structure-based 
compounds.    
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CHAPTER 5:  
EXPRESSION, PURIFICATION AND INHIBITION OF 
THE RECOMBINANT ACETYL-GLCN-INS 
DEACETYLASE  
 
5.1. INTRODUCTION 
 
Recently Metaferia and co-workers described the inhibition of mshB with natural 
product-inspired inhibitors which were grouped as heterocycles, amines and 
sulfonamides (Metaferia et al., 2007). The compounds tested by these researchers 
included structural features of groups which were previously shown to inhibit mca 
(Nicholas et al., 2003). These compounds inhibited mshB at micromolar 
concentrations, i.e, IC50 ranging from 105 to 7 μΜ and furher provide the basis for 
further development of more potent inhibitors against mshB (Metaferia et al., 2007). 
The synthesis of bicyclic thioglycoside mimics of N-acylated glucosamine has been 
described and these compounds were proposed to be potential inhibitors of the MSH 
biosynthetic enzymes (Slättegård et al., 2007). It remains to be explored whether these 
compounds are competitive inhibitors of mshB.  
 
In the present study the structural analogs of Acetyl-GlcN-Ins were evaluated as 
alternative substrates of mshB. In addition a library of chemically synthesized 
structure-based compounds which include thioglycosides, naphthoquinones and O-
glycosides were evaluated as inhibitors of mshB. The docking of best inhibitors to 
mshB is also reported. 
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5.2. METHODS 
 
5.2.1. Induction of MshB 
 
20 μL of E.coli BL21 pLysS glycerol stock was inoculated into 5 ml LB medium 
containing 34 μg/ml chloramphenicol and 50 μg/ml ampicillin. The cells were 
incubated at 37 0C on an orbital shaker until the OD600 reached 0.6. The cells were 
stored overnight at 4 0C and inoculated into 5 ml fresh medium containing the same 
amount of ampicillin and chloramphenicol. 
 
The cells were then inoculated into 50 ml of the same medium and incubated at 37 0C 
until the 0D600 reached 0.6. IPTG was added to a final concentration of 0.4 mM and 
the incubation continued for 3 hours at 18 0C. Aliquots were withdrawn at 1 hour 
intervals for analysis. The flasks were placed on ice for 5 minutes and harvested by 
centrifugation at 5000 x g for 5 minutes at 4 0C. The supernatant was discarded and 
pellet stored at -80 0C.   
 
5.2.2.1 Cell lysis 
 
3.5 grams of induced E.coli BL21 pLysS cells were suspended in 20 ml of lysis 
buffer, which contained 50 mM NaCl and 1.0 mM each of the protease inhibitors, 
TPCK, TLCK and PMSF in 50 mM Hepes, pH 7.5. The cells were then sonicated on 
ice for 10 minutes while monitor the temperature at 30 seconds interval. The mixture 
was clarified by centrifugation at 15 000 g for 30 minutes at 40C and the supernatant 
was diluted twice with 25 mM Tris-Cl, pH 8.0. 
 
5.2.2.2 Activity assay with Thin Layer Chromatography 
 
The GlcN-Ins produced by deacetylation was determined using minor modifications 
of method reported elsewhere (Anderberg et al, 1998). 5 μl Acetyl-GlcN-Ins was 
alliquoted into 1.5 ml an eppendorf tube and 5 μl 20 mM Hepes buffer, pH 8.0 
containing 5.0 μM zinc sulphate was added to each reaction mxture.  
The derivatization with AccQ-Fluor was carried out as described in the general 
methods. 2 μl from each derivatized enzymatic reactions were spotted on the Silica 
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Gel TLC plates containing a 254 nm fluorescent indicator. The TLC was developed 
with 4:2:2 butanol:acetic acid:water and visualized under the UV light. 
 
5.2.3. Ion exchange chromatography 
 
DEAE sepharose column (45 x 4.5cm) was packed and equilibrated by washing with 
6 volumes of starting buffer, 25 mM Tris-Cl, pH 8.0. 42 ml enzyme was loaded and 
eluted with 350 ml of 25 mM NaCl in 25 mM Tris-Cl, pH 8.0. And then with a 1 litre 
gradient from 25 mM to 600 mM NaCl in 25 mM Tris-Cl, pH 8.0. 9.0 ml fractions 
were collected. The enzymatic reaction was initiated by addition of 20 μl aliquots 
obtained from the fractions obtained from DEAE-sepharose. Every 5th fraction was 
assayed until the 180th fraction.  
 
5.2.4. Immobilized Metal Ion Affinity Chromatography 
 
Active fractions which eluted from the DEAE sepharose column were pooled and 
concentrated from 80ml to 18ml by ultrafiltration using a 30 000 daltons cutoff 
membrane. The preparation was then dialysed overnight against 1 litre of 50 mM 
phosphate buffer, pH 7.0 containing 0.5 M NaCl. 
  
Iminodiacetic acid agarose resin was packed on to the column with the dimensions: 
1.6 x 12.5 cm, and 50 mM ZnSO4 was run through the column followed by 
equilibration with starting buffer, 50 mM phosphate, pH 7.0 containing 0.5 M NaCl. 
The preparation obtained from DEAE-Sepharose was applied to the column and 
washed with 75 ml of 1 mM imidazole in 50 mM K-phosphate buffer, pH 7.0 
containing 0.5 M NaCl. The column was then eluted with a gradient from 1 to 20 mM 
imidazole in the starting buffer. Fractions were collected and assayed for protein by 
absorbance at 280 nm and for enzyme activity. 
 
5.2.5. Size Exclusion Chromatography 
 
The 32 ml fraction was ultrafiltered with 30 000 cut off membrane. The resultant 8.0 
ml was loaded on Sephacryl 300 size exclusion column (95 x 0.9 cm) and eluted with 
50 mM K-phosphate buffer, pH 7.0. 10 ml fractions were collected and the elution 
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pattern was plotted with absorbace at 280 nm. 7.0 ml of a pure mshB was mixed with 
1.8 ml glycerol and stored at -20 0C.  
 
5.2.6. Km determination of Acetyl-GlcN-Ins  
 
 
Assay mixtures contained 1.0 μmoles of Hepes buffer pH 7.5, 1.0 μmoles of NaCl, 
3.26 µg (2 µl of 1.63 mg/ml) of mshB and Acetyl-GlcN-Ins in a concetration range of 
50-2000 µM in the final volume of 40µl. The mixtures were incubated for 10 minutes 
at 37oC. The reaction was terminated by the addition of 20 µl acetonitrile and 20 µl 
0.1% TFA were added to stop the reaction followed by the heating for 10 minutes at 
60 oC. After cooling for 5 minutes on ice the mixtures were centrifuged for 3 minutes 
at 13 000 r.p.m. 70 µl of the supernatant was derivatized with AccQ-Fluor as 
described in the general methods. The samples were then analyzed by HPLC for Gln-
Ins, as the AccQ-fluor derivative, using a C-18 column and method 2.  
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5.2.7. Evaluation of thiophenyl-containing compounds as mshB substrates 
 
O
OH
HO
HO
SNHO
O
OH
HO
HO
SNHO
O2N
NO2
SO
OH
HO
HO
NH
O
O
OH
HO
HO
NH
O
S
N-(tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-
2-(phenylthio)-2H-pyran-3-yl)acetamide (MCL2)
N-(2-(2,3-dinitrophenylthio)-tetrahydro-4,5-dihydroxy
-6-(hydroxymethyl)-2-H-pyran-3-yl)acetamide (J1)
N-(tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-
2-(phenylthio)-2H-pyran-3-yl)acetamide (JDF1)
N-(2-(benzylthio)-tetrahydro-4,5-dihydroxy-6-
(hydroxymethyl)-2H-pyran-3-yl)acetamide (JDF2)
 
Figure 5.1: Compounds tested as substrates of MshB. 
MCL2, JDF1 and JDF2 were chemically synthesized in the laboratory of Prof David 
Gammon, Chemistry department, University of Cape Town. J1 was synthesized in the 
laboratory of Dr Anwar Jardine, Chemistry department, University of Stellenbosch. 
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Stock solutions of MCL2, JDF1, JDF2 and J1 (5.0 mM of each) were prepared in 20% 
acetonitrile and distilled water. Each compound was evaluated separately as a 
substrate of mshB. For the compounds which were cleavable by the enzyme, the 
kinetic constants were determined by assaying at the following substrate 
concentrations: 250 µM, 500 µM, 750 µM, 1000 µM, 1250 µM, 1500 µM, 1750 µM 
and 2000 µM. The assay mixtures contained 1 µmol NaCl, 1 µmol Hepes buffer, pH 
7.5, the substrate and 8.15 µg (5 µl of 1.63 mg/ml) of MshB in a total volume of 40 
µl. The mixtures were incubated for 10 minutes at 370C.  
 
The reactions were then terminated by addition of 20 µl TEA:acetic acid 
(0.088%:0.57%) and 20 µl of 100% acetonitrile and the samples were injected onto a 
Phenomenex Luna C-18 HPLC column (250 x 4.6mm) which was eluted using 
method 1. To quantify the amounts of product formed, the reactions were left to go to 
completion with known amounts of substrate to construct a calibration curve. 
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5.2.8. Evaluation of cyclohexane-containing compounds as mshB substrates 
 
O
OH
HO
HO
S
O
Me
HO
O
NH
O
O
OH
HO
HO
ONH
O
O
OH
HO
HO
SNH
O
O
OH
HO
HO
SNH
O
Cl
N-(2-(cyclohexyloxy)-tetrahydro-4,5-dihydroxy-
6-(hydroxymethyl)-2H-pyran-3-yl)acetamide (MCL1)
N-(2-(cyclohexylthio)-tetrahydro-4,5-dihydroxy-
6-(hydroxymethyl)-2H-pyran-3-yl)acetamide (SP1)
2-chloro-N-(2-(cyclohexylthio)-tetrahydro-4,5-dihydroxy-
6-(hydroxymethyl)-2H-pyran-3-yl)acetamide (SP2)
N-(tetrahydro-4,5-dihydroxy-6-(hydroxymethyl)-2-(tetrahydro-5-hydroxy-6-
methoxy-2H-pyran-3-ylthio)-2H-pyran-3-yl)acetamide (A1120)
 
Figure 5.2: Compounds tested as substrates of MshB. 
MCL1 was synthesized by Prof D. Gammon Chemistry department, University of 
Cape Town. SP1 and SP2 were chemically synthesized in the laboratory of Prof 
Spencer Knapp, Rutgers State University of New Jersey. A1120 was synthesized in 
the laboratory of Dr Anwar Jardine, Chemistry department, University of 
Stellenbosch. 
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Each of the cyclohexane-containing compounds, MCL1, SP1, SP2 and A1120 was 
evaluated separately as a substrate for MshB. The reaction mixtures contained 
variable substrate concentrations ranging from 150-2000 µM. The assay mixtures 
contained 1 µmol NaCl, 1 µmol Hepes buffer, pH 7.5, the substrate and 8.15 µg (5 µl 
of 1.63 mg/ml) of mshB in a total volume of 40 µl. The mixtures were incubated for 
10 minutes at 370C. The reactions were terminated as described in section 5.2.7. 
The dansylation reactions where carried out as described in the general methods. The 
column was eluted by running method 1 at a rate of 0.8 ml/min in which buffer A was 
TEA:acetic acid (0.088%:0.57%) and buffer B was 100% acetonitrile.  
 
5.2.9. MshB Inhibition reactions 
 
21 compounds, J1, J2, JDF1, JDF2, SP2, SP3, SP4, SP5, SP6, SP7, Th1, Th2, Th3, 
Th4, Th5, Th6, Th7, Vu1, Vu2, Vu3 and Vu4 were tested as inhibitors of mshB. In 
each reaction mixture, 5 µL of 1.63 mg/ml mshB, inhibitor at final concentration of 
500 μM  and the substrate, Acetyl-GlcN-Ins, also at final concentration of 500 μM 
were mixed with 1 µmol NaCl and 1 µmol Hepes buffer, pH 7.5 in a final volume of 
40 μL. Mixtures were incubated for 10 minutes at 37oC. 20 µL acetonitrile and 20 µL 
0.1% TFA were added to stop the reaction followed by the heating for 10 minutes at 
60 oC. After cooling for 5 minutes on ice the mixtures were centrifuged for 3 minutes 
at 13 000 rpm.  
 
70 µL of the supernatant was mixed with 45 µL of 200 mM Hepes, pH 8.0, and 20 µL 
acetonitrile. After vortexing for 5 seconds 15 µL of 10 mM AccQ-Fluor was added to 
start the derivatization reaction. The mixture was vortexed briefly and left standing at 
room temperature for 1 minute followed by heating at 60 0C for 10 minutes. The 
samples were diluted 2-fold with distilled water and stored at -80 0C. 100 µL was 
injected injected on HPLC where method 2 was run. The inhibition percentage for 
each inhibitor was determined by calculating the amount of GlcN-Ins formed as an 
AccQ-Fluor derivative relative to the control reaction. Control reactions were treated 
the same way except for the addition of inhibitors.  
 
 
5.2.10. Determination of Inhibition constants of MshB Inhibitors 
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The inhibtion constants (Ki) of compounds which gave more than 50% inhibition 
against mshB were determined by HPLC using the same procedure as in section 5.2.9. 
The inhibition assays were performed by keeping the enzyme concentration constant 
and varying the inhibitor concentrations. The Ki value for Vu2 was determined at the 
following inhibitor concentrations: 25, 50, 100 and 200 μM; and for Vu3 and Vu4, the 
inhibitor concentrations were 50, 100, 150 and 200 μM. For Vu5, the inhibitor 
concentration range was 10, 25, 50 and 100 μM. All assays were performed in 
presence of the substrate, Acetyl-GlcN-Ins, at the following concentrations: 50, 60, 
80, 100 and 250 μM.   
 
5.2.11. Docking of Inhibitors to MshB 
 
The x-ray crystal structure of MshB (Maynes et al., 2003), was selected for docking 
of the inhibitors, Vu2 and Vu5. In silico experiments were performed using Accelrys 
Dicovery Studio 17 protocol.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
5.3 RESULTS AND DISCUSSION 
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5.3.1. Expression of MshB 
 
MshB was first cloned by Newton and coworkers in the expression vector pET16b, 
and found to be active in E. coli crude extracts. However, the protein lost activity 
during purification due to appearance of another smaller protein, 26 kDa, which was 
also found in elevated levels and was speculated to be a degradation product of the 
deacetylase (Newton et al., 2000). The degradation was circumvented when mshB 
was cloned to contain a C-terminal His-6 tag where a pure protein was obtained with 
10-fold higher activity than the previous attempt (Newton et al., 2006). 
 
 
Figure 5.3: SDS-PAGE (prepared as described in section 2.2.9 in the general 
methods) of mshB before and after induction. The lanes 1 and 2 show the 
supernatant and pellet of samples induced with IPTG for 3 hours. Lanes 3 and 4 show 
the supernatant and pellet after 2 hour induction and 5 and 6 after 1 hour of induction. 
In lanes 7 and 8 is the supernatant and pellet of uninduced samples and the protein 
marker is in lane 9. 
 
In the current study mshB, which had been cloned into the expression vector pET17b, 
was transformed into E. coli BL21 (DE3). After induction with IPTG for 3 hours the 
mshB band could be observed at 33 kDa on SDS-PAGE (figure 5.3) 
 
 
 
94 kDa 
67 kDa 
43 kDa 
30 kDa 
MshB 
33 kDa 
     Lanes: 1         2       3        4       5      6       7        8              9 
20 kDa 
        14 kDa 
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5.3.2 Purification of MshB 
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Figure 5.4: Elution of mshB from DEAE Sepharose column.  
 
Recombinant mshB was purified 28-fold using a three-step procedure and the results 
are summarized in table 5.1. The crude extracts were applied to a DEAE Sepharose 
column and eluted with A 1 litre of a 25-600 mM NaCl gradient. The protein content 
from 9 ml gradient fractions is shown in figure 5.4 which also shows a peak of 
activity which eluted between fractions 92 and 101. The deacetylase cloned in the 
expression vector pET17b was previously reported to behave as a dimer (Newton et 
al., 2006), and in the current study an additional minor deacetylase activity was also 
found in a small peak from 103 to 110. However, only fractions from the sharp peak 
were pooled together for further analysis. From this purification step, 99.9 mg of 
protein with a total activity of 1321 nmol/min and the specific activity of 13.2 
nmol/min/mg was obtained.  
 
After overnight dialysis against 50 mM phosphate buffer, pH 7.0, containing 0.5 M 
NaCl, the enzyme was applied to a Zn-IMAC affinity column (1.6 x 12.5 cm) and 
eluted with 1 to 20 mM imidazole gradient. 
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Figure 5.5: The elution pattern of mshB from IMAC column. 
The protein content is plotted in blue and the deacetylase activity in red. The activity 
was found in fractions 2-6. 
 
 
The deacetylase activity eluted in fractions 2, 3, 4, 5 and 6 (figure 5.5), indicating that 
the enzyme did not bind to the IMAC resin with Zn but eluted with 1 mM imidazole. 
The purity of these fractions was assayed by SDS-PAGE (figure 5.6, lanes 5-9) where 
a molecular mass of 33 000 Da was obtained. Although the fractions were still 
contaminated with E. coli proteins, the a finity chromatography proved useful in 
separating smaller peaks which eluted between fraction 25 and 30 as well as between 
fraction 63 and 65 in figure 5.5. 58.16 mg of protein with the total activity of 783.2 
nmol/min and a specific activity of 13.5 nmol/min/mg was generated from this 
purification step. 
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Figure 5.6: SDS-PAGE analysis of mshB with bands stained with Coomassie 
blue. Lane 1, protein marker; lane 2, crude extract; lane 3, DEAE sepharose before 
dialysis; lane 4, DEAE after dialysis against 50 mM phosphate buffer, pH 7.0, 
containing 0.5 M NaCl; lanes 5-9, IMAC active fractions 2, 3, 4, 5 and 6.  
 
The active fractions from the IMAC coumn were pooled and concentrated by 
ultrafiltration to 8 ml which was loaded on Sephacryl S-300. The deacetylase activity 
was recovered in fractions 12 to 16 which corresponded to the only protein in the 
purification profile in figure 5.7.  
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Figure 5.7: Purification of mshB on Sephacryl S-300. The activity, shown in red, 
eluted in fractions 12 to 16, coinciding with the only protein peak, shown in blue. 
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Figure 5.8: SDS-PAGE analysis of M. tuberculosis mshB.  
Lane 1, protein marker; lane 2, crude extract; lane 3, DEAE sepharose; lane 4, IMAC; 
lanes 5-9, fractions 12, 13, 14, 15 and 16 from Sephacryl S-300. 
 
SDS-PAGE analysis of fractions from Sephacryl S-300 showed that fractions 12 and 
13 were still contaminated with E. coli proteins, but fractions 14, 15 and 16 gave a 
single band with molecular mass of 33 kDa, indicating that mshB was successfully 
purified (figure 5.8). The pure fractions were pooled and concentrated by 
ultrafiltration. The pure mshB was mixed with 20% glycerol and frozen at -20 0C. The 
purification of mshB is summarized in table 5.1. There was about 4-fold activation of 
the enzyme through IMAC and Sephacryl S-300. It is not clear what caused such 
activation but in their work during the purification of mca from M. smegmatis, 
Newton et al in 2000 also saw some activation, but by a factor of 1.5 going through 
their DEAE and Phenylsepharose steps. 
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Table 5.1: Purification of recombinant M. tuberculosis mshB  
 
 
5.3.3. Formation of GlcN-Ins following the deacetylation of Acetyl-GlcN-Ins 
 
The deacetylation of Acetyl-GlcN-Ins with MshB was assayed by normal-phase TLC 
during purification of the enzyme and by HPLC for quantitative analysis as described 
in the general materials and methods (section 2.2.8.3). The scheme in figure 5.9 
illustrates the derivatization of GlcN-Ins with AccQ-Fluor. 
 
 
  
Purification 
Step 
Protein 
Concent
ration 
(mg/ml) 
 
Total 
Volume 
 
(ml) 
Total 
Protein  
 
(mg) 
Total 
Activity 
 
(nmols/m
in) 
Specific 
Activity 
 
 (nmol 
/mg/min) 
Yield 
TA/TA1 
 
% 
Purificatio
n Factor 
 
Crude 
Extract 
9.88 40 395.2 2544 6.44 100 1 
DEAE 
Sepharose 
5.55 18 99.9 1321 13.2 51.9 2.05 
IMAC 7.27 8.0 58.16 783.2 13.5 30.8 2.1 
Sephacryl  
S-300 
1.63 8.8 14.3 2587 181 101 28 
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Figure 5.9: Acetyl-GlcN-Ins deacetylase (MshB) assay. 
The product of the MshB cleavage, GlcN-Ins, is amino-derivatized with AccQ-Fluor 
to form a peak which absorbs at 250 nm on HPLC. N-hydroxysuccinimide is the other 
major fluorescent by-product released during the derivatization.   
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In a rapid, one step procedure at pH 8.0, AccQ-Fluor attaches to the GlcN-Ins amine 
group that is exposed after the removal of the acetyl moiety. The resultant GlcN-Ins-
AccQ-Fluor derivatives were readily detectable on a reverse-phase HPLC column 
with excitation at 250 nm and emmision at 395 nm. Using method 2 on C-18 
analytical column, the derivatized enzymatic product eluted at 24 minutes and the 
major fluorescent reaction by-product, AMQ, eluted at 30 minutes with free reagent 
eluting at 32 and 42 minutes (figure 5.10).  
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Figure 5.10: The HPLC elution profile of the AccQ-Fluor-derivatized GlcN-Ins.  
The MshB deacetylation product, GlcN-Ins, is derivatized with AccQ-Fluor and elutes 
at 24 minutes. The other derivatization by-product, AMQ, elutes at 30 minutes while 
the excess free reagent elutes at 32 and 42 minutes. 
 
5.3.4. Kinetic characterization of MshB with Acetyl-GlcN-Ins 
 
The catalytic characterization of MshB with its natural substrate was carried out as 
previously described by Newton et al. (Newton et al., 2006). The deacetylation of 
Acetyl-GlcN-Ins was assayed at 6 substrate concentrations ranging from 50 to 2000 
μM and the kinetic constants were obtained from the Lineweaver-Burk plot (figure 
5.11). The values were as follows, Km = 347.7 ± 27.2 μM, Vmax = 436.6 ± 148 
nmol/min/mg, kcat = 0.24 ± 0.08 sec-1 and kcat/Km = 690.3 M-1.sec-1. 
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Figure 5.11: Lineweaver-Burk plot of MshB with Acetyl-GlcN-Ins as a substrate.  
Method 2 was run for the HPLC determination of the kinetic values. The substrate 
concentrations were 50, 60, 80, 100, 250 and 2000 μM.  
 
The Km obtained in this study for Acetyl-GlcN-Ins as a substrate is comparable to the 
340 ± 80 μM reported for MshB in Newton et al., 2006. However, the Vmax in the 
current work is about half the value of 960 ± 150 nmol/min/mg reported by these 
authors. It is not known whether the higher activity obtained for the His-tagged 
enzyme is due to the shortened time required for its isolation or due to the presence of 
the Histag itself; by having either an effect on the activity of the enzyme or on its 
stability (Newton et al., 2006). Protein degradation was not apparent in the present 
study as witnessed by the pure band obtained at 33 kDa without evidence of a smaller 
band at 26 kDa (figure 5.8).  
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5.3.5. Evaluation of structural analogs of Acetyl-GlcN-Ins as MshB substrates 
 
MCL2, J1, JDF1 and JDF2 (figure 5.1) are all structural analogs of Acetyl-GlcN-Ins, 
which were chemically synthesized to contain thiophenol as aglycon in place of 
inositol. Because the phenyl group absorbs at 254 nm wavelength, these compounds 
are readily detectable on HPLC without the need for derivatization. The product 
resulting from their cleavage with mshB should also give an additional peak on 
HPLC. Amongst these thiophenyl compounds, MCL2 was the only one which was 
deacetylated by mshB, and it was therefore further analyzed in detail as a substrate.  
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Figure 5.12: HPLC elution profiles showing the cleavage of MCL2 with MshB. 
C-18 HPLC column (250 x 4.6mm) was eluted with method 1.  
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In the control experiment (figure 5.12, A), the uncleaved MCL2 gave two sharp peaks 
between 25 and 30 mins. When the compound was treated with the deacetylase the 
second large peak was consumed while the first smaller peak remained unchanged. 
This indicated that MCL2 eluted as the second peak and the first peak may be the β-
linked anomer or an uncharacterized contaminant. The deacetylation of MCL2 with 
mshB resulted in the formation of the product peak at 18 mins as shown in figure 
5.12, B. The kinetic parameters of mshB with MCL2 as a substrate were estimated by 
both Michaelis-Menten and Lineweaver-Burk plots: Km value = 1695 ± 151 µM, 
Vmax = 214 ± 57 nmol/min/mg, kcat= 0.120 ± 0.03 sec-1 and kcat/Km = 69.4 M-1.sec-1.  
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Figure 5.13: Michaelis-Menten plot showing the evaluation of Acetyl-GlcN-Ins, 
MCL2, MCL1, SP1 and SP2 as substrates for mshB. 
 
Each of the cyclohexane-containing compounds, MCL1, SP1, SP2 and A1120 (figure 
5.2), was evaluated separately as a substrate for MshB. The compounds contained a 
cyclohexane ring as a replacement for myo-inositol, present in the natural substrate of 
mshB. At the end of the incubation with mshB, the reaction mixtures were dansylated 
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for visualization of the amine formed upon cleavage of the amide bond. The result 
obtained by HPLC analysis of the dansylated reaction product formed by cleavage of 
the amide bond in Acetyl-GlcN-Ins is shown in figure 5.14. Dansylated GlcN-Ins 
eluted at 23 mins, while excess dansyl chloride (DnsCl) eluted at 36 mins. The other 
by-product of the dansylation, dansyl hydroxide, eluted at 25 mins. Of the four 
analogs, only A1120 was not cleavable by the deacetylase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Analysis of GlcN-Ins formed during the deacetylation of GlcNAc-
Ins by HPLC. Reaction mixtures were dansylated as described in section 2.2.8.2 and 
analysed by chromatography on a C-18 reversed phase column using a gradient in 
acetonitrile (Method 1, see Chapter 2).  
 
It seemed that the substrate concentration range used for the evaluation of MCL1, SP1 
and SP2 as substrates for mshB was too low to give more accurate kinetic values. The 
problem is that the compounds are probably not soluble enough to conduct assays in 
the range that will be suitable for estimation of kinetic parameters. As a result, the 
comparison between these compounds and the natural substrate was carried out by 
determining their specific activities. At 250 μM substrate concentration the specific 
activities were 106, 6.07, 27, 6.11, and 5.45 nmols/min/mg for Acetyl-GlcN-Ins, 
MCL1, MCL2, SP1 and SP2 respectively. 
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5.3.6. MshB Inhibition 
 
There are some difficulties associated with chemical synthesis of pseudodisaccharides 
containing inositol. Some methods involve protecting 5 out of 6 hydroxyl groups, 
leaving one specific hydroxyl available for substitution with glucosamine (Gammon 
et al., 2003). The findings in the current study that Acetyl-GlcN-Ins analogs, which 
contain either a cyclohexane or a phenyl group instead of myo-inositol, can serve as 
substrates of mshB indicate that the inositol moiety is not strictly required for binding 
to the active site. This therefore inspired the objectives of this study to incorporate 
testing of compounds containing phenyl and cyclohexyl conjugates as mshB 
inhibitors. Because the phenyl ring and the glucose moiety of MCL2 are joined by a 
sulphur atom, some of the potential inhibitors were designed to contain sulphur rather 
than oxygen. Such compounds are termed thioglycosides. 
 
21 chemically synthesized MSH analogs, grouped as 4 naphthoquinones, 10 various 
thioglycosides, and 7 O-glycosides, were tested as inhibitors of mshB at 500 μM 
using HPLC assays in the presence of 500 μM Acetyl-GlcN-Ins as a substrate. The 
inhibion percentages are shown in tables 5.2, 5.3 and 5.4 for thioglycosides, 
naphthoquinones and O-glycosides respectively, and summarized in figure 5.15. 
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Table 5.2: Inhibition of MshB by Thioglycosides 
 
O
OH
HO
HO
R1R2
NO2
O2N
S
O
O
H3C
HO
S
S
S
S
NH
O
NH
O
NH
O
NH
O
NH
O
Cl
R1 R2
S NH
S NH
S S
CH3
OO
NH
S N
HH2CN
NH
NH
OS
J1
A1120
JDF1
JDF2
SP2
SP3
SP4
SP5
SP6
SP7
MshB Inhibition
29%
0%
15%
13%
6%
15%
16%
0%
0%
17%
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Table 5.3: Inhibition of MshB by Naphthoquinones 
 
 
O
OH
HO
HO
NH
R
O S
O
O
OH
O
O OH
O
O
OH
O
O OH
MshB Inhibition
57%
82%
81%
95%
R
Vu2
Vu3
Vu4
Vu5
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Table 5.4: Inhibition of MshB by O-glycosides 
 
O
OH
HO
HO
OR
OH
O
O
O
Th1 (β-linkage)
Th2
Th3
Th4
Th6
Th5
Th7
R MshB Inhibition
0%
0%
0%
11%
7%
20%
7%  
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Figure 5.15: The inhibition of mshB. The 21 compounds were tested at 500 μM for 
inhibition of mshB using HPLC assays. The experiments were performed in the 
presence of 500 μM Acetyl-GlcN-Ins. The bars represent the average of two assays 
run in duplicates and the errors were within 10% of the indicated values.   
 
The naphthoquinones displayed the highest inhibition activity against mshB. Vu2, 
Vu3, Vu4 and Vu5 gave 57%, 82%, 81% and 95% inhibition, respectively, while all 
other compounds gave less than 30% inhibition. Because of their effectiveness, all the 
naphthoquinones were selected for a detailed kinetic characterization as mshB 
inhibitors. The inhibition constants (Ki) of these compounds were determined by 
HPLC assays using method 2. The assay mixtures contained a constant amount of 
mshB and varying inhibitor concentrations. The inhibition reactions were performed 
in presence of varying concentrations of the substrate Acetyl-GlcN-Ins. Figures 5.19a-
5.21b present the Lineweaver-Burk plots from which Ki values for Vu2, Vu4 and 
Vu5, were derived.  
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Ki determination for Vu2 against MshB 
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Figure 5.16a: Competitive inhibition of M. tuberculosis mshB with Vu2.  
The assays were performed by HPLC at the indicated inhibitor concentrations and 
substrate concentrations of 50, 60, 80, 100 and 250 μM. The 0 μM inhibitor was taken 
from the values used for mshB Km determination for Acetyl-GlcN-Ins where the 
substrate range was up to 2000 μM.      
 
 
Figure 5.16b: Ki determination for Vu2: Slopes from each inhibitor 
concentration in the Lineweaver-Burk inhibition plots were plotted against the 
Inhibitor concentrations (μM). The Ki for mshB is 162.7 ± 15 μM. 
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Figure 5.17a: Competitive inhibition of M. tuberculosis MshB with Vu4.  
The assays were performed by HPLC at the inhibitor concentrations of 50, 100, 150 
and 200 μM and the substrate concentration of 50, 60, 80, 100 and 250 μM. The 0 μM 
inhibitor was taken from the values used for mshB Km determination for Acetyl-
GlcN-Ins where the substrate range was up to 2000 μM.      
 
 
Figure 5.17b: Ki determination for Vu4: Slopes from each inhibitor 
concentration in the Lineweaver-Burk inhibition plots were plotted against the 
Inhibitor concentrations (μM). Ki = 93.92 ± 11 μM. 
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Figure 5.18a: Competitive inhibition of M. tuberculosis MshB with Vu5.  
The assays were performed by HPLC at the indicated inhibitor concentrations and 
substrate concentrations of 50, 60, 80, 100 and 250 μM.  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18b: Ki determination for Vu5: Slopes from each inhibitor 
concentration in the Lineweaver-Burk inhibition plots were plotted against the 
Inhibitor concentrations (μM). Ki = 16.8 ± 1.9 μM. 
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Figure 5.19: Docking of inhibitors Vu2 (green) and Vu5 (white) to MshB.  
In all figures Zn2+ is shown as a yellow sphere and hydrogen bonding between the 
ligands and the mshB residues is indicated by dotted green lines. A. The active site of 
mshB showing the amino acids which play a major role in the catalysis. B. Ligands, 
Vu2 (green) and Vu5 (white and red), in the active site of mshB. C. Vu2 docked to 
mshB. D. Vu5 docked to mshB. The distance between Zn2+ and Vu5 is 3.216 Å. 
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The x-ray crystal structure of mshB from M. tuberculosis has been solved in presence 
of the natural substrate in the active site (Maynes et al., 2003: McCarthy et al., 2004). 
In order to understand the interaction of the novel inhibitors and mshB, the crystal 
structure solved by Maynes et al was used to dock the naphthoquinones using the 
Accelrys Discovery Studio 17. Proper zinc coordination geometry is a prerequisite for 
quality docking of zinc metalloproteinase inhibitors (Hu et al., 2004), thus because 
mshB is also a metalloproteinase, the runs were performed in search of Zn2+ as a 
guide to finding the active site.  
 
The two ligands docked, Vu2 and Vu5, figure 5.22B, occupied the cavity formed by 
the same residues involved in the binding of Acetyl-GlcN-Ins. The residues in this 
region include His 13, His 144, His 147, Asp 15, Asp 16, Asp 95, Ser 260, Arg 68 and 
Gln 45, which were reported to form a cleft-like binding cavity in the active site of 
mshB (Metaferia et al., 2007). These results therefore show that the naphthoquinones 
bind to the active site of mshB and therefore competitively inhibit the deacetylase as 
also confirmed by the Lineweaver-Burk plots where Vmax values remained the same 
before and after the inhibition.  
 
The Ki values of Vu2, Vu4 and Vu5 were found to be 162.7, 93.9 and 16.8 μM 
against mshB.  These values are in agreement with the inhibition percentages of 57%, 
81%, and 95% exhibited by the naphthoquinones against the deacetylase as shown in 
table 5.3 and figure 5.15, indicating that the binding of the compounds to the enzyme 
increases with the length of the spacer between the naphthoquinone  and  GlcNAc. In 
figure 5.22D, the quinone group of Vu5 extends to the non-polar residues, Val 184 
and Leu 185, while Vu2, figure 5.22C, cannot stretch towards the residues. This 
observation is consistent with the observed dependence of active site affinity of the 
inhibitors on the number of carbon atoms in the spacer.  It would therefore be of great 
interest to evaluate additional naphthoquinones with variable spacer lengths as 
inhibitors. 
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CHAPTER 6: GENERAL DISCUSSION 
 
MSH S-conjugate amidase, mca, was discovered in the studies aimed at labelling 
intact M. smegmatis with monobromobimane (Newton et al., 2000b).  In a 
comparison of different alkylating agents MSmB was found to be the preferred 
substrate of this enzyme (Steffek et al., 2003), but unfortunately monobromobimane 
is expensive.  
In an attempt to discover simple methods for the synthesis of MSH and its precursors, 
MSSNaph (figure 4.6), which is much less expensive and can be used for the 
preparation of GlcN-Ins has been identified as an alternate mca substrate. MSSNaph is 
the immediate product obtained upon the reaction of MSH present in perchlorate 
extracts of mycobacteria with S-2-(2’-thiopyridyl)-6-hydroxylnaphthyldisulfide and 
its isolation has been optimized. Although its Km is almost 2-fold larger than that of 
MSmB (table 6.1), mca has a higher affinity for MSSNaph than for 11 out of 12 other 
compounds previously tested as substrates for mca (Steffek et al., 2003), and it can 
therefore be used as an alternative substrate of the amidase. MSSNaph can be used to 
assay for mca, without the need to first produce MSH and then MSmB by alkylation 
with monobromobimane.   
 
Table 6.1: Kinetic constants of mca 
 
 
 
 
8 structural analogs of Acetyl-GlcN-Ins (figure 5.1 and 5.2), which were chemically 
synthesized to contain either a spacefilling cyclohexane or a phenyl group instead of 
myo-inositol, were tested as substrates for mshB. Table 6.2 shows the compounds 
which were cleavable by mshB in the same way that the natural substrate is 
Substrate Km 
 
Vmax 
MSmB 187.6 ± 19.3 
μM 
64.2 ± 5.5 
nmols/min/mg 
MSSNaph 328 ± 22 
 μM 
189.6 ± 33 
nmols/min/mg 
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deacetylated. At 250 μM substrate concentration, the specific activity for MCL2 was 
27 nmols/min/mg, about 4-fold lower than that for Acetyl-GlcN-Ins. At the same 
substrate concentration the specific activities for MCL, SP1 and SP2 were about 20-
fold lower than that of the natural substrate, indicating that the presence of the myo-
inositol moiety increases the activity or is important for tighter binding to mshB as 
indicated by a 5-fold increase in the Km value when myo-inositol is substituted with 
the phenyl group.  
 
The active site of mshB contains the carboxylate groups (Asp-15, Asp-95, and Asp-
146), the hydroxyl groups (Ser-20, Tyr-142, and Ser-260), one amide from the side 
chain of Gln-247, four main chain carbonyls (Gly-140, Tyr-142, Glu-213, and Ile-
214), and two positively charged residues (Arg-68 and His-144), all contributing to 
the hydrophilic and electronegative nature of the substrate binding pocket (Maynes et 
al., 2003). Carbohydrate-binding molecules containing hydrophilic residues form 
hydrogen-bonding interactions with the sugar hydroxyl groups (Quiocho, 1993). This 
therefore explains why the the presence of highly hydrophilic inositol contribute to 
strong binding to the active site of mshB. 
  
Of all analogs tested MCL2 was the best in terms of binding affinity, giving a Km 
value of 1695 μM. For MCL1, SP1 and SP2 accurate Km and Vmax values could not 
be obtained at the substrate concentration range of 150 to 2000 μM. Because 
cyclohexane, the substituent on MCL1, SP1 and SP2 is apolar, these compounds were 
insoluble at higher concentrations where more accurate values can be obtained. The 
other impediment was that the amount of compounds provided were not enough to 
evaluate them as substrates at the much higher levels that would have been required. 
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Table 6.2: Specific activities of mshB with the structural analogs of Acetyl-GlcN-
Ins. 
 
                                                 
O
OH
HO
HO
RNHO
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R-substituent 
Specific activity at 250 μM 
substrate concentration 
(nmols/min/mg) 
OH
OH
OHOH
HO
O
Acetyl-GlcN-Ins 
 
106 nmols/min/mg 
S  
MCL2 
 
27.0 nmols/min/mg 
S
 
SP1 
 
6.11 nmols/min/mg 
O
 
MCL1 
 
6.07 nmols/min/mg 
S
 
SP2 
Also CH3 was substituted 
by Cl on the acetyl moiety 
 
 
5.45 nmols/min/mg 
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Newton et al showed that the removal of inositol from MSmB also reduces the mca 
activity by a factor of 45 000 (Newton et al., 2006), and elsewhere it was reported that 
the specific activity of mca for the bimane derivative prepared from the cyclohexane 
analog of MSH is 7 500 nmol.min-1.mg-1, about half the value of 14 200 nmol.min-
1.mg-1 for MSmB (Knapp et al., 2002).   
 
The disulfide form of des-myo-inositol mycothiol was also identified as a substrate of 
mtr with a Km of 400 μM (Patel and Blanchard, 1998), five-fold higher than that for 
the natural substrate MSSM (Km = 73 μM) (Patel and Blanchard, 1999). On the other 
hand Stewart et al. also reported that substituting inositol in MSSM with methyl and 
benzyl groups increased the Km values for the resultant compounds from 113 to 610 
and 438 μM, respectively (Stewart et al., 2008). Thus, space filling substitutes for 
inositol within MSSM analogs do not improve the binding of such substrates as 
compared to des-myo-inositol MSSM. 
 
The substitution of inositol with a cyclohexane or a phenyl seems to be an ideal 
solution in circumventing undesired enzymatic cleavage by glycosidases. The 
substitution of an oxygen with a sulphur as a linking atom between the rings also 
provides several possible advantages because R-GlcNAc thioconjugates can be 
prepared with high anomeric purities and in good yield by S-substitution reactions. 
(Knapp and Myers; 2002), and thioglycosides are more resistant to degradation by 
glycosidases than O-glycosides (Spencer et al., 1996; Cohen and Halcomb, 2000; 
Bousquet et al., 2000).  
These reports evidently support the advantages of substitution of oxygen with a 
sulphur atom and thus the thioglycosides, particularly the naphthoquinones, would be 
more resistant to the degradation by glycosidases if they were to be used as biological 
inhibitors. 
 
The disruption of the mshB gene results in a substantial decrease of MSH production, 
yielding only 5-10% of the level produced by M. smegmatis wild-type mc2155 (Rawat 
et al., 2003). Rv1170, the gene that encodes mshB in M. tuberculosis, was first 
identified as a homolog of mca (Newton et al., 2000a, b). Both mca and mshB are 
metalloproteinases depending on zinc for activity and they were both reported to have 
good activity against MS-acetophenone as a substrate (Steffek et al., 2003, Newton et 
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al., 2006). Because of these similarities, it is believed that mca is responsible for the 
deacetylase activity that produces minute mycothiol in the mshB mutants. Due to the 
overlapping deacetylase activities of mca and mshB (Newton et al., 2006), a complete 
disruption of MSH production at the deacetylase step can only be achieved by 
simultaneous inhibition of both these enzymes. 
 
 Mtr, the enzyme that maintains MSH at the reduced state, is known to reduce 
quinones (Patel and Blanchard, 1999). The napthoquinones that have been 
investigated in this study were initially designed as potential subversive substrates of 
mtr and it was surprising that they act as the best inhibitors of both mshB and mca. 
This, seen together with the work of Metafaria et al., 2007, which reported the first 
inhibitors of both mca and mshB, does raise the possibility of designing inhibitors that 
will inhibit several enzymes to do with mycothiol metabolism. 
 
In the present study 21 MSH analogs were, therefore, tested against both mca and 
mshB with the goal of finding a single compound that could inhibit both enzymes. 
The inhibition of mca and mshB with thioglycosides, naphthoquinones and O-
glycosides is shown in figure 4.9 and 5.15 respectively. The results identified the O-
glycoside, Th2, as the best inhibitor of mca with 74% inhibition, followed by the 
naphthoquinones Vu2, 3, 4 and 5, which gave 29, 38, 23 and 44% inhibition. On the 
other hand, the naphthoquinones, Vu2, 3, 4 and 5 were the best inhibitors against 
mshB giving inhibition percentages of 57, 82, 81 and 95% respectively, while all 
other compounds tested, including Th2, gave inhibition of less 30% against mshB.  
 
These results suggest that the naphthoquinoes are suitable lead compounds for the 
development of more potent inhibitors which could completely abolish the 
biosynthesis of MSH by inhibition of both mca and mshB. In order to rationalize the 
differences in potency of the available naphthoquinones a somewhat more detailed 
kinetic study was undertaken. Vu 2, 4 and 5 were all found to be competitive 
inhibitors of mshB and their Ki values were markedly dependent on the length of the 
spacer between the naphthoquinone and glucosamine moieties, as shown in Table 6.3. 
The Ki value of Vu3 was not determined as it was not expected to be significantly 
different from that of Vu4; based on their similar inhibition percentage against mshB 
(figure 5.15). 
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Table 6.3: Ki values for the most potent inhibitors of MshB   
Compounds Ki (µM) 
Vu2 162.7 ± 15 
Vu4 93.9 ± 11 
Vu5 16.8 ± 1.9 
 
The Ki values of the naphthoquinones indicate that the binding affinity increases with 
the number of carbon chains. To understand this phenomenon, the naphthoquinones 
with 2 carbons and 5 carbons, Vu2 and 5, were docked to mshB crystal structure 
previously published by Maynes et al., 2003. The docking results suggest a possible 
binding of the S-phenyl motif of the compounds to a hydrophobic region of mshB.  
The longer carbon chain of Vu5 extends the molecule such as to allow interaction of 
naphthoquinone moiety with the hydrophobic dipeptide of Val 184 and Leu 185. The 
docking of Vu2 and Vu5 into the active site of mshB provided a hypothetical model 
for the binding mode of the naphthoquinones as inhibitors of mshB. A similar pattern 
of inhibition was observed where naphthoquinones with longer carbon chains were 
also better inhibitors of mca.  
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CONCLUSION  
 
In this study MSH was extracted from M. smegmatis and used to synthesize the 
substrates for mca and mshB.  Mca was partially purified from M. smegmatis using 
ion exchange chromatography and hydroxyapatite. MSSNaph was found to be a 
substrate of mca with a Km value better than most of the alternate substrates reported. 
Although it was not better than MSmB as a substrate, MSSNaph provides an 
inexpensive alternate assay for mca. MshB was expressed in E. coli BL21 DE3 pLysS 
cells and purified to electrophoretic homogeneity using ion exchange, affinity and size 
exclusion chromatography. A thiophenyl structural analog of Acetyl-GlcN-Ins, 
MCL2, was found to be a substrate for mshB, albeit 5-fold higher Km value. 
 
The study has also discovered novel compounds which inhibit the MSH-biosynthetic 
enzyme, mshB, and mca, a key enzyme in the MSH-dependent detoxification pathway 
in M. tuberculosis. The fact that the naphthoquinones, which were ab initio  designed 
as potential subversive substrates of mycothioldisulfide reductase, were now found to 
be also the most potent inhibitors of mshB, and have also some activity against mca, 
suggest that the design of inhibitors which interfere simultaneously with the function 
of several different enzymes is a viable objective. 
 
FUTURE RESEARCH 
A more detailed comparative study of the inhibition of mca and mshB should be 
undertaken. An evaluation of compounds bearing apolar groups, attached through 
spacers of variable length to the glucosamine moiety, as potential inhibitors of both 
mca and mshB will be especially fruitful. Co-crystals of mshB and mca with such 
compounds will provide further insights and towards this end the availability of a 
resolved structure of mca will be invaluable.  
 
Experiments on the effect of the most potent inhibitors on mammalian cell lines could 
be useful in evaluating their cytotoxicity. The evaluation of the compounds against 
the growth of M. tuberculosis as well as in vivo models will also be necessary for 
future research. 
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APPENDIX 
 
Appendix A: Standard Curves 
 
 
A.1. GlcN-Ins standard curve: 
 
Amount of GlcN-Ins (nmols) Area of the absorbance peak 
0.00 0.00 
1.167 266414 
2.33 557191 
4.67 1189342 
5.83 1259233 
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0 2 4 6
Ab
so
rb
an
ce
 p
ea
k 
ar
ea
0.0
2.0e+5
4.0e+5
6.0e+5
8.0e+5
1.0e+6
1.2e+6
1.4e+6
1.6e+6
 
 
                    Figure A: Standard curve of GlcN-Ins 
 
 
 
 
 
 
 
 
 
 
 
 
Y=228389x + 15221 
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A.2. N-Acetyl-L-Cysteine-Bimane standard curve: 
 
 
Amount of N-Acetyl-L-Cysteine-Bimane 
(nmols) 
Area of the absorbance peak 
0 0 
2.5 322497 
5.0 647321 
10 1370537 
15 1834788 
20 2540788 
 
 
Y= 125714x + 19322
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              Figure B: Standard curve of N-Acetyl-L-Cysteine-Bimane 
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A.3. Standard curve for BIORAD protein assay: (Williams M.J, PhD Thesis, 
2007). 
 
 
 
                       Equation: Absorbance595 = BSA (μg) x 0.0662  
 
     Figure C: Standrad curve for BIORAD protein assay. 
 
 
A.4. Protein determination using BIORAD protein assay 
 
¾ Sample diluted appropriately in 800μl of water 
¾ Assay blank was prepared with 800 μl of either water or buffer 
¾ Added 200 μl of Dye R agent Concentrate to each sample 
¾ Incubation at room temperature for 5min 
¾ Absorbance measured for samples and blank at 595nm 
¾ Protein concentration was determined by the equation: [protein] = Abs595 x C 
¾ C is determined experimentally using a Bovine Serum albumin standard curve. 
 
 
A.5. Protein Molecular Weight Markers: 
 
The Electrophoresis Calibration Kit (Pharmacia) used contained the following protein 
standards: 
 
Phosphorylase b                                 94 000 Da 
Bovine Serum Albumin                     67 000 
Ovalbumin                                         43 000 
Carbonic Anhydrase                          30 000 
Soybean Trypsin Inhibitor                 20 100 
α-Lactalbumin                                   14 400 
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The Protein Molecular weight Marker (Fermentas) contains the following protein 
Standards 
 
β-galactosidase                                  116 000 Da 
Bovine Serum Albumin                       66 200 
Ovalbumin                                           45 000 
Lactate dehydrogenase                        35 000 
Restriction Endonuclease Bsp981       25 000 
β-lactoglobulin                                    18 400 
lysozyme                                             14 400 
 
 
Appendix B: Tables of data used for kinetic plots 
 
 
Table B1: Data used for the 1/v against 1/[S] plot of mca with MSmB as a 
substrate 
1/[MSmB] (μM-1) 1/v (min/nmols) 
0.00667 4.53 
0.005 4.07 
0.004 3.33 
0.002 2.93 
0.00133 2.45 
 
 
Table B2: Data used for the 1/v against 1/[S] plot of mca with MSSNaph as a 
substrate 
1/[MSSNaph] (μM-1) 1/v (min/nmols) 
0.0106 3.03 
0.00935 2.79 
0.00772 2.55 
0.00617 2.00 
0.00309 1.38 
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Table B3: Data used for the 1/v against 1/[S] plot of mshB with Acetyl-GlcN-Ins 
as a substrate 
1/[Acetyl-GlcN-Ins] 
(μM-1) 
1/v 
(min/nmols) 
0.0200 5.78 
0.0167 4.56 
0.0125 3.43 
0.0100 3.60 
0.0040 1.70 
0.0005 0.752 
 
 
 
Table B4: Data used for the v against [S] plot of mshB with MCL2 as a substrate 
 
 
 
 
Table B5: Data used for the v against [S] plot of mshB with MCL1 as a substrate 
 
 
 
 
Table B6: Data used for the v against [S] plot of mshB with SP1 as a substrate 
 [SP1] (µM) v (nmols/min) 
150 0.0290 
[MCL2] (μM) v (nmol/min) 
250 0.2198 
500 0.4608 
750 0.5405 
1000 0.4808 
1250 0.8000 
1500 0.8403 
1750 0.9804 
2000 0.9615 
[MCL1] (µM) v  (nmols/min) 
250 0.0495 
500 0.0912 
750 0.1271 
1000 0.1949 
1500 0.2770 
2000 0.3413 
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250 0.0498 
500 0.0943 
750 0.1318 
1000 0.1802 
1500 0.2717 
2000 0.2890 
 
Table B7: Data used for the v against [S] plot of mshB with SP2 as a substrate 
[Sp2] (µM) v (nmols/min) 
150 0.0271 
250 0.0444 
500 0.0954 
750 0.1300 
1500 0.2841 
2000 0.3984 
 
 
Table B8a: Data for Ki determination of Vu2 against mshB, 1/v versus 1/[S]   
1/[Acetyl-
GlcN-Ins] 
(μM-1) 
No inhibitor 
1/v 
(min/nmols) 
25μM Vu2 
1/v 
(min/nmols)
50μM Vu2 
1/v 
(min/nmols)
100μM Vu2 
1/v 
(min/nmols) 
200μM Vu2
1/v 
(min/nmols)
0.0200 5.78 7.22 8.07 9.17 12.4 
0.0167 4.56 5.78 7.61 8.15 10.1 
0.0125 3.43 4.61 5.46 6.54 8.02 
0.0100 3.60 3.97 4.56 5.21 6.40 
0.0040 1.70 2.00 2.14 2.15 2.70 
0.0005 0.752 
  
Table B8b: Data for Ki determination of Vu2 against mshB, slope versus [I] 
[Vu2] (μM)      Slope 
0 245 
25 316 
50 387 
100 442 
200 597 
 
 
Table B9a: Data for Ki determination of Vu4 against mshB, 1/v versus 1/[S]   
1/[Acetyl- No inhibitor 50μM Vu4 100μM Vu4 150μM Vu4 200μM Vu4
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GlcN-Ins] 
(μM-1) 
1/v 
(min/nmols) 
1/v 
(min/nmols)
1/v 
(min/nmols)
1/v 
(min/nmols) 
1/v 
(min/nmols)
0.0200 5.78 6.12 8.72 12.4 14.6 
0.0167 4.56 5.40 7.00 9.94 10.6 
0.0125 3.43 4.43 5.26 7.63 8.90 
0.0100 3.60 3.80 4.45 5.35 7.39 
0.0040 1.70 1.56 2.50 3.58 3.45 
0.0005 0.752 
  
 
Table B9b: Data for Ki determination of Vu4 against mshB, slope versus [I] 
[Vu4] (μM)      Slope 
0 245 
50 281 
100 390 
150 559 
200 655 
 
 
 
Table B10a: Data for Ki determination of Vu5 against mshB, 1/v versus 1/[S]   
1/[Acetyl-
GlcN-Ins] 
(μM-1) 
No inhibitor 
1/v 
(min/nmols) 
10μM Vu5 
1/v 
(min/nmols)
25μM Vu5 
1/v 
(min/nmols)
50μM Vu5 
1/v 
(min/nmols) 
100μM Vu5
1/v 
(min/nmols)
0.0200 5.78 9.00 15.0 28.8 40.6 
0.0167 4.56 7.60 12.6 24.6 33.3 
0.0125 3.43 6.23 10.0 18.7 24.3 
0.0100 3.60 4.90 7.85 14.8 19.6 
0.0040 1.70 2.26 3.50 6.28 9.36 
0.0005 0.752 
 
 
Table B10b: Data for Ki determination of Vu5 against mshB, slope versus [I] 
[Vu5] (μM)      Slope 
0 245 
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10 419 
25 720 
50 1418 
100 1958 
 
 
Appendix C: Laboratory Suppliers Contacts 
 
Beckman Coulter Inc. 
4300 N. Harbor Boulevard 
P.O. Box 3100 
Fullerton, CA 92834-3100 USA 
www.beckmancoulter.com 
 
BDH Laboratory Suppliers 
Poole, Dorset 
England BH15 1TD 
BioRAD Laboratories 
1000 Alfred Nobel Drive 
Hercules, CA 94547 
www.bio-rad.com 
 
Biospec Products 
POB 788 
Bartlesville 
OK 74005 
www.biospec.com 
 
BioTechnology Institute 
University of Minnesota 
1479 Gortner Avenue 
St. Paul, MN55108 
http://cbs.umn.edu/bti/ 
 
Boehringer Ingelheim 
Dept. Fine Chemicals 
Binger Straße 173 
D-55216 Ingelheim 
Germany 
www.boehringer-ingelheim.com/finechem 
 
 
Fermentas International Inc. 
830 Harrington Court 
Burlington 
Ontario L7N 3N4 
www.fermantas.com 
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Grace Vydac 
17434 Mojave Street 
Hesperia, CA 92345 USA 
www.vydac.com 
 
Invitrogen Ltd. 
3 Fountain Drive 
Inchinnan Business Park 
Paisley, UK 
PA4 9RF 
www.invitrogen.com 
 
KIMIX 
P.O. Box 93 
7475 Eppindust 
South Africa 
www.chemicalsupplier.co.za 
 
Merck 
Frankfurter StraBe 250 
D-6100 Darmstadt 1 
www.merck.co.za 
 
Oxoid Limited 
Wade Road, Basingstoke 
Hampshire RG24 8PW 
United Kingdom 
www.oxoid.com 
 
Perkin-Elmer 
940 Winter Street 
Waltham 
Massachusetts 02451 USA 
www.perkinelmer.com 
 
PhamaTech International 
21 Just Rd. Fairfield 
New Jersey 07004 USA 
www.oriondevel.com/pharmatech/index.aspx 
 
 
 
Phenomenex 
2320 W. 205th Street 
Torrance 
California 90501 USA 
www.phenomenex.com 
 
Research Organics Inc. 
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4353 East 49th Street 
Cleveland, OH. 44125 
http://resorg.com/body.cfm 
 
Roche Ltd. 
Group Headquarters 
Grenzacherstrasse 124 
CH-4070 Basel 
Switzerland 
www.roche.com 
 
Sigma-Aldrich / Fluka / Riedel-de Haën 
Box 14508, St. Louis 
Missouri 63178, USA 
www.sigma-aldrich.com 
 
The Nest Group Inc. 
45 Valley Road 
Southborough 
MA 01772-1323 
www.nestgrp.com 
 
Waters Corporation 
34 Maple Street 
Milford Massachusetts 
01757 USA 
www.waters.com 
 
Whatman 
info@whatman.com 
www.whatman.com 
 
